WO2016060443A2 - Compounds and compositions for modulating egfr mutant kinase activities - Google Patents

Compounds and compositions for modulating egfr mutant kinase activities Download PDF

Info

Publication number
WO2016060443A2
WO2016060443A2 PCT/KR2015/010784 KR2015010784W WO2016060443A2 WO 2016060443 A2 WO2016060443 A2 WO 2016060443A2 KR 2015010784 W KR2015010784 W KR 2015010784W WO 2016060443 A2 WO2016060443 A2 WO 2016060443A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
ylamino
pyrazol
acrylamide
methoxy
Prior art date
Application number
PCT/KR2015/010784
Other languages
French (fr)
Other versions
WO2016060443A3 (en
Inventor
Byung-Chul Suh
Paresh Devidas Salgaonkar
Jaekyoo Lee
Jong Sung Koh
Ho-Juhn Song
In Yong Lee
Jaesang Lee
Dong Sik Jung
Jung-Ho Kim
Se-Won Kim
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016060443(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX2020002168A priority Critical patent/MX2020002168A/en
Priority to SG11201701960XA priority patent/SG11201701960XA/en
Priority to KR1020177012969A priority patent/KR102073854B1/en
Priority to KR1020237000623A priority patent/KR102662358B1/en
Priority to KR1020217002019A priority patent/KR102487451B1/en
Priority to CA2962914A priority patent/CA2962914C/en
Priority to CN201580055717.9A priority patent/CN106795144B/en
Priority to BR112017007769-8A priority patent/BR112017007769B1/en
Priority to NZ730012A priority patent/NZ730012A/en
Priority to SI201531055T priority patent/SI3207035T1/en
Priority to RS20200101A priority patent/RS59900B1/en
Priority to MX2017003181A priority patent/MX2017003181A/en
Priority to RU2017116598A priority patent/RU2727700C2/en
Priority to PL15850314T priority patent/PL3207035T3/en
Priority to LTEP15850314.4T priority patent/LT3207035T/en
Priority to AU2015331166A priority patent/AU2015331166B2/en
Priority to EP15850314.4A priority patent/EP3207035B1/en
Priority to ES15850314T priority patent/ES2770058T3/en
Priority to DK15850314.4T priority patent/DK3207035T3/en
Priority to KR1020207002949A priority patent/KR102208775B1/en
Priority to PL19196713T priority patent/PL3604294T3/en
Priority to CN202010422259.0A priority patent/CN111686110B/en
Priority to EP19196713.2A priority patent/EP3604294B1/en
Priority to JP2017519685A priority patent/JP6524221B2/en
Priority to EP21171619.6A priority patent/EP3929190A1/en
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of WO2016060443A2 publication Critical patent/WO2016060443A2/en
Publication of WO2016060443A3 publication Critical patent/WO2016060443A3/en
Priority to PH12017500488A priority patent/PH12017500488A1/en
Priority to HRP20200201TT priority patent/HRP20200201T1/en
Priority to CY20201100143T priority patent/CY1122737T1/en
Priority to CY20211100670T priority patent/CY1124359T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Definitions

  • the present invention relates to novel chemical compounds and pharmaceutically acceptable compositions thereof which display inhibition activity against certain mutated forms of EGFR.
  • Protein kinases catalyze the transfer of the terminal phosphate from ATP or GTP to the hydroxyl group of tyrosine, serine and/or threonine residues of proteins. Protein kinases are categorized into families by the substrates they phosphorylate, for example, protein tyrosine kinases (PTK), and protein serine/threonine kinases. Phosphorylation via protein kinase(s) results in a functional change of the target protein (substrate) by changing enzyme activity, cellular location or association with other proteins. Protein kinases play vital role in variety of cellular processes; cell proliferation, cell survival, metabolism, carbohydrate utilization, protein synthesis, angiogenesis, cell growth and immune response.
  • PTK protein tyrosine kinases
  • Misregulation of the protein kinases has been implicated in numerous diseases and disorders such as central nervous system disorders (e.g., Alzheimer's disease), inflammatory and autoimmune disorders (e.g., asthma, rheumatoid arthritis, Crohn's disease, and inflammatory bowel syndrome, and psoriasis), bone diseases (e.g., osteoporosis), metabolic disorders (e.g., diabetes), blood vessel proliferative disorders, ocular diseases, cardiovascular disease, cancer, restenosis, pain sensation, transplant rejection and infectious diseases.
  • central nervous system disorders e.g., Alzheimer's disease
  • inflammatory and autoimmune disorders e.g., asthma, rheumatoid arthritis, Crohn's disease, and inflammatory bowel syndrome, and psoriasis
  • bone diseases e.g., osteoporosis
  • metabolic disorders e.g., diabetes
  • blood vessel proliferative disorders e.g., ocular diseases, cardiovascular disease, cancer, restenosis
  • EGFR is a transmembrane protein tyrosine kinase member of the erbB receptor family.
  • a growth factor ligand such as epidermal growth factor (EGF)
  • the receptor can dimerize with EGFR or with another family member such as erbB2 (HER2), erbB3 (HER3) and erbB4 (HER4).
  • HER2 epidermal growth factor
  • HER3 erbB3
  • HER4 erbB4
  • the dimerization of erbB receptors leads to the phosphorylation of key tyrosine residues in the intracellular domain and sequentially to stimulation of numerous intracellular signal transduction pathways involved in cell proliferation and survival.
  • Misregulation of erbB family signaling promotes proliferation, invasion, metastasis, angiogenesis, and tumor survival and has been described in many human cancers such as lung and breast.
  • the erbB family is a rational target for anticancer drug development and a number of compounds targeting EGFR or erbB2 are now clinically available, including gefitinib (IRESSATM) and erlotinib (TARCEVATM), the first generation inhibitor.
  • gefitinib IRESSATM
  • TARCEVATM erlotinib
  • L858R and del E746-A750 were sensitive to treatment of gefitinib or erlotinib but ultimately acquired resistance to therapy with gefitinib or erlotinib arises predominantly by mutation of the gatekeeper residue T790M, which is detected in approximately half of clinically resistant patients, resulting in double mutants, L858R/T790M and del E746-A750/T790M.
  • JAK3 is predominantly expressed in hematopoietic lineage such as NK cells, T cells and B cells and intestinal epithelial cells.
  • Targeting JAK3 could be a useful strategy to generate a novel class of immunosuppressant drugs. Due to primary expression in hematopoietic cells, so a highly selective JAK3 inhibitor should have precise effects on immune cells and minimal pleiotropic defects. The selectivity of a JAK3 inhibitor would also have advantages over the current widely used immunosuppressant drugs, which have abundant targets and diverse side effects.
  • a JAK3 inhibitor could be useful for treating autoimmune diseases, and JAK3 mediated leukemia and lymphoma.
  • JAK3 somatic mutations of JAK3 were also identified in a minority of acute megakaryoblastic leukaemia (AMKL) patients both in Down syndrome children and non- Down syndrome adults, and in a patient with acute lymphoblastic leukaemia.
  • JAK3 activation was identified in several lymphoproliferative disorders, including mantle cell lymphoma, Burkitt's lymphoma, human T-cell leukemia lymphoma, virus- 1 -induced adult T-cell lymphoma/leukemia and anaplastic large cell lymphoma. It was shown that constitutive activation of the JAK3/STAT pathway has a major role in leukemia and lymphoma cell growth and survival and in the invasive phenotype.
  • JAK3 constitutive activation of JAK3, which can result from J AK3 -activating mutations, is a frequent feature of several leukemia and lymphoma so that selective inhibition of JAK3 could be therapeutic target. Therefore, a strong need exists for compounds which selectively and potently inhibit JAK3 wildtype and mutants as well as are selective over other JAK family members to provide an effective and safe clinical therapy for the diseases associated with or mediated by J AK3.
  • a need also exists for methods of administering such compounds, pharmaceutical formulations and medicaments to patients or subjects in need thereof.
  • the present invention relates to novel chemical compounds and pharmaceutically acceptable compositions thereof which display inhibition activity against certain mutated forms of EGFR.
  • the invention provides pyrimidine derivatives represented by Formula (I) and their use for the treatment or prevention of a number of different cancers associated with one or more EGFR mutations.
  • Such compounds have general Formula (I) as well as pharmaceutically acceptable salts, diastereomers, enantiomers racemates, hydrates or solvates thereof,
  • X is CH or N
  • R 1 is H, R 8 or -OR 8 ;
  • R 2 is hydrogen, C 1-6 alkyl, 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the aryl or heteroaryl is optionally and independently substituted at one or more carbon atoms with R 13 ; and wherein the heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R ;
  • R 3 is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR 9 R 10 , NR n R 12 , or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R 13 ; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R 8 ;
  • R 4 is hydrogen, C 1-4 alkyl, C 3-5 cycloalkyl, F, CI, Br, CN, or CF 3 ;
  • R 5 is hydrogen, CF 3j C 1-6 alkyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R 13 ;
  • R 6 is hydrogen or C 1-6 alkyl
  • R 7 is hydrogen, -CH 2 OH, -CH 2 OR 8 , C 1-3 alkyl, (CH 2 ) n NR 9 R 10 , (CH 2 ) n NR n R 12 , C(O)NR 9 R 10 , or C(O)NR 1 ! R 12 , wherein each n is independently 1 or 2;
  • R 8 is selected from C 1-6 alkyl or C 3-7 cycloalkyl
  • R 9 is selected from C 1-6 alkyl, C 3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the Ci -6 alkyl or C 3- cycloalkyl is optionally substituted with halogen or -OR , and wherein the 4-7 membered o heterocyclyl having one nitrogen atom is optionally and independently substituted with -R , -C(0)R 8 , -C(0)OR 8 , or C(0)NHR 8 ;
  • R 10 is C 1-6 alkyl, C 3 . 7 cycloalkyl, or (CH 2 ) n NR 9 R 9 , wherein each n is independently l or 2;
  • heteroatoms in addition to the nitrogen atom to which R and R are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms (e.g., at one, two, or three carbon or nitrogen atoms) with -R , -C(O)R , -C(O)OR , - C(0)NHR 8 , -SO 2 R 8 , -SO 2 NH 2 , or -SO 2 NR 8 2 ; and
  • R 13 is selected from halogen, CN, CF 3 , R 8 , -OR 8 or C 2-4 alkenyl;
  • the present invention also relates to compositions comprising these compounds, methods of making these compounds, methods of inhibiting enzyme activity, particularly one or more EGFR mutant and JA 3 kinase activity, through use of these compounds, and a method of treating disease or disease symptoms in a mammal, particularly where inhibition of the kinase activity, can affect disease outcome.
  • Figure 1 shows visualization of Western blots showing the results of inhibition of phosphorylation level of mutant EGFR as compared to wildtype EGFR.
  • the present invention provides a group of aminopyrimidine derivatives and pharmaceutically acceptable salts thereof that are useful for inhibiting one or more protein kinases and for treating diseases and disorders that are mediated by the protein kinase, for example, cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease, and neurodegenerative disease and disorder.
  • the present invention also provides methods for synthesizing and administering the aminopyrimidine derivatives.
  • the present invention also provides pharmaceutical formulations comprising at least one of the compounds of Formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
  • the invention also provides useful intermediates generated during syntheses of the aminopyrimidine derivative compounds.
  • the present invention provides compositions and methods for modulating the activity of the epidermal growth factor receptor (EGFR) mutants and/or Janus kinase 3 (JAK3).
  • the invention provides compounds which act as inhibitors of EGFR mutants or J AK3.
  • a compound of Formula (I), individual stereoisomer, or mixture of isomers is provided herein.
  • X is CH or N
  • R 1 is H, R 8 or -OR 8 ;
  • R 2 is hydrogen, C 1-6 alkyl, 6-10 membered monocyclic or bicyclic aryl, or 5-10 - - membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the 5 aryl or heteroaryl is optionally and independently substituted at one or more carbon atoms
  • heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R 8 ;
  • R is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered 10 heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR 9 R 10 , NR n R 12 , or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R 13 ; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R 8 ;
  • R 4 is hydrogen, C 1-4 alkyl, C 3-5 cycloalkyl, F, CI, Br, CN, or CF 3 ;
  • R 5 is hydrogen, CF 3, C 1-6 alkyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R 13 ;
  • R 6 is hydrogen or C 1-6 alkyl
  • R 7 is hydrogen, -CH 2 OH, -CH 2 OR 8 , C 1-3 alkyl, (CH 2 ) n NR 9 R 10 , (CH 2 ) n NR n R 12 , C(0)NR 9 R 10 , or C(0)NR u R 12 , wherein each n is independently 1 or 2;
  • R is selected from C 1-6 alkyl or C 3-7 cycloalkyl
  • R 9 is selected from C 1-6 alkyl, C 3-7 cycloalkyl or 4-7 membered heterocyclyl 25 comprising 1-2 heteroatoms selected from N, O and S, wherein the C 1- alkyl or C 3-7 cycloalkyl is optionally substituted with halogen or -OR 8 , and wherein the 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R 8 , -C(0)R 8 , -C(0)OR 8 , or C(0)NHR 8 ;
  • R 10 is Ci-6 alkyl, C 3-7 cycloalkyl, or (CH 2 ) n NR 9 R 9 , wherein each n is independently 0 1 or 2;
  • said 3-8 5 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons (e.g., at one, two, or three carbon atoms) with halogen, hydroxyl, -OR 8 , -NR 9 R 10 , or -NR 1 ! R 12 ; or
  • heteroatoms in addition to the nitrogen atom to which R and R are bonded, 0 wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms (e.g., at one, two, or three carbon or nitrogen atoms) with -R 8 , -C(0)R 8 , -C(0)OR 8 , - C(0)NHR 8 , -S0 2 R 8 , -SO2NH2, or -S0 2 NR 8 2 ; and
  • R 13 is selected from halogen, CN, CF 3 , R 8 , -OR 8 or C 2-4 alkenyl;
  • R is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR 9 R 10 , NR n R 12 , or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R 13 ; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R 8 ;
  • R 4 is hydrogen, C 1-4 alkyl, C 3-5 cycloalkyl, F, CI, Br, CN, or CF 3 ;
  • R 5 is hydrogen, CF 3; C 1-6 alkyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R ;
  • R 6 is hydrogen or C 1-6 alkyl
  • R 7 is hydrogen, -CH 2 OH, -CH 2 OR 8 , C1.3 alkyl, (CH 2 ) n NR 9 R 10 , (CH 2 ) complicatNR 11 R 12 , C(0)NR 9 R 10 , or C(0)NR 1 R 12 , wherein each n is independently 1 or 2;
  • R is selected from C 1-6 alkyl or C 3-7 cycloalkyl
  • R 9 is selected from C 1-6 alkyl, C 3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the C 1-6 alkyl or C 3-7 cycloalkyl is optionally substituted with halogen or -OR , and wherein 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R 8 , -C(0)R 8 , -C(0)OR 8 , or C(0)NHR 8 ;
  • R 10 is C 1- alkyl, C3 -7 cycloalkyl, or (CH 2 ) n NR 9 R 9 , wherein each n is independently
  • R 1 ⁇ and R 12 taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
  • a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms in addition to the nitrogen atom to which R 11 and R 12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms (e.g., at one, two, or three carbon or nitrogen atoms) with -R 8 , -C(0)R 8 , -C(0)OR 8 , - C(0)NHR 8 , -S0 2 R 8 , -S0 2 NH 2 , or -S0 2 NR 8 2 ; and
  • R 13 is selected from halogen, CN, CF 3 , R 8 , -OR 8 or C 2-4 alkenyl.
  • R 13 is selected from halogen, CN, CF 3 , R 8 , -OR 8 or C 2-4 alkenyl.
  • R 3 is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR 9 R 10 , NR H R 12 , or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R , and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R ;
  • R 4 is hydrogen, CM alkyl, C 3-5 cycloalkyl, F, CI, Br, CN, or CF 3 ;
  • R 5 is hydrogen, CF 3i Ci -6 alkyl, C 3 . 7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R 13 ;
  • R 6 is hydrogen or C 1-6 alkyl
  • R 7 is hydrogen, -CH 2 OH, -CH 2 OR 8 , d -3 alkyl, (CH 2 ) n NR 9 R 10 , (CH 2 ) n NR' R 12 ,
  • R is selected from C 1-6 alkyl or C 3-7 cycloalkyl
  • R 9 is selected from Cj -6 alkyl, C 3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the C 1-6 alkyl or C 3-7 cycloalkyl is optionally substituted with halogen or -OR 8 , and wherein 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R 8 , -C(0)R 8 , -C(0)OR 8 , or C(0)NHR 8 ;
  • R 10 is Ci-6 alkyl, C 3-7 cycloalkyl, or (CH 2 ) n NR 9 R 9 , wherein each n is independently
  • a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which R and R are bonded wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons (e.g., at one, two, or three carbon atoms) with halogen, hydroxyl, -OR 8 , -NR 9 R 10 , or -NR n R 12 ; or
  • a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms in addition to the nitrogen atom to which R u and R 12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen
  • R 13 is selected from halogen, CN, CF 3 , R 8 , -OR 8 or C 2-4 alkenyl.
  • R 1 is -OCH 3 ;
  • R 4 is H, -CH 3 , F, or CI;
  • R 5 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, pyridinyl, thiophenyl, furanyl, N-methyl pyrrolidinyl, N-methyl pyrazolyl, or phenyl;
  • R is methyl; and
  • n is 1.
  • R 2 is H;
  • R 6 is H;
  • R 3 is morpholino, N-methyl piperazinyl, piperidinyl, azetidinyl, pyrrodinyl, 4-acetylpiperidinyl, N,N-dimethylamino, l,4-oxazepan-4-yl, or 4-methyl-l,4,-diazepan-l-yl; and
  • R 7 is -(CH 2 )NR 9 R 10 or - (CH 2 )NR n R 12 .
  • R 9 is methyl, ethyl, propyl, cyclopropylmethyl, or cyclobutylmethyl; and R 10 is methyl, ethyl, propyl, cyclopropylmethyl, oxetanyl, oxethanemethyl, N-methyazetinyl, ⁇ , ⁇ -dimethylethyl, or methoxyethyl; and NR n R 12 is azetidinyl, 3-hydroxy azetidinyl, 3-methoxy azetidinyl, pyrrolidinyl, (S)-3-hydroxy pyrrolidinyl, (R)-3-hydroxy pyrrolidinyl, (3R,4S)-3,4-dihydroxypyrrolidinyl, (3S,4R)-3- hydroxy-4-methoxypyrrolidinyl, piperidinyl, morpholinyl, N-methylpiperazinyl, aza
  • R 5 is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl, 2-thiophenyl, 2-furanyl, 3-furanyl, 3-pyridyl, 4-pyridyl or phenyl.
  • R 7 is - (CH 2 )NR 9 R 10 or -(CH )NR n R 12 .
  • R 9 is methyl, ethyl, propyl, cyclopropylmethyl, or cyclobutylmethyl; and R 10 is methyl, ethyl, propyl, cyclopropylmethyl, oxetanyl, oxethanemethyl, N-methyazetinyl, ⁇ , ⁇ -dimethylethyl, or methoxyethyl; and NR n R 12 is azetidinyl, 3-hydroxy azetidinyl, 3-methoxy azetidinyl, pyrrolidinyl, (S)-3-hydroxy pyrrolidinyl, (R)-3-hydroxy pyrrolidinyl, (3R,4S)-3,4-dihydroxypyrrolidinyl, (3S,4R)-3- hydroxy-4-methoxypyrrolidinyl, piperidinyl morpholinyl, N-methylpiperazinyl, aza
  • X is CH or N
  • R 1 is H, R 8 or -OR 8 ;
  • R is hydrogen; C 1-6 alkyl; 6-10 membered monocyclic or bicyclic aryl; or 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the aryl or heteroaryl is optionally and independently substituted at one or more carbon atoms
  • heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R ;
  • R 4 is hydrogen, C 1-4 alkyl, C 3-5 cycloalkyl, F, CI, Br, CN, or CF 3 ;
  • R 5 is hydrogen, CF 3; C 1-6 alkyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R ;
  • R 7 is hydrogen, -CH 2 OH, -CH 2 OR 8 , C 1-3 alkyl, (CH 2 ) n NR 9 R 10 , (CH 2 ) n NR n R 12 , C(0)NR 9 R 10 , or C(0)NR n R 12 , wherein each n is independently 1 or 2;
  • R 8 is selected from C 1-6 alkyl or C 3-7 cycloalkyl
  • R 9 is selected from C 1-6 alkyl, C 3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the Ci -6 alkyl or C 3-7 cycloalkyl is optionally substituted with halogen or -OR 8 , and wherein the 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R 8 , -C(0)R 8 , -C(0)OR 8 , or C(0)NHR 8 ;
  • R 10 is C 1-6 alkyl, C 3-7 cycloalkyl, or (CH 2 ) felicitNR 9 R 9 , wherein each n is independently
  • a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms in addition to the nitrogen atom to which R 11 and R 12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms atoms is optionally substituted with -R , -C(0)R , -C(0)OR , -C(0)NHR 8 , -S0 2 R 8 , -S0 2 NH 2 , or -S0 2 NR 8 2 ; and
  • R 13 is selected from halogen, CN, CF 3 , R 8 , -OR 8 or C 2-4 alkenyl.
  • R is H; R is furanyl, thiophenyl, N-methyl pyrazolyl, or phenyl; R 4 is H, -CH 3 , F, or CI ; R 5 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, pyridinyl, thiophenyl, furanyl, N-methyl pyrrolyl, N-methyl pyrazolyl, or phenyl; and n is 1.
  • R 5 is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl, 2-thiophenyl, 2-furanyl, 3 -furanyl, 3-pyridyl, 4-pyridyl or phenyl.
  • R 7 is -(CH 2 )NR 9 R 10 or -(CH 2 )NR n R 12 .
  • R 9 is methyl, ethyl, propyl, cyclopropylmethyl, or cyclobutylmethyl; and R 10 is methyl, ethyl, propyl, cyclopropylmethyl, oxetanyl, oxethanemethyl, N-methyazetinyl, ⁇ , ⁇ -dimethylethyl, or methoxyethyl; and NR n R 12 is azetidinyl, 3 -hydroxy azetidinyl, 3-methoxy azetidinyl, pyrrolidinyl, (S)-3 -hydroxy pyrrolidinyl, (R)-3-hydroxy pyrrolidinyl, (3R,4S)-3,4-dihydroxypyrrolidinyl, (3S,4R)-3- hydroxy-4-methoxypyrrolidinyl, piperidinyl morpholinyl, N-methylpiperazinyl
  • R is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl, 2-thiophenyl, 2-furanyl, 3-furanyl, 3-pyridyl, 4-pyridyl or phenyl.
  • the compound is a compound described herein or a pharmaceutically acceptable salt thereof.
  • the invention provides a method of treating protein kinase- mediated disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention (such as a compound of Formula (I)) or a pharmaceutically acceptable salt thereof, that is effective in treating abnormal cell growth and immune disease.
  • a compound of the invention such as a compound of Formula (I)
  • a pharmaceutically acceptable salt thereof that is effective in treating abnormal cell growth and immune disease.
  • the invention provides a method of inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR, in biological sample or in a patient, comprising contacting the biological sample with or administering to the patient a compound according of the invention, or a composition thereof (e.g., a pharmaceutical composition comprising the compound of the invention and a pharmaceutically acceptable carrier).
  • the at least one mutant is Del E746-A750, L858R or T790M.
  • the at least one mutant is at least one double mutant selected from Del E746-A750/T790M or L858R/T790M.
  • the invention provides a method of inhibiting Janus kinase 3 (JAK3) selectively as compared to other kinases, in biological sample or in a patient, comprising contacting the biological sample with or administering to the patient a compound of the invention, or a composition thereof, that is effective in treating abnormal cell growth including leukemia and lymphoma (B-cell & T-cell) and immune diseases including arthritis, rheumatoid arthritis and autoimmune diseases.
  • JNK3 Janus kinase 3
  • the invention provides a use of a compound of the invention (such as a compound of Formula (I)) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating protein kinase-mediated disease. Further, the invention provides a use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR.
  • the invention provides a pharmaceutical composition for treating protein kinase-mediated disease, comprising a compound of the invention (such as a compound of Formula (I)) or a pharmaceutically acceptable salt thereof as active ingredients. Further, the invention provides a pharmaceutical composition for inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR, comprising a compound of the invention or a pharmaceutically acceptable salt thereof as active ingredients.
  • alkyl used alone or as part of a larger moiety such as “arylalkyl” or “cycloalkyl” refers to a straight or branched hydrocarbon radical having from 1 to 15 carbon atoms or from 1-8 carbon atoms (unless stated otherwise) and includes, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso- pentyl, n-hexyl and the like.
  • An alkyl can be unsubstituted or substituted with one or more suitable substituents.
  • cycloalkyl refers to a monocyclic or polycyclic hydrocarbon ring group and includes, for example, cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbornyl, cyclohexyl, cyclopentyl, and the like.
  • a cycloalkyl group can be unsubstituted or substituted with one or more suitable substituents.
  • hetero refers to the replacement of at least one carbon atom member in a ring system with at least one heteroatom such as nitrogen, sulfur, and oxygen.
  • heterocycloalkyl means a non-aromatic monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 4 heteroatoms selected from nitrogen, sulfur, oxygen, sulfone, or sulfoxide.
  • a heterocycloalkyl group can have one or more carbon-carbon double bonds or carbon- heteroatom double bonds in the ring group as long as the ring group is not rendered aromatic by their presence.
  • heterocycloalkyl groups include azetidinyl, aziridinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholino, thiomorpholino, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, pyranyl, and the like.
  • a heterocycloalkyl group can be unsubstituted or substituted with one or more suitable substituents.
  • halogen includes fluoro, chloro, bromo, and iodo.
  • alkoxy refers to the alkyl groups above bound through oxygen, examples of which include methoxy, ethoxy, iso-propoxy, tert-butoxy, and the like.
  • alkoxy also refers to polyethers such as -0-(CH 2 )2- O-CH3, and the like.
  • An alkoxy can be unsubstituted or substituted with one or more suitable substituents.
  • aryl refers to unsubstituted or substituted aromatic monocyclic or polycyclic groups and includes, for example, phenyl and naphthyl.
  • aryl also includes a phenyl ring fused to a non-aromatic carbocyclic or heterocyclic ring.
  • aryl may be interchangeably used with “aryl ring,” aromatic group,” and “aromatic ring.
  • Heteroaryl groups have 4 to 14 atoms, 1 to 9 of which are independently selected from the group consisting of oxygen, sulfur and nitrogen. Heteroaryl groups have 1-3 heteroatoms in a 5-8 membered aromatic group.
  • An aryl or heteroaryl can be a mono- or bicyclic aromatic group.
  • Typical aryl and heteroaryl groups include, for example, phenyl, quinolinyl, indazoyl, indolyl, dihydrobenzodioxynyl, 3-chlorophenyl, 2,6- dibromophenyl, pyridyl, pyrimidinyl, 3- methylpyridyl, benzothienyl, 2,4,6- tribromophenyl, 4-ethylbenzothienyl, furanyl, 3,4- diethylfuranyl, naphthyl, 4,7- dichloronaphthyl, pyrrole, pyrazole, imidazole, thiazole, and the like.
  • An aryl or heteroaryl can be unsubstituted or substituted with one or more suitable substituents.
  • haloalkyl refers to any alkyl radical having one or more hydrogen atoms replaced by a halogen atom.
  • examples of haloalkyl include - CF 3 , -CHF 2 , -CH 2 F, and the like.
  • hydroxyl or "hydroxy” refers to -OH.
  • amino refers to -NH 2 .
  • hydroxyalkyl refers to any hydroxyl derivative of alkyl radical.
  • hydroxyalkyl includes any alkyl radical having one or more hydrogen atoms replaced by a hydroxy group.
  • a "substituent” as used herein, refers to a molecular moiety that is covalently bonded to an atom within a molecule of interest.
  • a ring substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member.
  • Substituents of aromatic groups are generally covalently bonded to a ring carbon atom.
  • substitution refers to replacing a hydrogen atom in a molecular structure with a substituent, such that the valence on the designated atom is not exceeded, and such that a chemically stable compound (i.e., a compound that can be isolated, characterized, and tested for biological activity) results from the substitution.
  • certain groups can be unsubstituted or substituted with one or more suitable substituents other than hydrogen at one or more available positions, typically 1, 2, 3, 4 or 5 positions, by one or more suitable groups (which may be the same or different). Certain groups, when substituted, are substituted with 1, 2, 3 or 4 independently selected substituents. Suitable substituents include halogen, alkyl, haloalkyl, aryl, hydroxy, alkoxy, hydroxyalkyl, amino, and the like.
  • the invention also provides (i) a method of preparing a compound of formula (c) by reacting a compound of formula (a) with a compound of formula (b) in the presence of the first base in the first organic solvent (see Scheme 1); (ii) a method of preparing a compound of formula (e) by reacting the compound of formula (c) with heteroaryl intermediates (d) in the presence of the second base, in the second organic solvent (see Scheme 1); (iii) a method of preparing a compound of formula (f) by reductive amination of the compound of formula (e) and an amine derivatives by using a reducing agent in the third solvent (see Scheme 1); (iv) a method of preparing a compound of Formula (I) by reduction of the compound of formula (f) by using a reducing agent in the fourth solvent and followed by amide formation in the presence of acryloyl chloride, the third base in the fifth solvent (see Scheme 1).
  • the invention also provides a method of preparing a compound of
  • the invention also provides a method of preparing a compound of formula (e) by reaction of the compound of formula (h) with aniline intermediates (g) in the presence of the fourth base in the first solvent, a ligand, a palladium catalyst in the first organic solvent (see Scheme 2).
  • the invention also provides a method of preparing a compound of Formula (I) according to Scheme 2.
  • the invention also provides (i) a method of preparing a compound of formula (j) -from the compound of formula (i) with aniline intermediates (g) with the procedure as described in WO2013/109882 Al ; (ii) a method of preparing a compound of formula (j) from the compound of formula (j) by oxidation with mCPBA or Oxone ® as described in WO2013/109882 Al; (iii) a method of preparing the compound of formula (e) from a compound of formula (k) by reaction with the compound of formula (d) in the presence of the second base in the second organic solvent (see Scheme 3).
  • the invention also provides a method of preparing a compound of Formula (I) according to Scheme 3.
  • the first organic solvent is generally selected from relatively polar, aprotic solvents such as acetone, tetrahydrofuran, N,N- dimethylformamide, ⁇ , ⁇ -dimethylacetamide, dichloromethane, dichloroethane, or acetonitrile
  • the second organic solvent is generally selected from aprotic solvents such as toluene, dioxane, tetrahydrofuran, N,N-dimethylformamide, ⁇ , ⁇ -dimethylacetamide or N- methylmorpholine
  • the third organic solvent is generally selected from relatively polar, solvents such as tetrahydrofuran, methanol, ethanol, dichloromethane, dichloroethane, N,N-dimethylacetamide or ⁇ , ⁇ -dimethylformamide
  • the fourth solvent is generally selected from relatively polar, protic solvents such as
  • the first and the second bases are generally selected from bases such as K 2 C0 3 , Cs 2 C0 3 , NaOH, KOH, NaH, tert-BuOK, ter-BuONa, triethylamine, or diisopropylethylamine;
  • the third base is generally selected from bases such as triethylamine, diisopropylethylamine, NaH, NaHC0 3 , tert- BuOK, tert-BuONa, Cs 2 C0 3j or K 2 C0 3 ;
  • the fourth base is selected generally from bases such as NaH, n-BuLi, Cs 2 C0 3 , triethylamine, or diisopropylethylamine;
  • a palladium catalyst is generally selected from Pd(OAc) 2 , Pd 2 (dba) 3 , Pd(PPh 3 ) 4 , or Pd(
  • cancer refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize.
  • types of cancer include, but is not limited to, solid tumors, such as those of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue (lymphoma), ovary, pancreas or other endocrine organ (thyroid), prostate, skin (melanoma) or hematological tumors (such as the leukemias).
  • EGFR mutation refers to mutation of T790M (resistant or oncogenic), L858R (activating), del E746-A750 (activating) or a combination thereof.
  • the invention selectively inhibits at one activating mutation and at one point mutation.
  • an at least one activating mutation is a deletion mutation, del E746-A750.
  • an at least one activating mutation is a point mutation L858R.
  • the at least one - resistant mutation is a point mutation, T790M.
  • the at least one mutation of EGFR is L858R and/or T790M.
  • mutant selective inhibition refers to the state that invention inhibits at least one mutation of EGFR (i.e. at least one deletion mutation, at least one activating mutation, at least one resistant mutation, or a combination of at least one deletion mutation and at least one point mutation) in at least one assay described herein (e.g., biochemical or cellular).
  • EGFR wildtype selectivity refers to that a selective inhibitor of at least one mutation of EGFR, as defined and described above and herein, inhibits EGFR at the upper limit of detection of at least one assay as described herein (e.g. cellular as described in detail in Table 1 and Table 2).
  • EGFR wildtype selectivity means that the invention inhibits WT EGFR with an IC50 of at least 200-1000nM or > lOOOnM.
  • the term “inhibitor” refers to a compound which inhibits one or more kinase described herein.
  • EGFR mutant inhibitor refers to a compound which inhibits the EGFR mutant receptor or reduces the signaling effect.
  • the term "pharmaceutically acceptable” refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compounds described herein. Such materials are administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • the term "pharmaceutically acceptable salt” refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compounds described herein.
  • the term "pharmaceutical combination” means a product that results from the mixing or combining of more than one active ingredient.
  • the term "pharmaceutical composition” refers to a mixture of a compound described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
  • prodrug refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. Prodrugs are bio-available by oral administration whereas the parent is not. Prodrugs improve solubility in pharmaceutical compositions over the parent drug.
  • a non-limiting example of a prodrug of the compounds described herein is a compound described herein administered as an ester which is then metabolically hydrolyzed to a carboxylic acid, the active entity, once inside the cell.
  • a further example of a prodrug is a short peptide bonded to an acid group where the peptide is metabolized to reveal the active moiety.
  • protein kinase-mediated disease or a "disorder or disease or condition mediated by inappropriate protein kinase activity” refers to any disease state mediated or modulated by protein kinases described herein.
  • disease states include, but are not limited to non-small cell lung cancer (NSCLC).
  • EGFR mutant-mediated disease or a "disorder or disease or condition mediated by inappropriate EGFR activity” refers to any disease state mediated or modulated by EGFR mutant kinase mechanisms.
  • disease states include, but are not limited to NSCLC, metastatic brain cancer and other solid cancers.
  • J AK3 -mediated disease or a "disorder or disease or condition mediated by inappropriate JAK3 activity” refers to any disease state mediated or modulated by JAK3 kinase mechanisms.
  • disease states include, but are not limited to rheumatoid arthritis, psoriasis and organ transplant rejection and some solid cancers.
  • the term "treat,” “treating” or “treatment” refers to methods of alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of Formula (I) or a pharmaceutically acceptable salt thereof) and a solvent.
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • suitable solvents include water, acetone, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid.
  • the term "subject” or “patient” encompasses mammals and non- mammals.
  • mammals include, but are not limited to, humans, chimpanzees, apes monkeys, cattle, horses, sheep, goats, swine; rabbits, dogs, cats, rats, mice, guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish and the like.
  • administering refers to providing a compound of the invention and/or prodrugs thereof to a subject in need of treatment.
  • carrier refers to chemical compounds or agents that facilitate the incorporation of a compound described herein into cells or tissues.
  • co-administration or “combined administration” or the like as used herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • the term "acceptable" with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
  • dilute refers to chemical compounds that are used to dilute a compound described herein prior to delivery. Diluents can also be used to stabilize compounds described herein.
  • an "effective amount” or “therapeutically effective amount” refer to a sufficient amount of a compound described herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an "effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms.
  • An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.
  • a therapeutically effective amount of a compound of the invention may be in the range of e.g., about 0.01 mg/kg/day to about 100 mg/kg/day, or from about 0.1 mg/kg/day to about 10 mg/kg/day.
  • kinases include, but are not limited to EGFR and JAK3 (JH1 domain- catalytic) kinases, and mutant forms thereof.
  • the compounds and compositions of the invention are useful for treating diseases or disorders in which such kinases contribute to the pathology and/or symptomology of a disease or disorder associated with or mediated by such kinase.
  • diseases are associated with abnormal cellular responses triggered by protein kinase mediated events. These diseases include, but are not limited to, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, respiratory diseases, allergies and asthma, Alzheimer's disease, and hormone related diseases.
  • Aberrant or excessive PTK activity has been observed in many disease states such as benign and malignant proliferative disorders, diseases resulting from inappropriate activation of the immune system and diseases resulting from inappropriate activation of the nervous systems.
  • Specific diseases or conditions include, but are not limited to, allograft rejection, graft vs.
  • the epidermal growth factor receptor (EGFR; ErbB-1 ; HER1 in human) is the cell- surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands.
  • the epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
  • EGFR exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor a (TGF ). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer . In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. ErbB2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon hetero- dimerization with other family members such as EGFR.
  • EGFR The dimerization of EGFR stimulates its intrinsic intracellular protein-tyrosine kinase activity.
  • This autophosphorylation elicits downstream activation and signaling by several other proteins that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains.
  • These downstream signaling proteins initiate several signal transduction cascades, principally the MAPK, Akt and JNK pathways, leading to DNA synthesis and cell proliferation.
  • Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation.
  • Activation of the receptor is important for the innate immune response in human skin.
  • the kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in that manner.
  • EGFR overexpression known as upregulation
  • overactivity have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforms. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division. In glioblastoma a more or less specific mutation of EGFR, called EGFRvIII is often observed. Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers.
  • NSCLC non-small cell lung carcinoma
  • EGFR epidermal growth factor receptor
  • EGFR mutations occur in 10- 15% of NSCLC patients of Caucasian descent and 30-35% of NSCLC patients of East Asian descent. Clinical features likely to be associated with EGFR mutations are non- smoker and of East Asian ethnicity.
  • Brain metastases are the most common intracranial neoplasm, occurring in 8-10% of cancer patients, and are a significant cause of cancer-related morbidity and mortality worldwide
  • NSCLC non-small cell lung cancer
  • the compounds described herein are inhibitors of EGFR mutant kinase activity and have therapeutic benefit in the treatment of disorders associated with inappropriate EGFR mutant activity, in particular in the treatment and prevention of disease states mediated by EGFR mutant.
  • disease states include NSCLC, breast cancer, metastatic brain cancer and other solid cancers.
  • the compounds, compositions and methods of the present invention provides methods of regulating, and in particular inhibiting, signal transduction cascades in which EGFR mutant(s) plays a role.
  • the method generally involves contacting a EGFR mutant- dependent receptor or a cell expressing a EGFR mutant -dependent receptor with an amount of a compound described herein, or prodrug a compound described herein, or an acceptable salt, hydrate, solvate, N-oxide and/or composition thereof, effective to regulate or inhibit the signal transduction cascade.
  • the methods are used to regulate, and in particular inhibit, downstream processes or cellular responses elicited by activation of the particular EGFR mutant-dependent signal transduction cascade.
  • the methods are practiced to regulate any signal transduction cascade where EGFR mutant is not known or later discovered to play a role.
  • the methods are practiced in in vitro contexts or in in vivo contexts as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by or associated with activation of the EGFR mutant-dependent signal transduction cascade.
  • Janus kinase 3 is a tyrosine kinase that belongs to the Janus family of kinases. Other members of the Janus family include JAK1, JAK2 and TYK2. They are cytosolic tyrosine kinases that are specifically associated with cytokine receptors. Since cytokine receptor proteins lack enzymatic activity, they are dependent upon JAKs to initiate signaling upon binding of their ligands (e.g. cytokines). The cytokine receptors can be divided into five major subgroups based on their different domains and activation motifs. JAK3 is required for signaling of the type I receptors that use the common gamma chain (yc).
  • yc common gamma chain
  • JAK3 In contrast to the relatively ubiquitous expression of JAK1, JAK2 and Tyk2, JAK3 is predominantly expressed in hematopoietic lineage such as NK cells, T cells and B cells and intestinal epithelial cells. JAK3 functions in signal transduction and interacts with members of the STAT (signal transduction and activators of transcription) family. JAK3 is involved in signal transduction by receptors that employ the common gamma chain (yc) of the type I cytokine receptor family (e.g. IL-2R, IL-4R, IL-7R, IL-9R, IL- 15R, and IL-21 R). Mutations of JAK3 result in severe combined immunodeficiency (SCID). Mice that do not express JAK3 have T-cells and B-cells that fail to respond to many cytokines.
  • SCID severe combined immunodeficiency
  • JAK3 Since JAK3 is required for immune cell development, targeting JAK3 could be a useful strategy to generate a novel class of immunosuppressant drugs. Moreover, unlike other JAKs, JAK3 is primarily expressed in hematopoietic cells, so a highly specific JAK3 inhibitor should have precise effects on immune cells and minimal pleiotropic defects. The selectivity of a JAK3 inhibitor would also have advantages over the current widely used immunosuppressant drugs, which have abundant targets and diverse side effects. A JAK3 inhibitor could be useful for treating autoimmune diseases, especially those in which a particular cytokine receptor has a direct role on disease pathogenesis. For example, signaling through the IL-15 receptor is known to be important in the development rheumatoid arthritis, and the receptors for IL-4 and IL-9 play roles in the development of allergic responses.
  • N nasal-type natural killer (N )/T-cell lymphoma
  • NKCL nasal-type natural killer (N )/T-cell lymphoma
  • STAT3 signal transducer and activator of transcription 3
  • JAK3 activation mostly results from constitutive Janus kinase 3(JAK3) phosphorylation on tyrosine 980, as observed in three of the four tested NKCL cell lines and in 20 of the 23 NKCL tumor samples.
  • constitutive JAK3 activation was related to an acquired mutation (A573V or V722I) in the JAK3 pseudokinase domain.
  • JAK3/STAT3 pathway constitutive activation of the JAK3/STAT3 pathway has a major role in NKCL cell growth and survival and in the invasive phenotype.
  • NKCL cell growth was slowed down in vitro by targeting JAK3 with chemical inhibitors or small-interfering RNAs.
  • JAK3 In a human NKCL xenograft mouse model, tumor growth was significantly delayed by the J AK3 inhibitor. Therefore, the constitutive activation of JAK3, which can result from J AK3 -activating mutations, is a frequent feature of NKCL so that it could be therapeutic target.
  • the compounds described herein are inhibitors of JAK3 kinase activity and have therapeutic benefit in the treatment of disorders associated with inappropriate JAK3 activity, in particular in the treatment and prevention of disease states mediated by JAK3.
  • disease states include rheumatoid arthritis, psoriasis and organ transplant rejection, lymphoma and some solid cancers.
  • compositions which comprise at least one compound provided herein, including at least one compound of Formula (I), pharmaceutically acceptable salts and/or solvates thereof, and one or more pharmaceutically acceptable carriers, diluents, adjuvant or excipients.
  • such compounds and compositions are administered singly or in combination with one or more additional therapeutic agents.
  • the methods of administration of such compounds and compositions include, but are not limited to, intravenous administration, inhalation, oral administration, rectal administration, parenteral, intravitreal administration, subcutaneous administration, intramuscular administration, intranasal administration, dermal administration, topical administration, ophthalmic administration, buccal administration, tracheal administration, bronchial administration, sublingual administration or optic administration.
  • Compounds provided herein are administered by way of known pharmaceutical formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, lotions, gels, ointments or creams for topical administration, and the like.
  • the therapeutically effective amount will vary depending on, among others, the disease indicated, the severity of the disease, the age and relative health of the subject, the potency of the compound administered, the mode of administration and the treatment desired.
  • the required dosage will also vary depending on the mode of administration, the particular condition to be treated and the effect desired.
  • Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • Pharmaceutically acceptable acidic/anionic salts include acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphosphate, polygalactu
  • Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, N-methyl-D-glucamine, L-lysine, L- arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
  • a pharmaceutically acceptable acid salt is formed by reaction of the free base form of a compound of Formula (I) with a suitable inorganic or organic acid including, but not limited to, hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, formic, acetic, propionic, fumaric, citric, tartaric, lactic, benzoic, salicylic, glutamic, aspartic, p- toluenesulfonic, benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2-naphthalenesulfonic, or hexanoic acid.
  • a suitable inorganic or organic acid including, but not limited to, hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, formic, acetic, propionic, fumaric, citric, tartaric, lactic, benzo
  • a pharmaceutically acceptable acid addition salt of a compound of Formula (I) can comprise or be, for example, a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, formarate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, naphthalenesulfonate (e.g., 2- naphthalenesulfonate) or hexanoate salt.
  • the free acid or free base forms of the compounds of the invention may be prepared from the corresponding base addition salt or acid addition salt form, respectively.
  • a compound of the invention in an acid addition salt form may be converted to the corresponding free base form by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
  • a compound of the invention in a base addition salt form may be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.).
  • a suitable acid e.g., hydrochloric acid, etc.
  • Prodrug derivatives of the compounds of the invention may be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al, Bioorg. Med. Chem. Letters, 1994, 4, 1985; the entire teachings of which are incorporated herein by reference).
  • Protected derivatives of the compounds of the invention may be prepared by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, "Protecting Groups in Organic Chemistry," 3rd edition, John Wiley and Sons, Inc., 1999, the entire teachings of which are incorporated herein by reference.
  • Compounds of the invention may be prepared as their individual stereoisomers by reaction of a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
  • Resolution of enantiomers may be carried out using covalent diastereomeric derivatives of the compounds of the invention, or by using dissociable complexes (e.g., crystalline diastereomeric salts).
  • Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and may be readily separated by taking advantage of these dissimilarities.
  • the diastereomers may be separated by chromatography, or by separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • Suitable pharmaceutically acceptable carriers, diluents, adjuvants, or excipients for use in the pharmaceutical compositions of the invention include tablets (coated tablets) made of for example collidone or shellac, gum Arabic, talc, titanium dioxide or sugar, capsules (gelatin), solutions (aqueous or aqueous ethanolic solution), syrups containing the active substances, emulsions or inhalable powders (of various saccharides such as lactose or glucose, salts and mixture of these excipients with one another) and aerosols (propellant-containing or -free inhale solutions).
  • tablets coated tablets
  • collidone or shellac made of for example collidone or shellac, gum Arabic, talc, titanium dioxide or sugar, capsules (gelatin), solutions (aqueous or aqueous ethanolic solution), syrups containing the active substances, emulsions or inhalable powders (of various saccharides such as lactose or glucose, salts and mixture of
  • Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g., petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g., ethanol or glycerol), carriers such as natural mineral powders (e.g., kaoline, clays, talc, chalk), synthetic mineral powders (e.g., highly dispersed silicic acid and silicates), sugars (e.g., cane sugar, lactose and glucose), emulsifiers (e.g., lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g., magnesium stearate, talc, stearic acid and sodium lauryl sulphate).
  • paraffins e.g., petroleum fractions
  • vegetable oils e.g. groundnut or sesame oil
  • Compounds of Formula (I) can be made according to a variety of methods, some of which are known in the art. For example, the methods disclosed in PCT Publication WO2011/060295 (incorporated herein by reference) can be used, with suitable modifications, to prepare compounds according to the present invention. Exemplary methods for preparing the compounds of the invention are described herein, including in the Examples.
  • compounds of Formula (I) are made by: (a) optionally converting a compound of the invention into a pharmaceutically acceptable salt; (b) optionally converting a salt form of a compound of the invention to a non-salt form; (c) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide; (d) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers; (e) optionally converting a non- derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and (f) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.
  • the mobile phase uses solvent A (water/0.1 % formic acid) and solvent B (acetonitrile/0.1 % formic acid): 95 %/5 % to 0 %/100 % (A/B) for 5 minute.
  • Step 1
  • N-(2-methoxy-5-nitrophenyl)formamide (0.30 g, 1.53 mmol) in 4 mL of THF and DMF mixture (1 :1) was added 122.4 mg of NaH (60%, 3.06 mmol) at 0 °C.
  • N- Formamide was prepared from 2-methoxy-5-nitroaniline with formic acid by the known procedure described in PCT Int, Appl. 2006102642. The resulting slurry was warmed to rt and stirred for 30 min and cooled again to 0 °C.
  • Step 1 Guanidine nitrate (1.22 g, 10.00 mmol) was added portionwise to a cooled mixture of 4- bromo-2-methoxyaniline (2.02 g, 10.00 mmol) in 85% sulfuric acid (15.68 mL, 250.00 mmol). The resulting blue mixture was stirred for 45 min at 0 °C and was slowly poured over a well-stirred mixture of IN NaOH (40 mL) and ice (120 g). The aqueous layer was extracted with ethyl acetate and the organic layer was concentrated in vacuo.
  • Step 1
  • Example 135 Compound 135: N-f2-f4-acetylpiperazin-l-yl)-5-(4-(4-((dimethylamino)methyl)-3- phenyl-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxyphenvnacrylamide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

Description

DESCRIPTION
COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT
KINASE ACTIVITIES
FIELD OF THE INVENTION
The present invention relates to novel chemical compounds and pharmaceutically acceptable compositions thereof which display inhibition activity against certain mutated forms of EGFR.
BACKGROUND OF THE INVENTION
Protein kinases catalyze the transfer of the terminal phosphate from ATP or GTP to the hydroxyl group of tyrosine, serine and/or threonine residues of proteins. Protein kinases are categorized into families by the substrates they phosphorylate, for example, protein tyrosine kinases (PTK), and protein serine/threonine kinases. Phosphorylation via protein kinase(s) results in a functional change of the target protein (substrate) by changing enzyme activity, cellular location or association with other proteins. Protein kinases play vital role in variety of cellular processes; cell proliferation, cell survival, metabolism, carbohydrate utilization, protein synthesis, angiogenesis, cell growth and immune response.
Misregulation of the protein kinases has been implicated in numerous diseases and disorders such as central nervous system disorders (e.g., Alzheimer's disease), inflammatory and autoimmune disorders (e.g., asthma, rheumatoid arthritis, Crohn's disease, and inflammatory bowel syndrome, and psoriasis), bone diseases (e.g., osteoporosis), metabolic disorders (e.g., diabetes), blood vessel proliferative disorders, ocular diseases, cardiovascular disease, cancer, restenosis, pain sensation, transplant rejection and infectious diseases.
Among them, overexpression and misregulation of EGFR is commonly found in breast, lung, pancreas, head and neck, as well as bladder tumors. EGFR is a transmembrane protein tyrosine kinase member of the erbB receptor family. Upon binding of a growth factor ligand such as epidermal growth factor (EGF), the receptor can dimerize with EGFR or with another family member such as erbB2 (HER2), erbB3 (HER3) and erbB4 (HER4). The dimerization of erbB receptors leads to the phosphorylation of key tyrosine residues in the intracellular domain and sequentially to stimulation of numerous intracellular signal transduction pathways involved in cell proliferation and survival. Misregulation of erbB family signaling promotes proliferation, invasion, metastasis, angiogenesis, and tumor survival and has been described in many human cancers such as lung and breast.
Therefore, the erbB family is a rational target for anticancer drug development and a number of compounds targeting EGFR or erbB2 are now clinically available, including gefitinib (IRESSA™) and erlotinib (TARCEVA™), the first generation inhibitor. It was reported that the most common EGFR activating mutations, L858R and del E746-A750 were sensitive to treatment of gefitinib or erlotinib but ultimately acquired resistance to therapy with gefitinib or erlotinib arises predominantly by mutation of the gatekeeper residue T790M, which is detected in approximately half of clinically resistant patients, resulting in double mutants, L858R/T790M and del E746-A750/T790M.
Biological and clinical importance of EGFR mutants has been recognized in the field and several second generation drugs such as BIBW2992 (Afatinib), HKI-272 and PF0299804 are in development and effective against the T790M resistance mutation but show concurrent strong inhibition of wildtype (WT) EGFR, which causes severe adverse effect. Therefore, a strong need still exists for compounds which potently inhibit EGFR single and double mutants as well as are selective over WT EGFR to provide an effective and safe clinical therapy for the diseases associated with or mediated by EGFR mutants.
Another example of misregulation of the protein kinases that has been implicated in numerous diseases and disorders is Janus kinase (JAK) 3. In contrast to the relatively ubiquitous expression of Janus family member, JAK1, JAK2 and Tyk2, JAK3 is predominantly expressed in hematopoietic lineage such as NK cells, T cells and B cells and intestinal epithelial cells. Targeting JAK3 could be a useful strategy to generate a novel class of immunosuppressant drugs. Due to primary expression in hematopoietic cells, so a highly selective JAK3 inhibitor should have precise effects on immune cells and minimal pleiotropic defects. The selectivity of a JAK3 inhibitor would also have advantages over the current widely used immunosuppressant drugs, which have abundant targets and diverse side effects. A JAK3 inhibitor could be useful for treating autoimmune diseases, and JAK3 mediated leukemia and lymphoma.
For example, somatic mutations of JAK3 were also identified in a minority of acute megakaryoblastic leukaemia (AMKL) patients both in Down syndrome children and non- Down syndrome adults, and in a patient with acute lymphoblastic leukaemia. In addition, JAK3 activation was identified in several lymphoproliferative disorders, including mantle cell lymphoma, Burkitt's lymphoma, human T-cell leukemia lymphoma, virus- 1 -induced adult T-cell lymphoma/leukemia and anaplastic large cell lymphoma. It was shown that constitutive activation of the JAK3/STAT pathway has a major role in leukemia and lymphoma cell growth and survival and in the invasive phenotype. Therefore, the constitutive activation of JAK3, which can result from J AK3 -activating mutations, is a frequent feature of several leukemia and lymphoma so that selective inhibition of JAK3 could be therapeutic target. Therefore, a strong need exists for compounds which selectively and potently inhibit JAK3 wildtype and mutants as well as are selective over other JAK family members to provide an effective and safe clinical therapy for the diseases associated with or mediated by J AK3.
A need also exists for methods of administering such compounds, pharmaceutical formulations and medicaments to patients or subjects in need thereof.
SUMMARY OF THE INVENTION
The present invention relates to novel chemical compounds and pharmaceutically acceptable compositions thereof which display inhibition activity against certain mutated forms of EGFR.
The invention provides pyrimidine derivatives represented by Formula (I) and their use for the treatment or prevention of a number of different cancers associated with one or more EGFR mutations.
Such compounds have general Formula (I) as well as pharmaceutically acceptable salts, diastereomers, enantiomers racemates, hydrates or solvates thereof,
Figure imgf000004_0001
I
wherein:
X is CH or N;
R1 is H, R8 or -OR8;
R2 is hydrogen, C1-6 alkyl, 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the aryl or heteroaryl is optionally and independently substituted at one or more carbon atoms with R13; and wherein the heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R ;
R3 is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR9R10, NRnR12, or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R13; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3j C1-6 alkyl, C3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
R6 is hydrogen or C1-6 alkyl;
R7 is hydrogen, -CH2OH, -CH2OR8, C1-3 alkyl, (CH2)nNR9R10, (CH2)nNRnR12, C(O)NR9R10, or C(O)NR1 !R12, wherein each n is independently 1 or 2;
R8 is selected from C1-6 alkyl or C3-7 cycloalkyl;
R9 is selected from C1-6 alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the Ci-6 alkyl or C3- cycloalkyl is optionally substituted with halogen or -OR , and wherein the 4-7 membered o heterocyclyl having one nitrogen atom is optionally and independently substituted with -R , -C(0)R8, -C(0)OR8, or C(0)NHR8;
R10 is C1-6 alkyl, C3.7 cycloalkyl, or (CH2)nNR9R9, wherein each n is independently l or 2;
1 1 1
R and R , taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which R11 and R12 are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons (e.g., at one, two, or three carbon atoms) with halogen, hydroxyl, -OR8, -NR9R10, or -NRnR12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1
1 1 1
or 2 heteroatoms, in addition to the nitrogen atom to which R and R are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms (e.g., at one, two, or three carbon or nitrogen atoms) with -R , -C(O)R , -C(O)OR , - C(0)NHR8, -SO2R8, -SO2NH2, or -SO2NR8 2; and
R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl;
or a pharmaceutically acceptable salt thereof.
The present invention also relates to compositions comprising these compounds, methods of making these compounds, methods of inhibiting enzyme activity, particularly one or more EGFR mutant and JA 3 kinase activity, through use of these compounds, and a method of treating disease or disease symptoms in a mammal, particularly where inhibition of the kinase activity, can affect disease outcome. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows visualization of Western blots showing the results of inhibition of phosphorylation level of mutant EGFR as compared to wildtype EGFR.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a group of aminopyrimidine derivatives and pharmaceutically acceptable salts thereof that are useful for inhibiting one or more protein kinases and for treating diseases and disorders that are mediated by the protein kinase, for example, cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease, and neurodegenerative disease and disorder. The present invention also provides methods for synthesizing and administering the aminopyrimidine derivatives. The present invention also provides pharmaceutical formulations comprising at least one of the compounds of Formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during syntheses of the aminopyrimidine derivative compounds.
The present invention provides compositions and methods for modulating the activity of the epidermal growth factor receptor (EGFR) mutants and/or Janus kinase 3 (JAK3). In one aspect, the invention provides compounds which act as inhibitors of EGFR mutants or J AK3.
In a first embodiment, provided herein is a compound of Formula (I), individual stereoisomer, or mixture of isomers.
Figure imgf000006_0001
I
wherein: X is CH or N;
R1 is H, R8 or -OR8;
R2 is hydrogen, C1-6 alkyl, 6-10 membered monocyclic or bicyclic aryl, or 5-10 - - membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the 5 aryl or heteroaryl is optionally and independently substituted at one or more carbon atoms
* 13
with R ; and wherein the heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
R is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered 10 heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR9R10, NRnR12, or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R13; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
15 R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3, C1-6 alkyl, C3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
20 R6 is hydrogen or C1-6 alkyl;
R7 is hydrogen, -CH2OH, -CH2OR8, C1-3 alkyl, (CH2)nNR9R10, (CH2)nNRnR12, C(0)NR9R10, or C(0)NRuR12, wherein each n is independently 1 or 2;
R is selected from C1-6 alkyl or C3-7 cycloalkyl;
R9 is selected from C1-6 alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl 25 comprising 1-2 heteroatoms selected from N, O and S, wherein the C1- alkyl or C3-7 cycloalkyl is optionally substituted with halogen or -OR8, and wherein the 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R8, -C(0)R8, -C(0)OR8, or C(0)NHR8;
R10 is Ci-6 alkyl, C3-7 cycloalkyl, or (CH2)nNR9R9, wherein each n is independently 0 1 or 2;
1 1 1
R and R , taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no
1 1 19
heteroatom other than the nitrogen atom to which R and R are bonded, wherein said 3-8 5 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons (e.g., at one, two, or three carbon atoms) with halogen, hydroxyl, -OR8, -NR9R10, or -NR1 !R12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1
1 1 1
or 2 heteroatoms , in addition to the nitrogen atom to which R and R are bonded, 0 wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms (e.g., at one, two, or three carbon or nitrogen atoms) with -R8, -C(0)R8, -C(0)OR8, - C(0)NHR8, -S02R8, -SO2NH2, or -S02NR8 2; and
R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl;
or a pharmaceutically acceptable salt thereof.
In a second embodiment, provided herein is a compound of Formula (II) or pharmaceutically acceptable salt thereof;
Figure imgf000008_0001
II
wherein:
R is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR9R10, NRnR12, or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R13; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3; C1-6 alkyl, C3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R ;
R6 is hydrogen or C1-6 alkyl;
R7 is hydrogen, -CH2OH, -CH2OR8, C1.3 alkyl, (CH2)nNR9R10, (CH2)„NR11R12, C(0)NR9R10, or C(0)NR1 R12, wherein each n is independently 1 or 2;
R is selected from C1-6 alkyl or C3-7 cycloalkyl;
R9 is selected from C1-6 alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the C1-6 alkyl or C3-7 cycloalkyl is optionally substituted with halogen or -OR , and wherein 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R8, -C(0)R8, -C(0)OR8, or C(0)NHR8;
R10 is C1- alkyl, C3-7 cycloalkyl, or (CH2)nNR9R9, wherein each n is independently
1 or 2;
R1 ·· and R12, taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which Ru and R12 are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons (e.g., at one, two, or three carbon atoms) with halogen, hydroxyl, -OR8, -NR9R10, or -NR1 *R12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms , in addition to the nitrogen atom to which R11 and R12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms (e.g., at one, two, or three carbon or nitrogen atoms) with -R8, -C(0)R8, -C(0)OR8, - C(0)NHR8, -S02R8, -S02NH2, or -S02NR8 2; and
R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl. In a third embodiment, provided herein is a compound of Formula (III) or pharmaceutically acceptable salt thereof:
wherein:
R3 is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR9R10, NRHR12, or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R , and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R ;
R4 is hydrogen, CM alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3i Ci-6 alkyl, C3.7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
R6 is hydrogen or C1-6 alkyl;
R7 is hydrogen, -CH2OH, -CH2OR8, d-3 alkyl, (CH2)nNR9R10, (CH2)nNR' R12,
C(0)NR9R10, or C(0)NRnR12, wherein each n is independently 1 or 2;
R is selected from C1-6 alkyl or C3-7 cycloalkyl;
R9 is selected from Cj-6 alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the C1-6 alkyl or C3-7 cycloalkyl is optionally substituted with halogen or -OR8, and wherein 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R8, -C(0)R8, -C(0)OR8, or C(0)NHR8;
R10 is Ci-6 alkyl, C3-7 cycloalkyl, or (CH2)nNR9R9, wherein each n is independently
1 or 2;
R11 and R12, taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which R and R are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons (e.g., at one, two, or three carbon atoms) with halogen, hydroxyl, -OR8, -NR9R10, or -NRnR12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms , in addition to the nitrogen atom to which Ru and R12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen
o atoms (e.g., at one, two, or three carbon or nitrogen atoms) with -R , -C(0)R , -C(0)OR , - C(0)NHR8, -S02R8, -S02NH2, or -S02NR8 2; and
R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl.
In certain embodiments of the compounds of Formula (I), (II), or (III), R1 is -OCH3; R4 is H, -CH3, F, or CI; R5 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, pyridinyl, thiophenyl, furanyl, N-methyl pyrrolidinyl, N-methyl pyrazolyl, or phenyl; R is methyl; and n is 1.
In certain further embodiments, R2 is H; R6 is H; R3 is morpholino, N-methyl piperazinyl, piperidinyl, azetidinyl, pyrrodinyl, 4-acetylpiperidinyl, N,N-dimethylamino, l,4-oxazepan-4-yl, or 4-methyl-l,4,-diazepan-l-yl; and R7 is -(CH2)NR9R10 or - (CH2)NRnR12.
In further embodiments, R9 is methyl, ethyl, propyl, cyclopropylmethyl, or cyclobutylmethyl; and R10 is methyl, ethyl, propyl, cyclopropylmethyl, oxetanyl, oxethanemethyl, N-methyazetinyl, Ν,Ν-dimethylethyl, or methoxyethyl; and NRnR12 is azetidinyl, 3-hydroxy azetidinyl, 3-methoxy azetidinyl, pyrrolidinyl, (S)-3-hydroxy pyrrolidinyl, (R)-3-hydroxy pyrrolidinyl, (3R,4S)-3,4-dihydroxypyrrolidinyl, (3S,4R)-3- hydroxy-4-methoxypyrrolidinyl, piperidinyl, morpholinyl, N-methylpiperazinyl, azamorpholinyl, N-methylazapiperazinyl, N-acetyl piperazinyl, or thiomorpholinyl.
In certain further embodiments, R5 is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl, 2-thiophenyl, 2-furanyl, 3-furanyl, 3-pyridyl, 4-pyridyl or phenyl.
In certain embodiments of the compound of Formula (I), (II), or (III), R7 is - (CH2)NR9R10 or -(CH )NRnR12.
In certain further embodiments, R9 is methyl, ethyl, propyl, cyclopropylmethyl, or cyclobutylmethyl; and R10 is methyl, ethyl, propyl, cyclopropylmethyl, oxetanyl, oxethanemethyl, N-methyazetinyl, Ν,Ν-dimethylethyl, or methoxyethyl; and NRnR12 is azetidinyl, 3-hydroxy azetidinyl, 3-methoxy azetidinyl, pyrrolidinyl, (S)-3-hydroxy pyrrolidinyl, (R)-3-hydroxy pyrrolidinyl, (3R,4S)-3,4-dihydroxypyrrolidinyl, (3S,4R)-3- hydroxy-4-methoxypyrrolidinyl, piperidinyl morpholinyl, N-methylpiperazinyl, azamorpholinyl, N-methylazapiperazinyl, N-acetyl piperazinyl, or thiomorpholinyl.
In a fourth embodiment, provided herein is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof:
Figure imgf000011_0001
wherein:
X is CH or N;
R1 is H, R8 or -OR8;
R is hydrogen; C1-6 alkyl; 6-10 membered monocyclic or bicyclic aryl; or 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the aryl or heteroaryl is optionally and independently substituted at one or more carbon atoms
1 T - » t ■ with R , and wherein the heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R ;
R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3; C1-6 alkyl, C3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R ;
R7 is hydrogen, -CH2OH, -CH2OR8, C1-3 alkyl, (CH2)nNR9R10, (CH2)nNRnR12, C(0)NR9R10, or C(0)NRnR12, wherein each n is independently 1 or 2;
R8 is selected from C1-6 alkyl or C3-7 cycloalkyl;
R9 is selected from C1-6 alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the Ci-6 alkyl or C3-7 cycloalkyl is optionally substituted with halogen or -OR8, and wherein the 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R8, -C(0)R8, -C(0)OR8, or C(0)NHR8;
R10 is C1-6 alkyl, C3-7 cycloalkyl, or (CH2)„NR9R9, wherein each n is independently
1 or 2;
R and R , taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which Ru and R12 are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons (e.g., at one, two, or three carbon atoms) with halogen, hydroxyl, -OR8, -NR9R10, or -NRnR12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms , in addition to the nitrogen atom to which R11 and R12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms atoms is optionally substituted with -R , -C(0)R , -C(0)OR , -C(0)NHR8, -S02R8, -S02NH2, or -S02NR8 2; and
R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl.
In certain embodiments of the compound of Formula (IV), R is H; R is furanyl, thiophenyl, N-methyl pyrazolyl, or phenyl; R4 is H, -CH3, F, or CI ; R5 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, pyridinyl, thiophenyl, furanyl, N-methyl pyrrolyl, N-methyl pyrazolyl, or phenyl; and n is 1.
In certain further embodiments, R5 is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl, 2-thiophenyl, 2-furanyl, 3 -furanyl, 3-pyridyl, 4-pyridyl or phenyl.
In certain further embodiments, R7 is -(CH2)NR9R10 or -(CH2)NRnR12.
In still further embodiments, R9 is methyl, ethyl, propyl, cyclopropylmethyl, or cyclobutylmethyl; and R10 is methyl, ethyl, propyl, cyclopropylmethyl, oxetanyl, oxethanemethyl, N-methyazetinyl, Ν,Ν-dimethylethyl, or methoxyethyl; and NRnR12 is azetidinyl, 3 -hydroxy azetidinyl, 3-methoxy azetidinyl, pyrrolidinyl, (S)-3 -hydroxy pyrrolidinyl, (R)-3-hydroxy pyrrolidinyl, (3R,4S)-3,4-dihydroxypyrrolidinyl, (3S,4R)-3- hydroxy-4-methoxypyrrolidinyl, piperidinyl morpholinyl, N-methylpiperazinyl, azamorpholinyl, N-methylazapiperazinyl, N-acetyl piperazinyl, or thiomorpholinyl. In certain embodiments of the compound of Formula (IV), R is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl, 2-thiophenyl, 2-furanyl, 3-furanyl, 3-pyridyl, 4-pyridyl or phenyl.
In a fifth embodiment, provided herein is a compound of Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof, wherein R1 is -OCH3; and n is 1. In a sixth embodiment, provided herein is a compound of Formula (IV), or a pharmaceutically acceptable salt thereof, wherein R1 is H; and n is 1.
In certain embodiments, the compound is a compound described herein or a pharmaceutically acceptable salt thereof.
In another aspect, the invention provides a method of treating protein kinase- mediated disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention (such as a compound of Formula (I)) or a pharmaceutically acceptable salt thereof, that is effective in treating abnormal cell growth and immune disease.
In another aspect, the invention provides a method of inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR, in biological sample or in a patient, comprising contacting the biological sample with or administering to the patient a compound according of the invention, or a composition thereof (e.g., a pharmaceutical composition comprising the compound of the invention and a pharmaceutically acceptable carrier). In certain embodiments, the at least one mutant is Del E746-A750, L858R or T790M. In certain embodiments, the at least one mutant is at least one double mutant selected from Del E746-A750/T790M or L858R/T790M.
In another aspect, the invention provides a method of inhibiting Janus kinase 3 (JAK3) selectively as compared to other kinases, in biological sample or in a patient, comprising contacting the biological sample with or administering to the patient a compound of the invention, or a composition thereof, that is effective in treating abnormal cell growth including leukemia and lymphoma (B-cell & T-cell) and immune diseases including arthritis, rheumatoid arthritis and autoimmune diseases.
In another aspect, the invention provides a use of a compound of the invention (such as a compound of Formula (I)) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating protein kinase-mediated disease. Further, the invention provides a use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR. In another aspect, the invention provides a pharmaceutical composition for treating protein kinase-mediated disease, comprising a compound of the invention (such as a compound of Formula (I)) or a pharmaceutically acceptable salt thereof as active ingredients. Further, the invention provides a pharmaceutical composition for inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR, comprising a compound of the invention or a pharmaceutically acceptable salt thereof as active ingredients.
The term "alkyl," used alone or as part of a larger moiety such as "arylalkyl" or "cycloalkyl" refers to a straight or branched hydrocarbon radical having from 1 to 15 carbon atoms or from 1-8 carbon atoms (unless stated otherwise) and includes, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso- pentyl, n-hexyl and the like. An alkyl can be unsubstituted or substituted with one or more suitable substituents.
The term "cycloalkyl" refers to a monocyclic or polycyclic hydrocarbon ring group and includes, for example, cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbornyl, cyclohexyl, cyclopentyl, and the like. A cycloalkyl group can be unsubstituted or substituted with one or more suitable substituents.
The term "hetero" refers to the replacement of at least one carbon atom member in a ring system with at least one heteroatom such as nitrogen, sulfur, and oxygen.
The term "heterocycloalkyl" means a non-aromatic monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 4 heteroatoms selected from nitrogen, sulfur, oxygen, sulfone, or sulfoxide. A heterocycloalkyl group can have one or more carbon-carbon double bonds or carbon- heteroatom double bonds in the ring group as long as the ring group is not rendered aromatic by their presence.
Examples of heterocycloalkyl groups include azetidinyl, aziridinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholino, thiomorpholino, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, pyranyl, and the like. A heterocycloalkyl group can be unsubstituted or substituted with one or more suitable substituents.
As used herein, the term "halogen" includes fluoro, chloro, bromo, and iodo.
As used herein, the term "alkoxy" refers to the alkyl groups above bound through oxygen, examples of which include methoxy, ethoxy, iso-propoxy, tert-butoxy, and the like. In addition, alkoxy also refers to polyethers such as -0-(CH2)2- O-CH3, and the like. An alkoxy can be unsubstituted or substituted with one or more suitable substituents. As used herein, the term "aryl" refers to unsubstituted or substituted aromatic monocyclic or polycyclic groups and includes, for example, phenyl and naphthyl. The term "aryl" also includes a phenyl ring fused to a non-aromatic carbocyclic or heterocyclic ring. The term "aryl" may be interchangeably used with "aryl ring," aromatic group," and "aromatic ring. " Heteroaryl groups have 4 to 14 atoms, 1 to 9 of which are independently selected from the group consisting of oxygen, sulfur and nitrogen. Heteroaryl groups have 1-3 heteroatoms in a 5-8 membered aromatic group. An aryl or heteroaryl can be a mono- or bicyclic aromatic group. Typical aryl and heteroaryl groups include, for example, phenyl, quinolinyl, indazoyl, indolyl, dihydrobenzodioxynyl, 3-chlorophenyl, 2,6- dibromophenyl, pyridyl, pyrimidinyl, 3- methylpyridyl, benzothienyl, 2,4,6- tribromophenyl, 4-ethylbenzothienyl, furanyl, 3,4- diethylfuranyl, naphthyl, 4,7- dichloronaphthyl, pyrrole, pyrazole, imidazole, thiazole, and the like. An aryl or heteroaryl can be unsubstituted or substituted with one or more suitable substituents.
As used herein, the term "haloalkyl" refers to any alkyl radical having one or more hydrogen atoms replaced by a halogen atom. Examples of haloalkyl include - CF3, -CHF2, -CH2F, and the like.
As used herein, the term "hydroxyl" or "hydroxy" refers to -OH.
As used herein, the term "amino" refers to -NH2.
As used herein, the term "hydroxyalkyl" refers to any hydroxyl derivative of alkyl radical. The term "hydroxyalkyl" includes any alkyl radical having one or more hydrogen atoms replaced by a hydroxy group.
A "substituent" as used herein, refers to a molecular moiety that is covalently bonded to an atom within a molecule of interest. For example, a ring substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member. Substituents of aromatic groups are generally covalently bonded to a ring carbon atom. The term "substitution" refers to replacing a hydrogen atom in a molecular structure with a substituent, such that the valence on the designated atom is not exceeded, and such that a chemically stable compound (i.e., a compound that can be isolated, characterized, and tested for biological activity) results from the substitution.
As described above, certain groups can be unsubstituted or substituted with one or more suitable substituents other than hydrogen at one or more available positions, typically 1, 2, 3, 4 or 5 positions, by one or more suitable groups (which may be the same or different). Certain groups, when substituted, are substituted with 1, 2, 3 or 4 independently selected substituents. Suitable substituents include halogen, alkyl, haloalkyl, aryl, hydroxy, alkoxy, hydroxyalkyl, amino, and the like.
In certain aspects, the invention also provides (i) a method of preparing a compound of formula (c) by reacting a compound of formula (a) with a compound of formula (b) in the presence of the first base in the first organic solvent (see Scheme 1); (ii) a method of preparing a compound of formula (e) by reacting the compound of formula (c) with heteroaryl intermediates (d) in the presence of the second base, in the second organic solvent (see Scheme 1); (iii) a method of preparing a compound of formula (f) by reductive amination of the compound of formula (e) and an amine derivatives by using a reducing agent in the third solvent (see Scheme 1); (iv) a method of preparing a compound of Formula (I) by reduction of the compound of formula (f) by using a reducing agent in the fourth solvent and followed by amide formation in the presence of acryloyl chloride, the third base in the fifth solvent (see Scheme 1). The invention also provides a method of preparing a compound of Formula (I) according to Scheme 1.
Scheme 1
Figure imgf000016_0001
In certain aspects, the invention also provides a method of preparing a compound of formula (e) by reaction of the compound of formula (h) with aniline intermediates (g) in the presence of the fourth base in the first solvent, a ligand, a palladium catalyst in the first organic solvent (see Scheme 2). The invention also provides a method of preparing a compound of Formula (I) according to Scheme 2.
S heme 2
Figure imgf000016_0002
In certain aspects, the invention also provides (i) a method of preparing a compound of formula (j) -from the compound of formula (i) with aniline intermediates (g) with the procedure as described in WO2013/109882 Al ; (ii) a method of preparing a compound of formula (j) from the compound of formula (j) by oxidation with mCPBA or Oxone® as described in WO2013/109882 Al; (iii) a method of preparing the compound of formula (e) from a compound of formula (k) by reaction with the compound of formula (d) in the presence of the second base in the second organic solvent (see Scheme 3). The invention also provides a method of preparing a compound of Formula (I) according to Scheme 3.
Scheme 3
Figure imgf000017_0001
j: R = SMe
k: R = S02Me
Figure imgf000017_0002
Formula (I) With reference to Schemes 1-3, while appropriate reaction solvents can be selected by one of ordinary skill in the art, the first organic solvent is generally selected from relatively polar, aprotic solvents such as acetone, tetrahydrofuran, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, dichloromethane, dichloroethane, or acetonitrile; the second organic solvent is generally selected from aprotic solvents such as toluene, dioxane, tetrahydrofuran, N,N-dimethylformamide, Ν,Ν-dimethylacetamide or N- methylmorpholine; the third organic solvent is generally selected from relatively polar, solvents such as tetrahydrofuran, methanol, ethanol, dichloromethane, dichloroethane, N,N-dimethylacetamide or Ν,Ν-dimethylformamide; the fourth solvent is generally selected from relatively polar, protic solvents such as methanol, ethanol, tert-butanol or water, and the fifth solvent is generally selected from solvents such as dichloromethane, tetrahydrofuran, N,N- dimethylformamide, N,N-dimethylacetamide, or water.
With reference to Schemes 1-3, while bases and other reactants can be selected by one of ordinary skill in the art, the first and the second bases are generally selected from bases such as K2C03, Cs2C03, NaOH, KOH, NaH, tert-BuOK, ter-BuONa, triethylamine, or diisopropylethylamine; the third base is generally selected from bases such as triethylamine, diisopropylethylamine, NaH, NaHC03, tert- BuOK, tert-BuONa, Cs2C03j or K2C03; the fourth base is selected generally from bases such as NaH, n-BuLi, Cs2C03, triethylamine, or diisopropylethylamine; a palladium catalyst is generally selected from Pd(OAc)2, Pd2(dba)3, Pd(PPh3)4, or Pd(dppf)Cl2; a ligand is generally selected from BINAP, Xantphos, or S-Phos; the oxidizing agent is selected from oxidizing agents such as m-chloroperbenzoic acid (mCPBA) or Oxone®; and the reducing agent is generally selected from NaBH(OAc)3, NaBH4, or NaBH(CN)3.
Representative compounds of Formula (I) are listed below:
N-(3-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol-1 -yl)pyrimidin-2-ylamino)- 4-methoxyphenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-4-methoxyphenyl)acrylamide,
N-(3-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)phenyl)acrylamide,
N-(3-(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)phenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-5-methylphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-(4-fluorophenyl)-l H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-l H-pyrazol- l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(4-methoxy-3 -(4-(3-methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)phenyl)acrylamide,
N-(3-(4-(4-((3-hydroxyazetidin-l -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-5-methylphenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin- 2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 2-morpholinophenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((3-hydroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2-ylamino)- 4-methoxy-2-(4-methylpiperazin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2-ylamino)- 4-methoxy-2-(piperidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-((3-hydroxyazetidin- 1 -yl)methyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin- 2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(((3R,4S)-3,4-dihydroxypyrrolidin-l-yl)methyl)-lH-pyrazol-l -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(((3 S,4R)-3-hydroxy-4-methoxypyrrolidin- 1 -yl)methyl)- 1 H-pyrazol- 1 - yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-lH-pyrazol-l-yl)-5-methylpyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(4-methoxy-5-(5-methyl-4-(4-((methyl(l-methylazetidin-3-yl)amino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(((3R,4S)-3,4-dihydroxypyrrolidin-l-yl)methyl)-3-methyl-lH-pyrazol- l-yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(((3 S,4R)-3-hydroxy-4-methoxypyrrolidin- 1 -yl)methyl)-3 -methyl- 1 H- pyrazol-l-yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
(R)-N-(5-(4-(4-((3-hydroxypyrrolidin-l-yl)methyl)-3 -methyl- 1 H-pyrazol- l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
(S)-N-(5-(4-(4-((3-hydroxypyrrolidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-l-yl)phenyl)acrylamide,
N-(5 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-methoxy-2-(piperidin-l-yl)phenyl)acrylamide,
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(4-((3 -hydroxyazetidin- 1- yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)-4- methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-l H-pyrazol- l-yl)-5-methy lpyrimidin-2-ylamino)- 4-methoxy-2-morpholinophenyl)acrylamide, N-(4-methoxy-5-(5-methyl-4-(4-(morpholinomethyl)-lH-pyrazol-l-yl)pyrimidin ylamino)-2-(4-methylpiperazin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4- methoxy-2-morpholinophenyl)acrylamide,
(S)-N-(5-(4-(4-((3-(dimethylamino)pyrrolidin-l-yl)methyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)- 4-methoxy-2-(4-methylpiperazin- 1 -yl)phenyl)acry lamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-2- (dimethylamino)-4-methoxyphenyl)acrylamide,
(R)-N-(5 -(4-(4-((3 -(dimethylamino)pyrrolidin- 1 -yl)methyl)- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5 -methylpyrimidin-2-ylamino)- 4-methoxy-2-( 1 ,4-oxazepan-4-yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)- 4-methoxy-2-(4-methyl- 1 ,4-diazepan- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-lH-pyrazol-l-yl)-5-methylpyrimidin-2-ylamino)- 2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(4-(((3S,4R)-3-hydroxy-4- methoxypyrrolidin- 1 -yl)methyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)-4- methoxyphenyl)acrylamide,
N-(4-methoxy-5-(4-(4-((3-methoxyazetidin-l -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-2-mo holinophenyl)acrylamide,
N-(5-(4-(4-(((3S,4R)-3-hydroxy-4-methoxypyrrolidin-l-yl)methyl)-3 -methyl- 1H- pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(4-methylpiperazin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(3-((3-hydroxyazetidin- 1 -yl)methyl)-4-methyl-l H-pyrrol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(5-chloro-4-(4-((3-hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5-chloropyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(5-chloro-4-(4-(((3S,4R)-3-hydroxy-4-methoxypyrrolidin-l-yl)methyl)-3- methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxy-2- morpholinophenyl)acrylamide, N-(5-(5-chloro-4-(4-((dimethylamino)methyl)-3-methyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylarnide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-( 1 H-pyrazol- 1 -yl)phenyl)acrylamide,
N-(5-(5 -chloro-4-(4-(((3R,4S)-3,4-dihydroxypyrrolidin- 1 -yl)methyl)-3 -methyl- 1 H- pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin- 1 - yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -cyclopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-(((3S,4R)-3-hydroxy-4-methoxypyrrolidin-l-yl)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-5-( 1 -methyl- 1 H-pyrazol-4-yl)phenyl)acrylamide,
N-(5-(4-(4-((3-hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-4-methoxy-2-( 1 -methyl- 1 H-pyrazol-4-yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-( 1 -methyl- 1 ,2,3 ,6-tetrahydropyridin-4-yl)phenyl)acrylamide,
N-(5-(4-(3-(azetidin- 1 -ylmethyl)-4-methyl- 1 H-pyrrol- 1 -yl)-5-fluoropyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(5 -fluoro-4-(4-(((3 S ,4R)-3 -hydroxy-4-methoxypyrrolidin- 1 -yl)methyl)-3 - methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxy-2- morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)-5-fluoropyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- -ylmethyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)- 4-isopropoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)-
4- methoxy-2-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamide,
N-(4-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-
5- methoxybiphenyl-2-yl)acrylamide,
N-(5-(4-(4-(hydroxymethyl)-3-methyl-lH-pyrazol-l -yl)pyrimidin-2-ylamino)-4- methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -tert-butyl- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin- 2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(4-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 2',5-dimethoxybiphenyl-2-yl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 2-(4,4-difluoropiperidin- 1 -yl)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3, 5 -dimethyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, N-(2-(dimethylamino)-5-(4-(4-((dimemy^
yl)pyriniidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((3-fluoroazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2 -ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 -methylpyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(5 -chloro-4-(4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-moφholinophenyl)acr lamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-2-(4-(2-fluoroethyl)piperazin-l-yl)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-p-tolyl-l H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -(4-fluorophenyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -p-tolyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-morpholinophenyl)acrylamide,
N-(2-(dimethylamino)-5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1- yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-(azetidin- 1 -yl)-5-(4-(4-((dimethylamino)methyl)-3-phenyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(4-methoxy-2-(4-methylpiperazin- 1 -yl)-5-(4-(3-phenyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)phenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-lH-pyrazol-l -yl)pyrimidin-2- ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(2-(azetidin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -(thiophen-2-yl)- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-4-methoxy-2-moφholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-(2,5-dimethylphenyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-moφholinophenyl)acrylamide,
N-(4-methoxy-2-moφholino-5-(4-(3-phenyl-4-(pyrrolidin-l-ylmethyl)-lH-pyrazol- 1 -yl)pyrimidin-2-ylamino)phenyl)acrylamide, N-(5-(4-(4-(hydroxymethyl)-3 -phenyl- 1 H-pyrazol- l-yl)p yrimidin-2-ylamino)-4- methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((ethyl(methyl)amino)methyl)-3-phenyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-((dimethylamino)methyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3-phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5 -(4-(4-(azetidin- l-ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -tert-butyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -tert-butyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(3 -tert-butyl -4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -tert-butyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3-cyclopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-3-cyclopropyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide, N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -cyclopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-isopropyl-lH-pyrazol-l-yl)pyrirnidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-isopropyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)arnino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-rnethoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-isopropyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -(thiophen-2-yl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylarnide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3 -cyclopropyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -cyclopropyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -isopropyl- 1 H-pyrazol- l-yl)-5- methylpyrimidin-2-ylamino)-4-rnethoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin- 2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(4-(3 -tert-butyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-2-(ethyl(2-methoxyethyl)amino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-(furan-3 -yl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-(pyridin-3-yl)-l H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-4-methoxy-2-rriorpholinophenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)- 1 H- pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(3 -(azetidin- 1 -ylmethyl)-4-(furan-3 -yl)- 1 H-pyrrol- 1 -yl)-5-fluoropyrimidin- 2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, N-(5-(4-(3 -((dimethylamino)methyl)-4-(furan-3 -yl)- 1 H-pyrrol- 1 -yl)-5 - fluoropyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)- lH-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol-
1- yl)pyrimidin-2-ylamino)-4-n ethoxyphenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H- pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -(pyridin-4-yl)- 1 H-pyrazol- 1 -yl)pyrimidin-
2- ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(2-(4-acetylpiperazin-l-yl)-5-(4-(3-cyclopropyl-4-((ethyl(methyl)amino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -cyclopropyl- 1 H- pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-(azetidin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)-3-cyclopropyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((ethyl(methyl)amino)methyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(2-(azetidin- 1 -yl)-5-(4-(3 -(azetidin- 1 -ylmethyl)-4-methyl- 1 H-pyrrol- 1 -yl)-5- fluoropyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(3 -(azetidin- 1 -ylmethyl)-4-methyl- 1 H-pyrrol- 1 -yl)-5-fluoropyrimidin-2- ylamino)-2-(dimethylamino)-4-methoxyphenyl)acrylamide,
N-(2-(dimethylamino)-5-(4-(3-((dimethylamino)rnethyl)-4-rnethyl-lH-pyrrol-l -yl)- 5-fluoropyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(3-((dimethylarnino)methyl)- 4-(trifluoromethyl)- 1 H-pyrrol- 1 -yl)-5-fluoropyrimidin-2-ylamino)-4- methoxyphenyl)acrylamide,
N-(5-(4-(4-((ethyl(methyl)amino)methyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
or a pharmaceutically acceptable salt thereof.
As used herein, the term "cancer" refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize. The types of cancer include, but is not limited to, solid tumors, such as those of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue (lymphoma), ovary, pancreas or other endocrine organ (thyroid), prostate, skin (melanoma) or hematological tumors (such as the leukemias).
As used herein, the term "EGFR mutation" refers to mutation of T790M (resistant or oncogenic), L858R (activating), del E746-A750 (activating) or a combination thereof.
In certain embodiments, the invention selectively inhibits at one activating mutation and at one point mutation. In some embodiments, an at least one activating mutation is a deletion mutation, del E746-A750. In some embodiments, an at least one activating mutation is a point mutation L858R. In some embodiments, the at least one - resistant mutation is a point mutation, T790M. In some embodiments, the at least one mutation of EGFR is L858R and/or T790M.
As used herein, the term "mutant selective inhibition", as used in comparison to inhibition of wildtype (WT) EGFR, refers to the state that invention inhibits at least one mutation of EGFR (i.e. at least one deletion mutation, at least one activating mutation, at least one resistant mutation, or a combination of at least one deletion mutation and at least one point mutation) in at least one assay described herein (e.g., biochemical or cellular).
As used herein, the term "selectively inhibits", as used in comparison to inhibition of other kinases, refers to that invention poorly inhibits at least one of kinase panel.
As used herein, the term "EGFR wildtype selectivity" refers to that a selective inhibitor of at least one mutation of EGFR, as defined and described above and herein, inhibits EGFR at the upper limit of detection of at least one assay as described herein (e.g. cellular as described in detail in Table 1 and Table 2). In some embodiments, the term "EGFR wildtype selectivity" means that the invention inhibits WT EGFR with an IC50 of at least 200-1000nM or > lOOOnM.
As used herein, the term "inhibitor" refers to a compound which inhibits one or more kinase described herein. For example, the term "EGFR mutant inhibitor" refers to a compound which inhibits the EGFR mutant receptor or reduces the signaling effect.
As used herein, the term "pharmaceutically acceptable" refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compounds described herein. Such materials are administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
As used herein, the term "pharmaceutically acceptable salt" refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compounds described herein.
As used herein, the term "pharmaceutical combination" means a product that results from the mixing or combining of more than one active ingredient.
As used herein, the term "pharmaceutical composition" refers to a mixture of a compound described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
As used herein, the term "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. Prodrugs are bio-available by oral administration whereas the parent is not. Prodrugs improve solubility in pharmaceutical compositions over the parent drug. A non-limiting example of a prodrug of the compounds described herein is a compound described herein administered as an ester which is then metabolically hydrolyzed to a carboxylic acid, the active entity, once inside the cell. A further example of a prodrug is a short peptide bonded to an acid group where the peptide is metabolized to reveal the active moiety.
As used herein, the term "protein kinase-mediated disease" or a "disorder or disease or condition mediated by inappropriate protein kinase activity" refers to any disease state mediated or modulated by protein kinases described herein. Such disease states include, but are not limited to non-small cell lung cancer (NSCLC).
As used herein, the term "EGFR mutant-mediated disease" or a "disorder or disease or condition mediated by inappropriate EGFR activity" refers to any disease state mediated or modulated by EGFR mutant kinase mechanisms. Such disease states include, but are not limited to NSCLC, metastatic brain cancer and other solid cancers.
As used herein, the term " J AK3 -mediated disease" or a "disorder or disease or condition mediated by inappropriate JAK3 activity" refers to any disease state mediated or modulated by JAK3 kinase mechanisms. Such disease states include, but are not limited to rheumatoid arthritis, psoriasis and organ transplant rejection and some solid cancers.
As used herein, the term "treat," "treating" or "treatment" refers to methods of alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of Formula (I) or a pharmaceutically acceptable salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Non-limiting examples of suitable solvents include water, acetone, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Non-limiting examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid.
As used herein, the term "subject" or "patient" encompasses mammals and non- mammals. Examples of mammals include, but are not limited to, humans, chimpanzees, apes monkeys, cattle, horses, sheep, goats, swine; rabbits, dogs, cats, rats, mice, guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like.
As used herein, the term "administration" or "administering" of the subject compound refers to providing a compound of the invention and/or prodrugs thereof to a subject in need of treatment.
As used herein, the term "carrier" refers to chemical compounds or agents that facilitate the incorporation of a compound described herein into cells or tissues. As used herein, the term "co-administration" or "combined administration" or the like as used herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
As used herein, the term "acceptable" with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
As used herein, the term "diluent" refers to chemical compounds that are used to dilute a compound described herein prior to delivery. Diluents can also be used to stabilize compounds described herein.
As used herein, the term "effective amount" or "therapeutically effective amount" refer to a sufficient amount of a compound described herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study. By way of example only, a therapeutically effective amount of a compound of the invention may be in the range of e.g., about 0.01 mg/kg/day to about 100 mg/kg/day, or from about 0.1 mg/kg/day to about 10 mg/kg/day.
Human Protein Kinase
Compounds of the present invention are screened against the kinase panel (wild type and/or mutation thereof) and inhibit the activity of at least one kinase on the kinase panel. Examples of kinases include, but are not limited to EGFR and JAK3 (JH1 domain- catalytic) kinases, and mutant forms thereof. As such, the compounds and compositions of the invention are useful for treating diseases or disorders in which such kinases contribute to the pathology and/or symptomology of a disease or disorder associated with or mediated by such kinase.
Many diseases are associated with abnormal cellular responses triggered by protein kinase mediated events. These diseases include, but are not limited to, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, respiratory diseases, allergies and asthma, Alzheimer's disease, and hormone related diseases.
Phosphorylation regulates a variety of cellular processes such as proliferation, growth, differentiation, metabolism, apoptosis, motility, transcription, translation and other signaling processes. Aberrant or excessive PTK activity has been observed in many disease states such as benign and malignant proliferative disorders, diseases resulting from inappropriate activation of the immune system and diseases resulting from inappropriate activation of the nervous systems. Specific diseases or conditions include, but are not limited to, allograft rejection, graft vs. host disease, diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, osteoarthritis, rheumatoid arthritis, synovial pannus invasion in arthritis, multiple sclerosis, myasthenia gravis, diabetes mellitus, diabetic angiopathy, retinopathy of prematurity, infantile hemangiomas, non-small cell lung, bladder and head and neck cancers, prostate cancer, breast cancer, ovarian cancer, gastric and pancreatic cancer, psoriasis, fibrosis, atherosclerosis, restenosis, autoimmune disease, allergy, respiratory diseases, asthma, transplantation rejection, inflammation, thrombosis, retinal vessel proliferation, inflammatory bowel disease, Crohn's disease, ulcerative colitis, bone diseases, transplant or bone marrow transplant rejection, lupus, chronic pancreatitis, cachexia, septic shock, fibroproliferative and differentiative skin diseases or disorders, central nervous system diseases, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, disorders or conditions related to nerve damage and axon degeneration subsequent to a brain or spinal cord injury, acute or chronic cancer, ocular diseases, viral infections, heart disease, lung or pulmonary diseases or kidney or renal diseases and bronchitis. Epidermal growth factor receptor (EGFR)
The epidermal growth factor receptor (EGFR; ErbB-1 ; HER1 in human) is the cell- surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
EGFR exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor a (TGF ). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer . In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. ErbB2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon hetero- dimerization with other family members such as EGFR.
The dimerization of EGFR stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of several tyrosine (Y) residues in the C- terminal domain of EGFR takes place. These include Y992, Y1045, Y1068, Y1 148 and Yl 173 at cytoplasmic domain. This autophosphorylation elicits downstream activation and signaling by several other proteins that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains. These downstream signaling proteins initiate several signal transduction cascades, principally the MAPK, Akt and JNK pathways, leading to DNA synthesis and cell proliferation. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. Activation of the receptor is important for the innate immune response in human skin. The kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in that manner.
Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforms. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division. In glioblastoma a more or less specific mutation of EGFR, called EGFRvIII is often observed. Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers.
The most common form of lung cancer is non-small cell lung carcinoma (NSCLC) and in a subset of these patients lung tumor growth is caused by activating mutations in the epidermal growth factor receptor (EGFR). The most common activating mutations, accounting for 85-90% of all EGFR mutations, are the in-frame deletion in exon 19 (DelE746-A750) and the L858R point mutation in exon 21. EGFR mutations occur in 10- 15% of NSCLC patients of Caucasian descent and 30-35% of NSCLC patients of East Asian descent. Clinical features likely to be associated with EGFR mutations are non- smoker and of East Asian ethnicity.
It was well known that the most common EGFR activating mutations, L858R and del E746-A750 were sensitive to treatment of gefitinib or erlotinib, which are associated with dose-limiting toxicities such as diarrhea and rash/acne in response to inhibition of wild-type EGFR in intestine and skin, respectively. Ultimately acquired resistance to therapy with gefitinib or erlotinib occurs predominantly by mutation of the gatekeeper residue T790M, which is detected in nearly half of clinically resistant patients, resulting in double mutants, L858R/T790M or del E746-A750/T790M.
Brain metastases are the most common intracranial neoplasm, occurring in 8-10% of cancer patients, and are a significant cause of cancer-related morbidity and mortality worldwide
Brain metastases develop in approximately 30% of patients with non-small cell lung cancer (NSCLC). Among the various histologies of NSCLC, the relative frequency of brain metastases in patients with adenocarcinoma and large cell carcinoma was much higher than that in patients with squamous cell carcinoma.
The compounds described herein are inhibitors of EGFR mutant kinase activity and have therapeutic benefit in the treatment of disorders associated with inappropriate EGFR mutant activity, in particular in the treatment and prevention of disease states mediated by EGFR mutant. Such disease states include NSCLC, breast cancer, metastatic brain cancer and other solid cancers. Furthermore, the compounds, compositions and methods of the present invention provides methods of regulating, and in particular inhibiting, signal transduction cascades in which EGFR mutant(s) plays a role. The method generally involves contacting a EGFR mutant- dependent receptor or a cell expressing a EGFR mutant -dependent receptor with an amount of a compound described herein, or prodrug a compound described herein, or an acceptable salt, hydrate, solvate, N-oxide and/or composition thereof, effective to regulate or inhibit the signal transduction cascade. The methods are used to regulate, and in particular inhibit, downstream processes or cellular responses elicited by activation of the particular EGFR mutant-dependent signal transduction cascade. The methods are practiced to regulate any signal transduction cascade where EGFR mutant is not known or later discovered to play a role. The methods are practiced in in vitro contexts or in in vivo contexts as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by or associated with activation of the EGFR mutant-dependent signal transduction cascade.
Janus kinase 3 (JAK3
Janus kinase 3 (JAK3) is a tyrosine kinase that belongs to the Janus family of kinases. Other members of the Janus family include JAK1, JAK2 and TYK2. They are cytosolic tyrosine kinases that are specifically associated with cytokine receptors. Since cytokine receptor proteins lack enzymatic activity, they are dependent upon JAKs to initiate signaling upon binding of their ligands (e.g. cytokines). The cytokine receptors can be divided into five major subgroups based on their different domains and activation motifs. JAK3 is required for signaling of the type I receptors that use the common gamma chain (yc).
In contrast to the relatively ubiquitous expression of JAK1, JAK2 and Tyk2, JAK3 is predominantly expressed in hematopoietic lineage such as NK cells, T cells and B cells and intestinal epithelial cells. JAK3 functions in signal transduction and interacts with members of the STAT (signal transduction and activators of transcription) family. JAK3 is involved in signal transduction by receptors that employ the common gamma chain (yc) of the type I cytokine receptor family (e.g. IL-2R, IL-4R, IL-7R, IL-9R, IL- 15R, and IL-21 R). Mutations of JAK3 result in severe combined immunodeficiency (SCID). Mice that do not express JAK3 have T-cells and B-cells that fail to respond to many cytokines.
Since JAK3 is required for immune cell development, targeting JAK3 could be a useful strategy to generate a novel class of immunosuppressant drugs. Moreover, unlike other JAKs, JAK3 is primarily expressed in hematopoietic cells, so a highly specific JAK3 inhibitor should have precise effects on immune cells and minimal pleiotropic defects. The selectivity of a JAK3 inhibitor would also have advantages over the current widely used immunosuppressant drugs, which have abundant targets and diverse side effects. A JAK3 inhibitor could be useful for treating autoimmune diseases, especially those in which a particular cytokine receptor has a direct role on disease pathogenesis. For example, signaling through the IL-15 receptor is known to be important in the development rheumatoid arthritis, and the receptors for IL-4 and IL-9 play roles in the development of allergic responses.
Extranodal, nasal-type natural killer (N )/T-cell lymphoma (NKCL) is an aggressive malignancy with poor prognosis in which, usually, signal transducer and activator of transcription 3 (STAT3) is constitutively activated and oncogenic. It was demonstrated that STAT3 activation mostly results from constitutive Janus kinase 3(JAK3) phosphorylation on tyrosine 980, as observed in three of the four tested NKCL cell lines and in 20 of the 23 NKCL tumor samples. In one of the cell lines and in 4 of 19 NKCL primary tumor samples, constitutive JAK3 activation was related to an acquired mutation (A573V or V722I) in the JAK3 pseudokinase domain. In addition, it was shown that constitutive activation of the JAK3/STAT3 pathway has a major role in NKCL cell growth and survival and in the invasive phenotype. Indeed, NKCL cell growth was slowed down in vitro by targeting JAK3 with chemical inhibitors or small-interfering RNAs. In a human NKCL xenograft mouse model, tumor growth was significantly delayed by the J AK3 inhibitor. Therefore, the constitutive activation of JAK3, which can result from J AK3 -activating mutations, is a frequent feature of NKCL so that it could be therapeutic target.
The compounds described herein are inhibitors of JAK3 kinase activity and have therapeutic benefit in the treatment of disorders associated with inappropriate JAK3 activity, in particular in the treatment and prevention of disease states mediated by JAK3. Such disease states include rheumatoid arthritis, psoriasis and organ transplant rejection, lymphoma and some solid cancers. Pharmaceutical Compositions, Formulation and Administration
For the therapeutic uses of compounds provided herein, including compounds of Formula (I), or pharmaceutically acceptable salts, solvates, N-oxides, prodrugs, or isomers thereof, such compounds are administered in therapeutically effective amounts either alone or as part of a pharmaceutical composition. Accordingly, provided herein are pharmaceutical compositions, which comprise at least one compound provided herein, including at least one compound of Formula (I), pharmaceutically acceptable salts and/or solvates thereof, and one or more pharmaceutically acceptable carriers, diluents, adjuvant or excipients. In addition, such compounds and compositions are administered singly or in combination with one or more additional therapeutic agents. The methods of administration of such compounds and compositions include, but are not limited to, intravenous administration, inhalation, oral administration, rectal administration, parenteral, intravitreal administration, subcutaneous administration, intramuscular administration, intranasal administration, dermal administration, topical administration, ophthalmic administration, buccal administration, tracheal administration, bronchial administration, sublingual administration or optic administration. Compounds provided herein are administered by way of known pharmaceutical formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, lotions, gels, ointments or creams for topical administration, and the like.
The therapeutically effective amount will vary depending on, among others, the disease indicated, the severity of the disease, the age and relative health of the subject, the potency of the compound administered, the mode of administration and the treatment desired. The required dosage will also vary depending on the mode of administration, the particular condition to be treated and the effect desired.
Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts. Pharmaceutically acceptable acidic/anionic salts include acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, hydrogensulfate, tannate, tartrate, teoclate, tosylate, and triethiodide salts. Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, N-methyl-D-glucamine, L-lysine, L- arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
A pharmaceutically acceptable acid salt is formed by reaction of the free base form of a compound of Formula (I) with a suitable inorganic or organic acid including, but not limited to, hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, formic, acetic, propionic, fumaric, citric, tartaric, lactic, benzoic, salicylic, glutamic, aspartic, p- toluenesulfonic, benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2-naphthalenesulfonic, or hexanoic acid. A pharmaceutically acceptable acid addition salt of a compound of Formula (I) can comprise or be, for example, a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, formarate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, naphthalenesulfonate (e.g., 2- naphthalenesulfonate) or hexanoate salt.
The free acid or free base forms of the compounds of the invention may be prepared from the corresponding base addition salt or acid addition salt form, respectively. For example a compound of the invention in an acid addition salt form may be converted to the corresponding free base form by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound of the invention in a base addition salt form may be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.). Prodrug derivatives of the compounds of the invention may be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al, Bioorg. Med. Chem. Letters, 1994, 4, 1985; the entire teachings of which are incorporated herein by reference).
Protected derivatives of the compounds of the invention may be prepared by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, "Protecting Groups in Organic Chemistry," 3rd edition, John Wiley and Sons, Inc., 1999, the entire teachings of which are incorporated herein by reference. Compounds of the invention may be prepared as their individual stereoisomers by reaction of a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. Resolution of enantiomers may be carried out using covalent diastereomeric derivatives of the compounds of the invention, or by using dissociable complexes (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and may be readily separated by taking advantage of these dissimilarities. The diastereomers may be separated by chromatography, or by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet and Samuel H. Wilen, "Enantiomers, Racemates and Resolutions," John Wiley And Sons, Inc., 1981, the entire teachings of which are incorporated herein by reference.
Suitable pharmaceutically acceptable carriers, diluents, adjuvants, or excipients for use in the pharmaceutical compositions of the invention include tablets (coated tablets) made of for example collidone or shellac, gum Arabic, talc, titanium dioxide or sugar, capsules (gelatin), solutions (aqueous or aqueous ethanolic solution), syrups containing the active substances, emulsions or inhalable powders (of various saccharides such as lactose or glucose, salts and mixture of these excipients with one another) and aerosols (propellant-containing or -free inhale solutions).
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g., petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g., ethanol or glycerol), carriers such as natural mineral powders (e.g., kaoline, clays, talc, chalk), synthetic mineral powders (e.g., highly dispersed silicic acid and silicates), sugars (e.g., cane sugar, lactose and glucose), emulsifiers (e.g., lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g., magnesium stearate, talc, stearic acid and sodium lauryl sulphate).
Compounds of Formula (I) can be made according to a variety of methods, some of which are known in the art. For example, the methods disclosed in PCT Publication WO2011/060295 (incorporated herein by reference) can be used, with suitable modifications, to prepare compounds according to the present invention. Exemplary methods for preparing the compounds of the invention are described herein, including in the Examples.
In certain embodiments, compounds of Formula (I) are made by: (a) optionally converting a compound of the invention into a pharmaceutically acceptable salt; (b) optionally converting a salt form of a compound of the invention to a non-salt form; (c) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide; (d) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers; (e) optionally converting a non- derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and (f) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.
The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety.
EXAMPLES The present invention is further exemplified by the following examples that illustrate the preparation of compounds of Formula (I) according to the invention. The examples are for illustrative purpose only and are not intended, nor should they be construed as limiting the invention in any manner. Those skilled in the art will appreciate that variations and modifications can be made without changing the scope of the invention.
Nuclear magnetic resonance (NMR) and mass spectrometry (MS) spectra obtained for compounds described in the examples below and those described herein were consistent with that of the compounds of formulae herein.
Liquid chromatography- mass spectrometry (LC-MS) Method:
1. Samples are run on Agilent Technologies 6120 MSD system with a Zorbax Eclipse XDB-C18 (3.5 μπι) reverse phase column (4.6 x 50 mm) run at room temperature with flow rate of 1.5 mL/minute.
2. The mobile phase uses solvent A (water/0.1 % formic acid) and solvent B (acetonitrile/0.1 % formic acid): 95 %/5 % to 0 %/100 % (A/B) for 5 minute.
3. The mass spectra (m/z) were recorded using electrospray ionization (ESI).
4. Ionization data was rounded to the nearest integer.
Proton NMR Spectra:
Unless otherwise indicated, all 1H NMR spectra are run on a Varian series Mercury 300 MHz or a Bruker 500MHz. All observed protons are reported as parts-per-million (ppm) downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g., s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). Intermediate 1 : l-(2-(2-Methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3-methyl-lH- pyr azole-4-carb aldehyde
Figure imgf000036_0001
Intermediate 1
Step 1 :
To a solution of N-(2-methoxy-5-nitrophenyl)formamide (0.30 g, 1.53 mmol) in 4 mL of THF and DMF mixture (1 :1) was added 122.4 mg of NaH (60%, 3.06 mmol) at 0 °C. N- Formamide was prepared from 2-methoxy-5-nitroaniline with formic acid by the known procedure described in PCT Int, Appl. 2006102642. The resulting slurry was warmed to rt and stirred for 30 min and cooled again to 0 °C. To the resulting mixture was added a solution of 4-chloro-2-(methylsulfonyl)pyrimidine (0.35 g, 1.84 mmol) in 2 mL of THF and DMF mixture (1 :1). 2-(Methylsulfonyl)pyrimidine was synthesized using wCPBA or Oxone® respectively by known procedures described in PCT Int, Appl. 2007117465 and PCT Int, Appl. 2007023105. The mixture was stirred for 30 min at 0 °C. Cold water and 3mL of IN aqueous NaOH was added to form solid. The mixture was stirred for 30 min at rt. The resulting solids were collected by filtration, rinsed with water and then vacuum dried to give 4-chloro-N-(2-memoxy-5-nitrophenyl)pyrimidin-2-amine as a yellow solid (0.40 g, 88%); MS (ESI) m/z 281 [M+H]+.
Step 2:
To a solution of 3 -methyl- lH-pyrazole-4-carbaldehyde (59.0 mg, 0.53 mmol) in 2 mL of DMF was added 28.6 mg of NaH (60%, 0.72 mmol) at 0 °C. The resulting slurry was stirred at rt for 30 min and then was cooled to 0 °C. To the resulting mixture was added a solution of the above intermediate (0.10 g, 0.36 mmol) in DMF (1 mL). The mixture was heated at 60 °C for 30 min and was quenched with MeOH. Solvent was removed in vacuo. Cold water was added and solid precipitate was filtered to give the desired Intermediate 1
Figure imgf000036_0002
Intermediate 1 l-(2-Chloropyrimidin-4-yl)-3 -methyl- lH-pyrazole-4-carbaldehyde (130 mg, 0.59 mmol) was added to a mixture of 2-methoxy-5-nitroaniline (88.6 mg, 0.53 mmol), Pd(OAc)2 (6.5 mmol, 0.029 mmol) , (+)-2,2'-bis(diphenylphosphino)-l,l'-binaphthalene (BINAP, 36.5 mg, 0.059 mmol), K2C03 (161.8 mg, 1.17 mmol) in 10 mL of 1,4-dioxane (degassed for 20 min prior to use). l-(2-Chloropyrimidin-4-yl)-3 -methyl- lH-pyrazole-4-carbaldehyde was prepared by the known procedure as described in WO 2013/109882 Al .
The resulting mixture was stirred at 100 °C for 5 h and then concentrated in vacuo. Cold water was added and the precipitated solid was collected by filtration, washed with DCM (5 mL) and dried to give the desired Intermediate 1 as a yellow solid (0.13 g, 65%); MS (ESI) m/z 355.4 [M+H]+.
Intermediate 2 : 3-methyl-l-(2-(3-nitrophenylainmo)pyrimidiii-4-yl)-lH-pyrazole-4- carbaldehyde
Using N-(3-nitrophenyl)formamide, Intermediate 2 was prepared as described in Method A; MS (ESI) m/z 325.2 [M+H]+.
Intermediate 3: 3-methyl-l-(2-(3-methyl-5-nitrophenylaniino)pyrimidin-4-yl)-lH- pyrazole-4-carbaIdehyde
Using N-(3-methyl-5-nitrophenyl)formamide, Intermediate 3 was prepared as described in Method A; MS (ESI) m/z 339.1 [M+H]+. Intermediate 4: 3-isopropyl-l-r2-(2-methoxy-4-morpholmo-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-lH-pyrazoIe-4-carbaldehyde
Using N-(2-methoxy-4-morpholino-5-nitrophenyl)formamide and 3-isopropyl-lH- pyrazole-4-carb aldehyde, Intermediate 4 was prepared as described in Method A; MS (ESI) m/z 482 [M+H]+.
Intermediate 5: l-(2-(2-methoxy-5-nitrophenylamino)-5-methylpyrimidin-4-yl)-3- methyl-lH-pyrazole-4-carbaldehyde Using 2-methoxy-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-3 -methyl- 1H- pyrazole-4-carbaldehyde , Intermediate 5 was prepared as described in Method B; MS (ESI) m/z 369.1 [M+H]+.
Intermediate 6; N-(2-methoxy-5-nitrophenyl)-4-(3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-amine Using 3 -methyl- IH-pyrazole, Intermediate 6 was prepared as described in Method A; MS (ESI) m/z 327.1 [M+H]+. Intermediate 7: 3-methyl-l-(5-methyl-2-(3-methyl-5-nitrophenylamino)pyrimidin-4- yi)- lH-pyrazole-4-carb aldehyde
Using 3-methyl-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-3-methyl-lH- pyrazole-4-carbaldehyde, Intermediate 7 was prepared as described in Method B; MS (ESI) m/z 353.1 [M+H]+.
Intermediate 8: l-(2-(2-methoxy-5-nitrophenylamino)-5-methylpyrimidm-4-yl)-lH- pyrazole-4-carbaldehyde Using 2-methoxy-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-lH-pyrazole-4- carbaldehyde, Intermediate 8 was prepared as described in Method B; MS (ESI) m/z 355.1 [M+H]+.
Intermediate 9 : l-(2-(4-fluoro-3-nitrophenylamino)pyrimidin-4-yl)-3-methyl-lH- pyrazole-4-carbaldehyde
Using 4-fluoro-3-nitroaniline and l-(2-chloropyrimidin-4-yl)-3 -methyl- lH-pyrazole-4- carbaldehyde, Intermediate 9 was prepared as described in Method B; MS (ESI) m/z 343.1 [M+H]+.
Intermediate 10 : 3-methyl-l-(2-(4-morpholmo-3-nitrophenyIanMno)pyrimidin-4-yl)- lH-pyrazole-4-carbaldehyde
To a solution of Intermediate 9 (200 mg, 0.59 mmol), DIPEA (0.20 mL, 1.1.7 mmol) in DMAA (10 mL) was added morpholine (0.076 mL, 0.88 mmol). The reaction mixture was heated to 80 °C for 2h. Solvent was removed in vacuo and the mixture was extracted with DCM. The crude mixture was purified by column chromatography (0 to 5% MeOH in DCM) to give the desired intermediate as a red solid (220.2 mg, 92%); MS (ESI) m/z 410.2 [M+H]+.
Intermediate 11; l-(2-(4-(4-acetylpiperazm-l-yl)-3-nitrophenylammo)pyrimidin-4-yl)- 3-methyl-lH-pyrazole-4-carbaldehyde
Using l-(piperazin-l-yl)ethanone, Intermediate 11 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 451.2 [M+H]+. Intermediate 12 : l-(2-(4-fluoro-2-methoxy-5-nitrophenylammo)pyrimidin-4-yl)-3- methyl-lH-pyrazole-4-carbaldehyde Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloropyrimidin-4-yl)-3-methyl-lH- pyrazole-4-carbaldehyde, Intermediate 12 was prepared as described in Method B; MS (ESI) m/z 373.1 [M+H]+.
Intermediate 13 : l-(2-(2-methoxy-4-morpholmo-5-nitrophenylamino)pyrimidin-4-yl)- 3-methyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 12, Intermediate 13 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 440.2 [M+H]+. Intermediate 14: l-(2-(4-((2-(dimethylanimo)ethyl)(methyl)amino)-2-methoxy-5- nitrophenvIamino)pyrimidin-4-yI)-3-methyl-lH-pyrazole-4-carbaIdehyde
Using Intermediate 12, Intermediate 14 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 455.2 [M+H]+.
Intermediate 15j l-(2-(2-methoxy-4-(4-methylpiperazin-l-yl)-5- nitrophenylammo)pyrimidin-4-yI)-3-methyI-lH-pyrazole-4-carbaldehyde
Using Intermediate 12, Intermediate 15 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 453.2 [M+H]+.
Intermediate 16: l-(2-(2-methoxy-5-nitro-4-(piperidm-l-yl)phenylanimo)pyrimidin-4- yl)-3-methyl-lH-pyrazoIe-4-carbaldehyde Using Intermediate 12, Intermediate 16 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 438.2 [M+H]+.
Intermediate 17: l-(2-(4-fluoro-2-methoxy-5-nitrophenyIamino)-5-methylpyrimidin- 4-yI)-lH-pyrazole-4-carbaldehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-lH- pyrazole-4-carbaldehyde, Intermediate 17 was prepared as described in Method B; MS (ESI) m/z 373.1 [M+H]+. Intermediate 18j l-(2-(2-methoxy-4-morpholmo-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-lH-pyrazole-4-carbaldehyde
Using Intermediate 17, Intermediate 18 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 440.2 [M+H]+.
Intermediate 19: l-(2-(4-fluoro-2-methoxy-5-nitrophenvIammo)-5-methylpyrimidin- 4-yl)-3-methyl-lH-pyrazole-4-carbaIdehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-3- methyl- lH-pyrazole-4-carbaldehyde, Intermediate 19 was prepared as described in Method B; MS (ESI) m/z 387.1 [M+H]+.
Intermediate 20j l-(2-(2-methoxy-4-morpholino-5-nitrophenylamino)-5- methylpyrimidm-4-yl)-3-methyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 19, Intermediate 20 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 454.2 [M+H]+.
Intermediate 21 : l-(2-(2-methoxy-4-(4-methylpiperazm-l-yl)-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-3-methyl-lH-pyrazole-4-carbaIdehyde
Using Intermediate 19, Intermediate 21 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 467.2 [M+H]+. Intermediate 22: l-(2-(2-methoxy-5-nitro-4-(piperidin-l-yl)phenyIamino)-5- methylpyrimidin-4-yl)-3-methyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 19, Intermediate 22 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 452.2 [M+H]+.
Intermediate 23 : l-(2-(4-((2-(dimethylammo)ethyI)(methyl)amino)-2-methoxy-5- nitrophenylammo)-5-methylpyrimidin-4-yl)-3-methyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 19, Intermediate 23 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 469.2 [M+H]+.
Intermediate 24: l-(2-(2-methoxy-4-(4-methylpiperazm-l-yI)-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-lH-pyrazole-4-carbaldehyde
Using Intermediate 17, Intermediate 24 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 453.2 [M+H]+.
Intermediate 25 : l-(2-(4-fluoro-2-methoxy-5-nitrophenylanuno)pyrimidin-4-yl)-lH- pyrazole-4-carbaldehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloropyrimidin-4-yl)-lH-pyrazole-4- carbaldehyde, Intermediate 25 was prepared as described in Method B; MS (ESI) m/z 359.1 [M+H]+. Intermediate 26: l-(2-(2-methoxy-4-morphomio-5-nitrophenyIamino)pyrimidin-4-yl)- lH-pyrazole-4-carbaldehyde
Using Intermediate 25, Intermediate 26 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 426 A [M+H]+.
Intermediate 27: l-(2-(4-(4-acetylpiperazin-l-yl)-2-methoxy-5-nitrophenylamino)-5- methylpyrimidin-4-yI)-lH-pyrazole-4-carbaldehyde
Using Intermediate 17, Intermediate 27 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 481.2 [M+H]+.
Intermediate 28: l-(2-(4-(dimethyIanmio)-2-methoxy-5-nitrophenylammo)pyrimidin- 4-yl)-lH-pyrazole-4-carbaldehyde Using Intermediate 25, Intermediate 28 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 384.1 [M+H]+.
Intermediate 29: l-(2-(2-methoxy-5-nitro-4-(l,4-oxazepan-4-yI)phenylamino)-5- methylpyrimidin^4-yl)-lH-pyrazole-4-carbaldehyde
Using Intermediate 17, Intermediate 29 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 454.2 [M+H]+.
Intermediate 30j l-(2-(2-methoxy-4-(4-methyl-l.,4-diazepan-l-yD-5- nitrophenylamino)-5-methyIpyrimidin-4-yl)-lH-pyrazole-4-carbaldehyde
Using Intermediate 17, Intermediate 30 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 467.2 [M+H]+.
Intermediate 31: l-(2-(4-((2-(dimethylamino)ethyI)(methyl)amino)-2-methoxy-5- nitrophenylaminoV5-methylpyriinidm-4-yl)-lH-pyrazole-4-carbaldehvde
Using Intermediate 17, Intermediate 31 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 455.2 [M+H]+.
Intermediate 32 : l-( 2-(4-fluoro-2-methoxy-5-nitrophenylamino)-5-methylp yrimidin- 4-yl)-4-methyl-lH-pyrrole-3-carbaldehvde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-4- methyl- lH-pyrrole-3-carbaldehyde, Intermediate 32 was prepared as described in Method B; MS (ESI) m/z 386.1 [M+H]+.
Intermediate 33: l-(2-(2-methoxy-4-morpholmo-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-4-methyl-lH-pyrroIe-3-carbaldehyde
Using Intermediate 32, intermediate 33 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 455.2 [M+H]+.
Intermediate 34: l-(5-chioro-2-(4-fluoro-2-methoxy-5-nitrophenylammo)pyrimidin-4- yl)-3-methyl-lH-pyrazole-4-carbaldehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2,5-dichloropyrimidin-4-yl)-3 -methyl- 1H- pyrazole-4-carbaldehyde, Intermediate 34 was prepared as described in Method B; MS (ESI) m/z 407.1 [M+H]+.
Intermediate 35j l-(5-chloro-2-(2-methoxy-4-morpholino-5- nitrophenylamino)pyrimidin-4-yl)-3-methyI-lH-pyrazole-4-carbaldehvde
Using Intermediate 34, Intermediate 35 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 474.1 [M+H]+.
Intermediate 36: l-(2-(2-methoxy-5-nitro-4-(lH-pyrazoI-l-yI)phenylamino)pyriinidin- 4-yl)-3-methyl-lH-pyrazole-4-carbaldehvde
Figure imgf000042_0001
Intermediate 12 Intermediate 36 To a solution of Intermediate 12 (350 mg, 0.94 mmol), pyrazole (96.0 mg, 1.41 mmol) in DMAA (10 mL) was added cesium carbonate (612.5 mg, 1.88 mmol). The reaction mixture was heated at 80 °C for 16h. Solvent was removed in vacuo and the mixture was extracted with DCM. The crude mixture was purified by column chromatography (0 to 5% MeOH in DCM) to give Intermediate 36 as a red solid (315.9 mg, 80%); MS (ESI) m/z 421.1 [M+H]+.
Intermediate 37: l-(5-chIoro-2-(2-methoxy-4-(4-methylpiperazin-l-yi)-5- nitrophenylammo)pyrimidin-4-yl)-3-methyl-lH-pyrazole-4-carbaIdehyde
Using Intermediate 34, Intermediate 37 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 487.2 [M+H]+. Intermediate 38 3-cyclopropyl-l-(2-(4-fluoro-2-methoxy-5- nitrophenylamino)pyrimidin-4-yl)-lH-pyrazole-4-carbaldehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloropyrimidin-4-yl)-3-cyclopropyl- lH-pyrazole-4-carbaldehyde, Intermediate 38 was prepared as described in Method B; MS (ESI) m/z 399.1 [M+H]+.
Intermediate 39j 3-cyclopropyl-l-(2-(2-methoxy-4-morpholino-5- nitrophenylammo)pyrimidin-4-yl)-lH-pyrazole-4-carbaldehvde Using Intermediate 38, Intermediate 39 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 466.2 [M+H]+.
Intermediate 40 : N-(3-(l-methyl-lH-pyrazol-4-yl)-5-nitrophenyl')formamide
Figure imgf000043_0001
Intermediate 40 Step 1 :
To a solution of 5-bromo-l,3-dinitrobenzene (0.25 g, 1.01 mmol) in 10 mL dimethoxyethane was added 1 -methyl- lH-pyrazole-4-boronic acid (0.14 g, 1.11 mmol), [l, -Bis(diphenylphosphino)ferrocene] dichloropalladium(II) (41 mg, 0.05 mmol) and 1M Na2C03 (2.5 mL). The reaction mixture was heated at 80 °C for 16h. The reaction mixture was, diluted with ethyl acetate, washed with sat. NaHC03 solution, brine, dried over Na2S04, concentrated in vacuo and then purified by column chromatography (0^-50% ethyl acetate in hexane) to give 0.16 g of the title compound as yellow solid; MS (ESI) m/z 249.1 [M+H]+.
Step 2:
To a mixture of dinitro compound above (0.16 g, 0.65 mmol) in ethanol (3 mL) was added ammonium sulfide (0.5 mL). The reaction was heated at 90 °C for 2h. Reaction mixture cooled to room temperature followed by addition of water. The precipitated solid was filtered, washed with ethanol and water, then dried to give 0.13 g of amino compound; MS (ESI) m/z 219.1 [M+H]+.
Step 3:
To a solution of amino compound (60 mg, 0.27 mmoles) in acetonitrile (10 mL) was added formic acid (0.2 mL). The reaction mixture was heated at 80 °C overnight. Reaction mixture was concentrated in vacuo and residue was diluted with water. Precipitated solid (40 mg) was filtered and used directly for next step; MS (ESI) m/z 247 Λ [M+H]+.
Intermediate 41i 3-methyI-l-(2-(3-(l-methyl-lH-pyrazol-4-yi)-5- nitrophenylamino)py rimidin-4- yl)- lH-pyr azoIe-4-carb aldehyde
Using Intermediate 40, Intermediate 41 was prepared as described in Method A; MS (ESI) m/z 405.1 [M+H]+. Intermediate 42j N-(2-methoxy-4-(l-methyl-lH-pyrazol-4-yl)-5- nitrophenyl)formamide
Figure imgf000044_0001
Intermediate 42
Step 1 : Guanidine nitrate (1.22 g, 10.00 mmol) was added portionwise to a cooled mixture of 4- bromo-2-methoxyaniline (2.02 g, 10.00 mmol) in 85% sulfuric acid (15.68 mL, 250.00 mmol). The resulting blue mixture was stirred for 45 min at 0 °C and was slowly poured over a well-stirred mixture of IN NaOH (40 mL) and ice (120 g). The aqueous layer was extracted with ethyl acetate and the organic layer was concentrated in vacuo. Purified by column chromatography (0-40% ethyl acetate in hexane) to give 1.20 g of 4-bromo-2- methoxy-5-nitrobenzenamine; MS (ESI) m/z 247.0 [M+H]+.
Step 2:
To a solution of 4-bromo-2-methoxy-5-nitroaniline (0.25 g, 1.01 mmol) in 10 mL of 1,4- dioxane was added 1 -methyl- lH-pyrazole-4-boronic acid (0.14 g, 1.11 mmol), [Ι, - Bis(diphenylphosphino)ferrocene] dichloropalladium(II) (41 mg, 0.05 mmol) and 1M Na2C03 (2.5 mL). The reaction mixture was heated at 80 °C for 16h. The reaction mixture was diluted with ethyl acetate, washed with sat. NaHC03 solution, brine, dried over Na2S04, concentrated in vacuo and then purified by column chromatography (0-50% ethyl acetate in hexane) to give the title compound; MS (ESI) m/z 259.1 [M+H]+.
Step 3:
To a solution of 4-pyrazoloamino compound (0.16 g, 0.65 mmol) in acetonitrile (16 mL) was added formic acid (0.7 mL). The reaction mixture was heated to 80 °C for 16h. Reaction mixture was concentrated in vacuo and the resulting residue was diluted with water. Precipitated solid (0.14 g) was filtered and used directly for next step; MS (ESI) m/z 277.1 [M+H]+.
Intermediate 43j l-(2-(2-methoxy-4-(l-methvI-lH-pyrazoI-4-yl)-5- nitrophenylainmo)pyriinidm-4-yl)-3-methyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 42, Intermediate 43 was prepared as described in Method A; MS (ESI) m/z 435.2 [M+H]+.
Intermediate 44: N-(2-methoxy-4-(l-methyl-l,2,3i6-tetrahydropyridin-4-yl)-5- nitrophenyDformamide
Using l-(tert-butoxycarbonyl)-l,2,3,6-tetrahydropyridin-4-ylboronic acid, Intermediate 44 was prepared as described in the preparation of Intermediate 42; MS (ESI) m/z 292.1 [M+H]+.
Intermediate 45: l-(2-(2-methoxy-4-(l-methyl-l.,2,3-6-tetrahvdropyridin-4-vI)-5- nitrophenyIamino)pyrimidin-4-yl)-3-methyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 44, Intermediate 45 was prepared as described in Method A; MS (ESI) m/z 450.2 [M+H]+. Intermediate 46: 2-methoxy-4-morpholino-5-nitroaniline
Figure imgf000046_0001
Intermediate 46
Using 4-fluoro-2-methoxy-5-nitroaniline, Intermediate 46 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 254.1 [M+H]+.
Intermediate 47: l-(5-fluoro-2-(2-methoxy-4-morpholino-5- nitrophenylamino)pyrimidin-4-vI)-4-methyl-lH-pyrrole-3-carbaldehvde Using l-(2-chloro-5-fluoropyrimidin-4-yl)-4-methyl-lH-pyrrole-3-carbaldehyde and Intermediate 46, Intermediate 47 was prepared as described in Method B; MS (ESI) m/z 457.2 [M+H]+.
Intermediate 48: l-(5-fluoro-2-(2-methoxy-4-morpholino-5- nitrophenylamino)pyrimidin-4-vn-3-methyl-lH-pyrazole-4-carbaIdehvde
Using 1 -(2-chloro-5-fluoropyrimidin-4-yl)-3-methyl- 1 H-pyrazole-4-carbaldehyde and Intermediate 46, Intermediate 48 was prepared as described in Method B; MS (ESI) m/z 458.2 [M+H]+.
Intermediate 49: l-(2-(4-fluoro-2-isopropoxy-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-lH-pyrazole-4-carbaldehvde
Using 4-fluoro-2-isopropoxy-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-lH- pyrazole-4-carbaldehyde, Intermediate 49 was prepared as described in Method B; MS (ESI) m/z 401.1 [M+H]+.
Intermediate 50j l-(2-(2-isopropoxy-4-morpholino-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-lH-pyrazoIe-4-carbaldehyde
Using Intermediate 49, Intermediate 50 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 468.2 [M+H]+. Intermediate 51: l-(2-(2-methoxy-4-(l-methvI-l,2,3,6-tetrahvdropyridin-4-yl)-5- nitrophenviamino)-5-methvIpyrimidin-4-yl)-lH-pyrazole-4-carbaidehvde Using Intermediate 44, Intermediate 51 was prepared as described in Method A; MS (ESI) m/z 450.2 [M+H]+.
Intermediate 52: 5-methoxy-2-nitrobiphenyl-4-amine Using benzene boronic acid and 4-bromo-2-methoxy-5-nitroaniline, Intermediate 52 was prepared as described in the preparation of Intermediate 42; MS (ESI) m/z 245.1 [M+H]+.
Intermediate 53 : l-(2-(5-methoxy-2-nitrobiphenvI-4-ylamino)pyrimidin-4-yI)-3- methyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 52, Intermediate 53 was prepared as described in Method B; MS (ESI) m/z 431.1 [M+H]+.
Intermediate 54: (1 -(2-(2-methoxy-4-morphoIino-5-nitrophenvIamino)pyrimidin-4- yI)-3-methyl-lH-pyrazoI-4-yl)methanol
Using Intermediate 46 and (l-(2-chloropyrimidin-4-yl)-3-methyl-lH-pyrazol-4- - yl)methanol, Intermediate 54 was prepared as described in Method B; MS (ESI) m/z 442.2 [M+H]+.
Intermediate 55: 3-tert-butyl-l-(2-(4-fluoro-2-methoxy-5-nitrophenyIamino)-5- methyipyrimidin-4-yl)-lH-pyrazole-4-carbaldehvde Using 4-fluoro-2-methoxy-5-nitroaniline and 3-tert-butyl-lH-pyrazol-4-carbaldehyde, Intermediate 55 was prepared as described in Method B; MS (ESI) m/z 429.2 [M+H]+.
Intermediate 56: 2',5-dimethoxy-2-nitrobiphenyI-4-amine Using 2-methoxyphenylboronic acid and 4-bromo-2-methoxy-5-nitroaniline, Intermediate 56 was prepared as described in Intermediate 42; MS (ESI) m/z 275.1 [M+H]+.
Intermediate 57: l-(2-(2',5-dimethoxy-2-nitrobiphenyl-4-ylamino)pyrimidin-4-yI)-3- methyl-lH-pyrazoIe-4-carbaIdehyde Using Intermediate 56, Intermediate 57 was prepared as described in Method B; MS (ESI) m/z 461.2 [M+H]+.
Intermediate 58: 4-(4.4-difluoropiperidin-l-ylV2-methoxy-5-nitroaniline
Using 4-fluoro-2-methoxy-5-nitroaniline and 4,4-difluoropiperidine , Intermediate 58 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 288.1 [M+H]+.
Intermediate 59j l-(2-(4-(4,4-difluoropiperidin-l-vI)-2-methoxy-5- nitrophenylamino)pyrimidin-4-vn-3-methyl-lH-pyrazole-4-carbaldehvde
Using Intermediate 58, Intermediate 59 was prepared as described in Method B; MS (ESI) m/z 474.2 [M+H]+. Intermediate 60: l-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3,5- dimethyl-lH-pyrazole-4-carbaldehvde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloropyrimidin-4-yl)-3,5-dimethyl-lH- pyrazole-4-carbaldehyde, Intermediate 60 was prepared as described in Method B; MS (ESI) m/z 387.1 [M+H]+.
Intermediate 61 : l-(2-(2-methoxy-4-morpholino-5-nitrophenylamino)pyrimidin-4-vn- 3,5-dimethyl-lH-pyrazole-4-carbaldehvde Using Intermediate 60, Intermediate 61 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 454.2 [M+H]+.
Intermediate 62: l-(2-(4-(dimethylamino)-2-methoxy-5-nitrophenylamino)pyrimidin- 4-vD-3-methyl-lH-pyrazole-4-carbaIdehvde
Using Intermediate 12, Intermediate 62 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 398.2 [M+H]+.
Intermediate 63: l-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3- phenyl-lH-pyrazole-4-carbaldehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloropyrimidin-4-yl)-3 -phenyl- 1H- pyrazole-4-carbaldehyde, Intermediate 63 was prepared as described in Method B; MS (ESI) m/z 435.1 [M+H]+. Intermediate 64 : l-(2-(2-methoxy-4-morpholino-5-nitrophenvtamino)pyrimidin-4-vI)-
3- phenyl-lH-pyrazole-4-carbaIdehyde
Using Intermediate 63, Intermediate 64 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 502.2 [M+H]+.
Intermediate 65: l-f5-chloro-2-f4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4- yl 1 H-p yrazole-4-carb aldehyde Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2,5-dichloropyrimidin-4-yl)-lH-pyrazole-
4- carbaldehyde, Intermediate 65 was prepared as described in Method B; MS (ESI) m/z 393.0 [M+H]+.
Intermediate 66: l-(5-chloro-2-(2-methoxy-4-morpholino-5- nitrophenylamino)pyrimidin-4-yl")-lH-pyrazole-4-carbaldehvde
Using Intermediate 65, Intermediate 66 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 460.1 [M+H]+. Intermediate 67: l-(2-(4-(4-(2-fluoroethvnpiperazin-l-yl)-2-methoxy-5- nitrophenylamino)pyrimidin-4-yl)-3-methyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 12 and l-(2-fluoroethyl)piperazine hydrochloride, Intermediate 67 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 485.2 [M+H]+.
Intermediate 68: l-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3-p- tolyl-lH-pyrazole-4-carbaIdehyde Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloropyrimidin-4-yl)-3-p-tolyl-lH- pyrazole-4-carbaldehyde, Intermediate 68 was prepared as described in Method B; MS (ESI) m/z 449.1 [M+H]+.
Intermediate 69: l-(2-(2-methoxy-4-morpholino-5-nitrophenylamino pyrimidin-4-vn- 3-p-tolyl-lH-pyrazole-4-carbaldehvde
Using Intermediate 68, Intermediate 69 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 516.2 [M+H]+. Intermediate 70: l-(2-(4-flnoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3-(4- fluorophenvI)-lH-pyrazoIe-4-carbaldehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloropyrimidin-4-yl)-3-(4- fluorophenyl)- lH-pyrazole-4-carbaldehyde, Intermediate 70 was prepared as described in Method B; MS (ESI) m/z 453.1 [M+H]+.
Intermediate 71: 3-(4-fluorophenyl)-l-(2-(2-methoxy-4-morpholino-5- nitrophenylamino)pyrimidin-4-yl)-lH-pyrazole-4-carbaldehvde Using Intermediate 70, Intermediate 71 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 520.2 [M+H]+.
Intermediate 72 : 3-tert-butyl-l-(2-(2-methoxy-4-morpholino-5-nitrophenyIamino)-5- methylpyrimidin-4-yl)-lH-pyrazoIe-4-carbaldehyde
Using Intermediate 55, Intermediate 72 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 496.2 [M+H]+.
Intermediate 73: l-(2-(4-(dimethylamino)-2-methoxy-5-nitrophenylamino)pyrimidin- 4-yl)-3-phenyl-lH-pyrazoIe-4-carbaldehyde
Using Intermediate 63, Intermediate 73 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 460.2 [M+H]+.
Intermediate 74: l-(2-(4-(azetidin-l-yl)-2-methoxy-5-nitrophenvIamino)pyrimidin-4- v0-3-phenyl-lH-pyrazole-4-carbaldehvde
Using Intermediate 63, Intermediate 74 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 472.2 [M+H]+.
Intermediate 75: 2-chloro-4-(3-phenyl-lH-pyrazol-l-yl)pyrimidine
Using 2,4-dichloropyrimidine and 4 3-phenyl-lH-pyrazole, Intermediate 75 was prepared as described in WO 2013/109882; MS (ESI) m/z 257.1 [M+H]+.
Intermediate 76: 2-methoxy-4-(4-methylpiperazin-l-yl)-5-nitroaniline
Using 4-fluoro-2-methoxy-5-nitroaniline, Intermediate 76 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 267.1 [M+H]+. Intermediate 77: N-(2-methoxy-4-(4-methylpiperazin-l-yl)-5-nitrophenyI)-4-(3- phenyl-lH-pyrazol-l-yl)pyrimidin-2-amine
Using Intermediate 75 and Intermediate 76, the Intermediate 77 was prepared as described in Method B; MS (ESI) m/z 487.2 [M+H]+.
Intermediate 78: 3-tert-butyl-l-(2-(4-fluoro-2-methoxy-5- nitrophenylamino)pyrimidin-4-yQ-lH-pyrazole-4-carbaldehyde Using 4-fluoro-2-methoxy-5-nitroaniline and 3-tert-butyl-lH-pyrazol-4-carbaldehyde, Intermediate 78 was prepared as described in Method B; MS (ESI) m/z 415.2 [M+H]+.
Intermediate 79j 3-tert-butvI-l-(2-(2-methoxy-4-morpholino-5- nitrophenylamino)pyrimidin-4-vn-lH-pyrazole-4-carbaldehvde
Using Intermediate 78, Intermediate 79 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 482.2 [M+H]+.
Intermediate 80: l-(2-(2-methoxy-4-morpholino-5-nitrophenylamino)pyrimidin-4-vI)- 3-(thiophen-2-yi -lH-pyrazole-4-carbaldehvde
Using N-(2-methoxy-4-morpholino-5-nitrophenyl)formamide and 3-(thiophen-2-yl)-lH- pyrazole-4-carbaldehyde, Intermediate 80 was prepared as described in Method A; MS (ESI) m/z 508.1 [M+H]+.
Intermediate 81: 3-(2,5-dimethylphenviVl-(2-(4-fluoro-2-methoxy-5- nitrophenylamino)pyrimidin-4-vI)-lH-pyrazole-4-carbaIdehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloropyrimidin-4-yl)-3-(2,5- dimethylphenyl)-lH-pyrazole-4-carbaldehyde, Intermediate 81 was prepared as described in Method B; MS (ESI) m/z 447.2 [M+H]+.
Intermediate 82: 3-(2,5-dimethylphenvI)-l-(2-(2-methoxy-4-morpholino-5- nitrophenylamino)pyrimidin-4-vI)-lH-pyrazole-4-carbaldehvde
Using Intermediate 81, Intermediate 82 was prepared as described in the preparation of Intermediate 10; MS (ESI) m z 530.2 [M+H]+.
Intermediate 83 : (l-(2-(2-methoxy-4-morpholino-5-nitrophenylamino)pyrimidin-4- yl)-3-phenyl-lH-pyrazol-4-yl)methanol To a solution of Intermediate 64 (0.2 g, 0.40 mmol) in THF (5 mL) was added 4.0 mL of DIBAL (1M solution in toluene) at 0 °C. The reaction mixture was heated at 50 °C for 16 h. Ice water was added into the reaction. Solvent was removed in vacuo and the resulting mixture was extracted with DCM, dried over NaS04. The desired intermediate was purified by column chromatography (0-20% MeOH in DCM) to give 0.16 g as a yellow solid; MS (ESI) m/z 474.2 [M+H]+.
Intermediate 84: 3-isopropyl-l-(2-(2-methoxy-4-morpholino-5- nitrophenvIamino)pyrimidin-4-yl)-lH-pyrazole-4-carbaldehvde
Using N-(2-methoxy-4-morpholino-5-nitrophenyl)formamide and 3-isopropyl-lH- pyrazole-4-carbaldehyde, Intermediate 84 was prepared as described in Method A; MS (ESI) m/z 468.2 [M+H]+.
Intermediate 85: l-(2-(2-methoxy-4-((2-methoxyethvn(methyl)amino)-5- nitrophenylamino)pyrimidin-4-vn-3-phenyl-lH-pyrazole-4-carbaldehvde
Using Intermediate 63, the Intermediate 85 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 504.2 [M+H]+.
Intermediate 86j l-(2-(2-methoxy-4-(methyl(oxetan-3-yl)amino)-5- nitrophenylamino)pyrimidin-4-yl)-3-phenyl-lH-pyrazole-4-carbaldehvde Using Intermediate 63, Intermediate 86 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 502.2 [M+H]+.
Intermediate 87: l-(2-(2-methoxy-5-nitro-4-(pyrrolidin-l-yl)phenyIamino)pyrimidin- 4-vD-3-phenyl-lH-pyrazole-4-carbaldehyde
Using Intermediate 63, Intermediate 87 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 486.2 [M+H]+.
Intermediate 88: 3-tert-butyl-l-(2-f2-methoxy-4-((2-methoxyethyl)(methyl)amino)-5- nitrophenylamino)pyrimidin-4-vI)-lH-pyrazole-4-carbaldehyde
Using Intermediate 78, Intermediate 88 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 484.2 [M+H]+.
Intermediate 89: 3-tert-butyI-l-(2-(2-methoxy-4-(methyl(oxetan-3-yI)amino)-5- nitrophenylammo)pyrimidin-4-yl)-lH-pyrazole-4-carbaidehyde
Using Intermediate 78, Intermediate 89 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 482.2 [M+H]+.
Intermediate 90: 3-tert-butyl-l-(2-(2-methoxy-5-nitro-4-(pyrrolidin-l- yl)phenylamino')pyrimidin-4-yl)-lH-pyrazole-4-carbaldehvde
Using Intermediate 78, Intermediate 90 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 466.2 [M+H]+.
Intermediate 91 : 3-cycIopropyl-l-(2-(2-methoxy-4-((2-methoxyethyl)(methyl)amino)- 5-nitrophenylamino)pyrimidin-4-vn-lH-pyrazole-4-carbaldehvde Using Intermediate 38, Intermediate 91 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 468.2 [M+H]+.
Intermediate 92; 3-cvclopropyl-l-(2-(2-methoxy-4-(methv oxetan-3-yl)amino)-5- nitrophenylamino)pyrimidin-4-yl)-lH-pyrazole-4-carbaldehyde
Using Intermediate 38, Intermediate 92 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 466.2 [M+H]+.
Intermediate 93: 3-cvclopropyl-l-(2-(2-methoxy-5-nitro-4-(pyrrolidin-l- yl)phenylamino)pyrimidin-4-yl)-lH-pyrazole-4-carbaIdehyde
Using Intermediate 38, Intermediate 93 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 450.2 [M+H]+. Intermediate 94: 3-isopropyl-l-(2-(2-methoxy-4-((2-methoxyethyl)(methvI)amino)-5- nitrophenylamino)pyrimidin-4-vI)-lH-pyrazole-4-carbaldehyde
Using N-(2-methoxy-4-((2-methoxyethyl)(methyl)amino)-5-nitrophenyl)formamide and 3- isopropyl-lH-pyrazole-4-carbaldehyde, Intermediate 94 was prepared as described in Method A; MS (ESI) m/z 470.2 [M+H]+.
Intermediate 95 : 3-isopropyI-l-(2-(2-methoxy-4-(methyl(oxetan-3-yl)amino)-5- nitrophenylamino)pyrimidin-4-yl)-lH-pyrazole-4-carbaldehvde Using N-(2-methoxy-4-(methyl(oxetan-3-yl)amino)-5-nitrophenyl)formamide and 3- isopropyl-lH-pyrazole-4-carbaldehyde, Intermediate 95 was prepared as described in Method A; MS (ESI) m/z 468.2 [M+H]+.
Intermediate 96: 3-isopropyl-l-(2-(2-methoxy-5-nitro-4-(pyrrohdin-l- yl)phenylamino)pyrimidin-4-yl)-lH-pyrazole-4-carbaldehyde
Using N-(2-methoxy-5-nitro-4-(pyrrolidin-l-yl)phenyl)formamide and 3-isopropyl-lH- pyrazole-4-carbaldehyde, Intermediate 96 was prepared as described in Method A; MS (ESI) m/z 452.2 [M+H]+.
Intermediate 97: l-(2-(4-fluoro-2-methoxy-5-nitrophenylaminoV5-methvIpyrimidin-
4- yl)-3-phenyl-lH-pyrazole-4-carbaldehvde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-3- phenyl- lH-pyrazole-4-carbaldehyde, Intermediate 97 was prepared as described in Method B; MS (ESI) m/z 449.1 [M+H]+.
Intermediate 98: l-(2-(2-methoxy-4-morpholino-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-3-phenyl-lH-pyrazole-4-carbaIdehyde
Using Intermediate 97, Intermediate 98 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 516.2 [M+H]+.
Intermediate 99: 3-cvclopropyl-l-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)-5- methylpyrimidin-4-yl)-lH-pyrazoIe-4-carbaldehyde
Using 4-fluoro-2-methoxy-5-nitroaniline and l-(2-chloro-5-methylpyrimidin-4-yl)-3- cyclopropyl-lH-pyrazole-4-carbaldehyde, Intermediate 99 was prepared as described in Method B; MS (ESI) m/z 413.1 [M+H]+.
Intermediate 100: 3-cvcIopropyl-l-(2-(2-methoxy-4-morphoIino-5-nitrophenylamino)-
5- methylpyrimidin-4-yl)-lH-pyrazoIe-4-carbaldehyde
Using Intermediate 99, Intermediate 100 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 480.2 [M+H]+.
Intermediate 101 : 3-tert-butvI-l-(2-(4-(ethvU2-methoxyethyl)amino)-2-methoxy-5- nitrophenviamino)pyrimidin-4-yl)-lH-pyrazole-4-carbaldehyde Using Intermediate 78, Intermediate 101 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 498.2 [M+H]+.
Intermediate 102: 3-(furan-3-yl)-l-(2-(2-methoxy-4-morphoIino-5- nitrophenylamino)pyrimidin-4-vn-lH-pyrazole-4-carbaldehvde
Using N-(2-methoxy-4-morpholino-5-nitrophenyl)formamide and 3-(furan-3-yl)-lH- pyrazole-4-carbaldehyde, Intermediate 102 was prepared as described in Method A; MS (ESI) m/z 492.2 [M+H]+.
Intermediate 103: l-(2-((2-methoxy-4-morphoIino-5-nitrophenyl)amino)pyrimidin-4- yl)-3-(pyridine-3-yl)-lH-pyrazole-4-carbaldehvde
Using N-(2-methoxy-4-morpholino-5-nitrophenyl)formamide and 4-(pyridin-3-yl)-lH- pyrazole-3-carbaldehyde, Intermediate 103 was prepared as described in Method A; MS (ESI) m/z 503.2 [M+H]+.
Intermediate 104: l-(2-(4-(4-acetylpiperazin-l-yl)-2-methoxy-5- nitrophenylamino)pyrimidin-4-yl)-3-cvclopropyl-lH-pyrazole-4-carbaldehvde
Using Intermediate 38, Intermediate 104 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 507.2 [M+H]+.
Intermediate 105: l-(5-fluoro-2-(2-methoxy-4-morpholino-5- nitrophenylamino)pyrimidin-4-yl>-4-(furan-3-yl)-lH-pyrrole-3-carbaldehvde
Using N-(2-methoxy-4-morpholino-5-nitrophenyl)formamide and 4-(furan-3-yl)-lH- pyrrole-3-carbaldehyde, Intermediate 105 was prepared as described in Method A; MS (ESI) m/z 509.2 [M+H]+.
Intermediate 106: 3-cvclopropyl-l-(2-(2-methoxy-4-(methyl(oxetan-3-vnamino)-5- nitrophenylamino")-5-methylpyrimidin-4-yl)-lH-pyrazole-4-carbaIdehvde
Using Intermediate 99, Intermediate 106 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 480.2 [M+H]+.
Intermediate 107: l-(2-(4-(4-acerylpiperazin-l-yl)-2-methoxy-5- nitrophenylamino)pyrimidin-4-yl)-3-phenyI-lH-pyrazole-4-carbaldehyde Using Intermediate 63, Intermediate 107 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 543.2 [M+H]+.
Intermediate 108: l-f2-(2-methoxy-4-morpholino-5-nitrophenylamino)pyrimidin-4- vn-3-(pyridin-4-ylVlH-pyrazoIe-4-carbaldehyde
Using N-(2-methoxy-4-morpholino-5-nitrophenyl)formamide and 3-(pyridin-4-yl)-lH- pyrazole-4-carbaldehyde, Intermediate 108 was prepared as described in Method A; MS (ESI) m/z 503.2 [M+H]+. Intermediate 109: l-(2-(4-(azetidin-l-yl)-2-methoxy-5-nitrophenylamino)pyrimidin-4- Vi)-3-cvclopropyI-lH-pyrazoIe-4-carbaldehvde
Using Intermediate 38, Intermediate 109 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 436.2 [M+H]+.
Intermediate 110: l-(2-(4-(azetidin-l-yl)-2-methoxy-5-nitrophenytamino)-5- fluoropyrimidin^-vD^-methyl-lH-pyrroIe -carbaldehyde
Using 1 -(2-chloro-5-fluoropyrimidin-4-yl)-4-methyl-l H-pyrrole-3-carbaldehyde and (azetidin-l-yl)-2-methoxy-5-nitrobenzenamine, Intermediate 110 was prepared described in Method B; MS (ESI) m/z 427.2 [M+H]+.
Intermediate 111: l-(2-(4-(dimethylamino)-2-methoxy-5-nitrophenylamino)-5- fluoropyrimidin-4-ylV4-methyl-lH-pyrroIe-3-carbaldehyde
Using l-(2-chloro-5-fluoropyrimidin-4-yl)-4-methyl-lH-pyrrole-3-carbaldehyde and 5- methoxy-NI,N1-dimethyl-2-nitrobenzene-l,4-diamine, Intermediate 111 was prepared as described in Method B; MS (ESI) m/z 415.2 [M+H]+. Intermediate 112: l-(5-fluoro-2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin- 4-yl)-4-(trifluoromethyI)-lH-pyrrole-3-carbaldehyde
Using 1 -(2-chloro-5-fluoropyrimidin-4-yl)-4-(trifluoromethyl)- 1 H-pyrrole-3 -carbaldehyde and 4-fluoro-2-methoxy-5-nitroaniline, Intermediate 112 was prepared as described in Method B; MS (ESI) m/z 444.1 [M+H]+.
Intermediate 113: l-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5- nitrophenylamino -5-fluoropyrimidin-4-yl)-4-(trifluoromethyl)-lH-pyrrole-3- carbaldehyde Using Intermediate 112, Intermediate 113 was prepared as described in the preparation of Intermediate 10; MS (ESI) m/z 523.2 [M+H]+.
Example 1
Compound 1: N-(3-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxyphenyl)acrylamide
Figure imgf000057_0001
Step 1 :
To a solution of Intermediate 1 (35.0 mg, 0.10 mmol), diisopropylethylamine (DIPEA, 50 Ε, 0.30 mmol) in dimethylacetamide (DMAA, 2 mL) was added 18.5 mg of azetidine hydrochloride (0.20 mmol) at rt. After being stirred for 20 min, 62.8 mg of sodium triacetoxyborohydride (NaBH(OAc)3, 0.30 mmol) was added into the mixture and the resulting mixture was stirred at rt for 16 h. Solvent was evaporated in vacuo and the mixture was purified by column chromatography (0 to 10% MeOH in DCM) to give 4-(4- (azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-N-(2-methoxy-5-nitrophenyl)pyrimidin- 2-amine as a red solid (32.0 mg, 82%); MS (ESI) m/z 396.2 [M+H]+.
Step 2:
To a solution of the nitro compound above (56.0 mg, 0.14 mmol) in 3 mL mixture of ethanol and water (5: 1) were added 78.2 mg of iron (1.42 mmol) and ammonium chloride (38.0 mg, 0.71 mmol). The mixture was heated to 80 °C for 2h. 2M solution of ammonia in MeOH (2mL) was added and the resulting mixture was filtered through Celite. The filtrate was concentrated. The resulting residue was extracted with DCM, washed with
sat.NaHC03 solution, brine, dried over anhydrous Na2S04. The crude oil was purified by column chromatography (0 to 20% MeOH in DCM with 0.1% NH3) to give N-(4-(4- (azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-yl)-6-methoxybenzene- 1,3- diamine as an off-white solid (38.0 mg, 69%); MS (ESI) m/z 366.2 [M+H]+.
Step 3:
To a solution of above aniline (36.0 mg, 0.10 mmol) and DIPEA (18.8 xL, 0.1 1 mmol) in DCM (2 mL) was added a solution of acryloyl chloride (8.01 iL, 0.10 mmol) in DCM (0.2 mL) at -20 °C. The mixture was stirred for 1 h and quenched by addition of sat NaHC03 solution. The mixture was extracted with DCM and dried over anhydrous Na2S04. The crude mixture was purified by column chromatography (0 to 10% MeOH in DCM with 0.1 % NH3) to give the title compound as an off-white solid. (26.9 mg, 65%); MS (ESI) m/z 420.2 [M+H]+. Example 2
Compound 2: N-(3-(4-f4-f(3-hvdroxyazetidin-l-yl)methyl)-3-methyI-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrvIamide
Using Intermediate 1 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 436.2 [M+H]+.
Example 3
Compound 3: N-(3-(4-f4-fazetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino")phenyl)acrylamide
Using Intermediate 2 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 390.2 [M+H]+.
Example 4
Compound 4; N-(3-(4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)phenyl)acrylamide
Using Intermediate 2 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 406.2 [M+H]+.
Example 5
Compound 5: N-(3-(4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l- vnpyrimidin-2-ylamino)-5-methylphenyl)acrylamide
Using Intermediate 3 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 420.2 [M+H]+.
Example 6
Compound 6: N-(,5-(4-(4-((dimethylamino methvn-3-(4-fluorophenyl)-lH-pyrazol-l- vDpyrimidin^-ylamino^^-methoxy^-morpholinophenvnacrvIamide
Using Intermediate 71 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 573.3 [M+H]+.
Example 7
Compound 7: N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide Using Intermediate 72 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 549.3 [M+H]+.
Example 8
Compound 8: N-(3-(4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l-yl)- 5-methylpyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 5 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 450.2 [M+H]+.
Example 9
Compound 9j N-(4-methoxy-3-(4-(3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)phenyl)acrylamide
Using Intermediate 6, the title compound was prepared as described in Example 1; MS (ESI) m/z 351.2 [M+H]+.
Example 10
Compound 10: N-f3-(4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l- yl)-5-methylpyrimidin-2-ylamino)-5-methylphenyl¼crylamide
Using Intermediate 7 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 434.2 [M+H]+.
Example 11
Compound 11: N-(3-(4-(4-((3-hydroxyazetidin-l-yl)methyl)-lH-pyrazol-l-vn-5- methylpyrimidin-2-ylaminoV4-methoxyphenyl)acrylamide
Using Intermediate 8 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 436.2 [M+H]+.
Example 12
Compound 12: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-vnpyrimidin- 2-ylamino)-2-morpholinophenyl)acrylamide
Using Intermediate 10 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 475.3 [M+H]+.
Example 13
Compound 13: N-(2-(4-acetylpiperazin-l-yl -5-(4-(4-(azetidin-l-ylmethyl)-3-methyl- lH-pyrazoI-l-vUpyrimidin^-ylamino^phenvnacrylamide
Using Intermediate 11 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 516.3 [M+H]+.
Example 14
Compound 14: N-(5-(4-(4-(azetidin-l-ylmethylV3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-vIammo)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 13 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 505.3 [M+H]+.
Example 15
Compound 15: N-(5-(4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l- yl)pyrimidin-2-vIamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 13 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 521.3 [M+H]+.
Example 16
Compound 16: N-(5-(4-(4-(azetidin-l-vImethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Using Intermediate 14 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 520.3 [M+H]+.
Example 17
Compound 17: N-(5-(4-f4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-4-methoxy-2-(4-methylpiperazin-l-yl)phenyl)acrylamide
Using Intermediate 15 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 518.3 [M+H]+.
Example 18
Compound 18: N-(5-(4-(4-fazetidin-l-ylmethyl)-3-methvI-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-4-methoxy-2-(piperidin-l-vI phenvnacrylamide
Using Intermediate 16 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 503.3 [M+H]+. Example 19
Compound 19: N-(5-(4-(4-((3-hvdroxya¾etidi-i-l-yl)methvn-lH-pyrazol-l-ylV5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenvnacrylamide
Using Intermediate 18 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 521.3 [M+H]+.
Example 20
Compound 20: N-(5-r4-(4-(((3R.4SV3.4-dihvdroxypyrrolidin-l-vnmethyl)-lH-
Pyrazol-l-yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2- morpholinophenvDacrylamide
Using Intermediate 18 and (3R,4S)-pyrrolidine-3,4-diol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 551.3 [M+H]+.
Example 21
Compound 21: N-f5-(4-(4-(((3S,4R)-3-hvdroxy-4-methoxypyrrolidin-l-yl)methyl)-lH- pyrazol-l-yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2- morpholinophenvDacrylamide
Using Intermediate 18 and (3S,4R)-4-methoxypyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 565.3 [M+H]+.
Example 22
Compound 22: N-(5-(4-(4-((dimethylamino)methyl)-lH-pyrazol-l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 18 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 493.3 [M+H]+.
Example 23
Compound 23: N-(4-methoxy-5-(5-methyl-4-(4-((methyl(l-methylazetidin-3- yl)amino)methyl)-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-2- morpholinophenvDacrylamide
Using Intermediate 18 and N,l-dimethylazetidin-3 -amine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 548.3 [M+H]+.
Example 24
Compound 24: N-(5-(4-r4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l- yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 20 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 535.3 [M+H]+.
Example 25
Compound 25: N-(5-(4-(4-( 3R,4S)-3,4-dihvdroxypyrroIidin-l-yl)methyl)-3-methyl- lH-pyrazol-1 -yI)-5-methylpyrimidin-2-ylamino)-4-methoxy-2- morpholinophenyDacrylamide
Using Intermediate 20 and (3R,4S)-pyrrolidine-3,4-diol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 565.3 [M+H]+.
Example 26
Compound 26 : N-( 5-( 4-( 4-( ((3S.4RV3-hy droxy-4-methoxypyrrolidin-l-yl)methyl)-3- methyl-lH-pyrazol-l-yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2- morpholinophenyl)acrylamide
Using Intermediate 20 and (3S,4R)-4-methoxypyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 579.3 [M+H]+.
Example 27
Compound 27: (R)-N-(5-(4-(4-((3-hvdroxypyrroIidin-l-yl)methvn-3-methyl-lH- pyrazol-l-vn-5-methylpyrimidin-2-ylaminoV4-methoxy-2- morpholinophenvDacrylamide
Using Intermediate 20 and (R)-pyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 549.3 [M+H]+.
Example 28
Compound 28: fSVN-(5-f4-f4-rt3-hvdroxypyrrolidin-l-ynmethvn-3-methyl-lH- pyrazol-l-yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2- morpholinophenvOacrylamide
Using Intermediate 20 and (S)-pyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 549.3 [M+H]+.
Example 29
Compound 29: N-(5-(4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l- yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2-(4-methyIpiperazin-l- vDphenvDacrylamide
Using Intermediate 21 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 548.3 [M+H]+.
Example 30
Compound 30: N-(5-(4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methvI-lH-pyrazol-l- yl)-5-methvIpyrimidin-2-ylamino)-4-methoxy-2-(piperidin-l-yl)phenyl)acrylamide
Using Intermediate 22 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 533.3 [M+H]+.
Example 31
Compound 31: N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(4-((3- hvdroxyazetidin-l-vnmethyl)-3-methyl-lH-pyrazol-l-yl)-5-methylpyrimidin-2- ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 23 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 550.3 [M+H]+.
Example 32
Compound 32: N-(5-(4-(4-(azetidin-l-ylmethylVlH-pyrazol-l-yl)-5-methylpyrimidin- 2-ylaminoV4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 18 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 505.3 [M+H]+.
Example 33
Compound 33: N-(4-methoxy-5-(5-methyl-4-(4-(morpholinomethyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-2-(4-methylpiperazin-l-yl)phenyl)acrylamide
Using Intermediate 24 and morpholine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 548.3 [M+H]+.
Example 34
Compound 34: N-(5-(4-(4-(azetidin-l-ylmethylVlH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 26 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 491.2 [M+H]+. Example 35
Compound 35: (S)-N-(5-(4-(4-r(3-(dimethylamino)pyrrolidin-l-yl)methyl)-lH- Pyrazol-l-yl)pyrimidin-2-ylamino -4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 26 and (S)-N,N-dimethylpyrrolidin-3 -amine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 548.3 [M+H]+.
Example 36
Compound 36: N-(5-(4-(4-fazetidin-l-ylmethyl)-lH-pyrazol-l-yl)-5-methylpyrimidin- 2-ylamino)-4-methoxy-2-(4-methylpiperazin-l-vI)phenyl)acrylamide
Using Intermediate 24 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 518.3 [M+H]+.
Example 37
Compound 37: N-(2-(4-acetylpiperazin-l-yl)-5-(4-(4-(azetidin-l-ylmethyl)-lH- PVrazol-l-yl)-5-methylpyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 27 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 546.3 [M+H]+.
Example 38
Compound 38: N-(5-(4-(4-(azetidin-l-ylmethyl)-lH-pyrazol-l-vnpyrimidin-2- ylamino)-2-(dimethylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 28 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 449.2 [M+H]+.
Example 39
Compound 39: (R)-N-(5-(4-(4-((3-(dimethylamino)pyrrolidin-l-yl)methyl)-lH- pyrazol-l-vnpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 26 and (R)-N,N-dimethylpyrrolidin-3 -amine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 548.3 [M+H]+.
Example 40
Compound 40: N-(5-(4-(4-(azetidin-l-ylmethyl)-lH-pyrazoI-l-vI)-5-methylpyrimidin- 2-ylamino)-4-methoxy-2-(l,4-oxazepan-4-yl)phenyl)acrylamide Using Intermediate 29 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 519.3 [M+H]+.
Example 41
Compound 41 : N-(5-(4-(4-(azetidin-l-ylmethvIVlH-pyrazol-l-ylV5-methylpyrimidin- 2-ylamino)-4-methoxy-2-(4-methyl-l,4-diazepan-l-yl)phenyl)acrylamide
Using Intermediate 30 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 532.3 [M+H]+.
Example 42
Compound 42; N-(5-(4-(4-(azetidin-l-ylmethyi)-lH-pyrazol-l-yl)-5-methylpyrimidin- 2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Using Intermediate 31 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 520.3 [M+H]+.
Example 43
Compound 43: N-(2-((2-(dimethylamino)ethyl methvnaminoV5-(4-(4-(((3S.4RV3- hvdroxy-4-methoxypyrrolidin-l-yl)methyl)-lH-pyrazo -l-yl)-5-methylpyrimidin-2- ylamino')-4-methoxyphenyl¼crylamide
Using Intermediate 31 and (3S,4R)-4-methoxypyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 580.3 [M+H]+.
Example 44
Compound 44: N-f4-methoxy-5-(4-(4-((3-methoxyazetidin-l-yl)methyl)-3-methyl-lH- pyrazol-l-vnpyrimidin-2-vIamino)-2-morpholinophenyl)acrylamide
Using Intermediate 13 and 3-methoxyazetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 535.3 [M+H]+.
Example 45
Compound 45: N-(5-(4-(4-(f(3S,4R)-3-hydroxy-4-methoxypyrrolidin-l-vI)methyI)-3- methvI-lH-pyrazol-l-vDpyrimidin-2-ylaminoV4-methoxy-2- morpholinophenvDacrylamide
Using Intermediate 13 and (3S,4R)-4-methoxypyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 565.3 [M+H]+. Example 46
Compound 46: N-(5-(4-(4-((dimethylamino)methylV3-methyl-lH-pyrazoI-l- yl)pyrimidin-2-vIaminoV4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 13 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 493.3 [M+H]+.
1H NMR: δ (DMSO-de), 2.13 ppm (6H, s), 2.26 ppm (3H, s), 2.83-2.86 ppm (4H, t), 3.80-3.81 ppm (4H, t), 3.90 ppm (3H, s), 5.80 ppm (1H, d), 6.34-6.39 ppm (1H, d), 6.67-6.76 ppm (1H, q), 6.94 (1H, s), 7.17 ppm (1H, d), 8.09 ppm (1H, s), 8.45 ppm (1H, d), 8.91 ppm (1H, s), 9.01 ppm (1H, s), 9.12 ppm (1H, s)
Example 47
Compound 47: N-(5-(4-(4-((dimethylamino)methvn-3-methyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-l-yl)phenyl)acrylamide
Using Intermediate 15 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 506.3 [M+H]+.
Example 48
Compound 48: N-(5-(4-(3-((3-hydroxyazetidin-l-yl)methyl)-4-methyl-lH-pyrrol-l-vn- 5-methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 33 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 534.3 [M+H]+.
Example 49
Compound 49: N-(5-(5-chloro-4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH- pyrazol-l-yl)pyrimidin-2-ylaminoV4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 35 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 555.2 [M+H]+.
Example 50
Compound 50: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yI)-5- chloropyrimidin-2-ylamino')-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 35 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 539.2 [M+H]+. Example 51
Compound 51 : N-(5-(5-chloro-4-(4-(((3S,4RV3-hvdroxy-4-methoxypyrrolidin-l- vI)methyl)-3-methvI-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxy-2- morpholinophenvDacrylamide
Using Intermediate 35 and (3S,4R)-4-methoxypyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 599.2 [M+H]+.
Example 52
Compound 52 : N-(5-(5-chloro-4-(4-( (dimethylamino)methyr)-3-methy 1- 1 H-pyrazol-1 - yl)pyrimidin-2-ylaminoV4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 35 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 527.2 [M+H]+.
Example 53
Compound 53: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-4-methoxy-2-(lH-pyrazol-l-yl)phenyl)acrylamide
Using Intermediate 36 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 539.2 [M+H]+.
Example 54
Compound 54: N-(5-f 5-chloro-4-(4-( ( (3R,4S)-3,4-dihvdroxypyrrolidin-l -yl)methyl)-3- methyl-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-l- vDphenvDacrylamide
Using Intermediate 37 and (3R,4S)-pyrrolidine-3,4-diol hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 598.3 [M+H]+.
Example 55
Compound 55: N-(5-(4-(4-(azetidin-l-ylmethv -3-cvclopropyl-lH-pyrazol-l- yl")pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl¼crylamide
Using Intermediate 39 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 531.3 [M+H]+.
Ή NMR: δ (DMSO-de), 0.90-0.95 ppm (4H, m), 1.92-2.03 ppm (3H, m), 2.84-2.85 ppm (4H, m), 3.14 ppm (4H, t), 3.53 ppm (2H, s), 3.80-3.82 ppm (4H, m), 3.89 ppm (3H, s), 5.82 ppm (IH, d), 6.39-6.44 (IH, d), 6.69-6.78 ppm (IH, q), 6.93 ppm (IH, s), 7.09 ppm (IH, d), 8.09 ppm (IH, s), 8.43 ppm (IH, d), 8.85 ppm (IH, s), 8.98 ppm (IH, s), 9.14 ppm (lH, s)
Example 56
Compound 56: N-(5-(4-(3-cvc opropyl-4-(((3S,4R)-3-hvdroxy-4-methoxypyrrolidin-l- yl)methylVlH-pyrazoI-l-yl)pyrimidin-2-ylamino)-4-methoxy-2- morpholinophenvDacrylamide
Using Intermediate 39 and (3S,4R)-4-methoxypyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 591.3 [M+H]+.
Example 57
Compound 57: N-(3-(4-(4-((3-hvdroxyazetidin-l-yl methyl)-3-methyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-5-(l-methyl-lH-pyrazol-4-yl)phenyl¼crylamide
Using Intermediate 41 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 486.2 [M+H]+.
Example 58
Compound 58: N-(5-(4-(4-((3-hvdroxyazetidin-l-yl)methyl)-3-methyl-lH-pyrazol-l- vDpyrimidin-l-ylamino^^-methoxy^-d-methyl-lH-pyrazoM-yDphenyDacrylamide
Using Intermediate 43 and azetidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 516.2 [M+H]+.
Example 59
Compound 59: N-f5-f4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-vnpyrimidin- 2-ylamino)-4-methoxy-2-(l-methyl-l,2,3,6-tetrahvdropyridin-4-vI)phenyl)acrylamide
Using Intermediate 45 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 515.3 [M+H]+.
Example 60
Compound 60: N-(5-(4-(3-(azetidin-l-yImethyl)-4-methyl-lH-pyrrol-l-vn-5- fluoropyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 47 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 522.3 [M+H]+. Example 61
Compound 61 ; N-(5-(5-fluoro-4-(4-(((3S,4R -3-hvdroxy-4-methoxypyrrolidin-l- yl)methyl)-3-methyI-lH-pyrazol-l-vI')pyrimidin-2-ylamino)-4-methoxy-2- morpholinophenvDacrylamide
Using Intermediate 48 and (3S,4R)-4-methoxypyrrolidin-3-ol hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 583.3 [M+H]+.
Example 62
Compound 62: N-(5-(4-("4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl -5- fluoropyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl¼crylamide
Using Intermediate 48 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 523.3 [M+H]+.
Example 63
Compound 63: N-(5-(4-(4-(azetidin-l-ylmethyl)-lH-pyrazol-l-yl)-5-methylpyrimidin- 2-ylamino)-4-isopropoxy-2-morpholinophenyl)acrylamide
Using Intermediate 50 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 533.3 [M+H]+.
Example 64
Compound 64: N-(5-(4-(4-(azetidin-l-ylmethyl)-lH-pyrazol-l-yl)-5-methylpyrimidin- 2-ylamino)-4-methoxy-2-(l-methvI-l,2,3,6-tetrahvdropyridin-4-yl)phenvnacrylamide
Using Intermediate 51 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 515.3 [M+H]+.
Example 65
Compound 65: N-(4-(4-(4-(azetidin-l-ylmethyl -3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino -5-methoxybiphenyl-2-yl)acrylamide
Using Intermediate 53 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 496.2 [M+H]+.
Example 66
Compound 66: N-(5-(4-(4-(hvdroxymethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide Using Intermediate 54, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 466.2 [M+H]+.
Example 67
Compound 67: N-(5-(4-(4-(azetidin-l-ylmethvn-3-tert-butyl-lH-pyrazol-l-vn-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 72 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 561.3 [M+H]+.
Example 68
Compound 68: N-(4-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-2',5-dimethoxybiphenyl-2-yl)acrylamide
Using Intermediate 57 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 526.3 [M+H]+.
Example 69
Compound 69: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-2-(4<4-difluoropiperidin-l-vn-4-methoxyphenyI)acrylamide
Using Intermediate 59 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 539.3 [M+H]+.
Example 70
Compound 70: N-(5-(4-(4-(azetidin-l-ylmethyl)-3,5-dimethyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 61 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 519.3 [M+H]+.
Example 71
Compound 71 : N-(2-(dimethylamino)-5-(4-(4-((dimethylamino)methylV3-methyl-lH- pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxypheny0acrylamide
Using Intermediate 62 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 451.3 [M+H]+.
Example 72
Compound 72: N-(5-f4-(4-((3-fluoroazetidin-l-vI)methyl)-3-methyI-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morphoIinophenyl acrylamide
Using Intermediate 13 and 3-fluoroazetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 523.3 [M+H]+.
Example 73
Compound 73: N-f5-(4-(4-(fdimethylamino)methyl)-3-phenyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide Using Intermediate 64 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 555.3 [M+H]+.
1H NMR: δ (DMSO-di), 2.21 ppm (6H, s), 2.85-2.86 ppm (4H, t), 3.46 ppm (2H, s), 3.81-3.83 ppm (4H, t), 3.91 ppm (3H, s), 5.82-6.43 ppm (2H, dd), 6.72-6.76 ppm (IH, dd), 6.96 ppm (IH, s), 7.34-7.35 (IH, d), 7.41-7.43 ppm (IH, t), 7.47-7.50 ppm (2H, t), 8.04-8.05 ppm (2H, d), 8.18 ppm (IH, s), 8.53-8.54 ppm (IH, d), 9.07 ppm (IH, s), 9.15 ppm (2H, s)
Example 74
Compound 74: N-(5-(4-(3-cvclopropyl-4-((dimethylamino)methyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 39 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 519.3 [M+H]+.
1H NMR (500MHz, DMSO-d6) δ ppm 0.92-0.95 (m, 4H), 2.00-2.06 (m, IH), 2.19 (br s, 4H), 3.18 (br s, 4H), 3.44 (s, 2H), 3.82 (d, J = 4.5 Hz, 4H), 3.91 (s, 3H), 5.80 (dd, J = 1.5 Hz, 10 Hz, IH), 6.37 (dd, J = 2.0 Hz, 17 Hz, IH), 6.45-6.68 (m, IH), 6.96 (s, IH), 7.13 (d, J = 5.0 Hz, IH), 8.00 (s, IH), 8.44 (d, J = 5.0 Hz, IH), 8.86 (s, IH), 9.05 (br d, J = 7.0 Hz, IH)
Example 75
Compound 75: N-(5-(4-(4-((dimethylamino)methyl)-3-methyl-lH-pyrazol-l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 20 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 507.3 [M+H]+.
Ή NMR: δ (DMSO-d6), 2.12 ppm (6H, s), 2.26 ppm (3H, s), 2.82-2.84 ppm (4H, t), 3.79-3.81 ppm (4H, t), 3.90 ppm (3H, s), 5.79 ppm (IH, d), 6.31-6.36 ppm (IH, d), 6.66-6.75 ppm (1H, q), 6.93 (1H, s), 7.96 ppm (1H, d), 8.37 ppm (1H, s), 8.83 ppm (1H, d), 8.89 ppm (1H, s), 9.1 1 ppm (1H, s)
Example 76
Compound 76: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenvI)acrylamide
Using Intermediate 20 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 519.3 [M+H]+.
Example 77
Compound 77: N-(5-(5-chloro-4-(4-((dimethylamino)methyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 66 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 513.2 [M+H]+.
Example 78
Compound 78: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-phenyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 64 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 567.3 [M+H]+.
1H NMR (500 MHz, DMSO-d6) δ 2.01-1.96 (m, 2H), 2.89-2.87 (m, 4H), 3.18 (s, 2H),
3.21-3.18 (m, 4H), 3.85-3.83 (m, 4H), 3.93 (s, 3H), 5.85 (d, J = 10 Hz, 1H), 6.46 (d, J = 17 Hz, 1H), 6.73 (dd, J = 17.0, 10.0 Hz, 1H), 6.99 (s, 1H), 7.35 (d, J = 5.5 Hz, 1H), 7.45-7.42 (m, 1H), 7.51 (t, J = 8.0 Hz, 2H), 8.01 (d, J = 8.5 Hz, 2H), 8.12 (s, 1H), 8.53 (d, J = 5.0 Hz, 1H), 9.07 (s, 1H), 9.08 (b rs, 1H).
Example 79 - - - - - ·■ -— -
Compound 79: N-(5-(4-(4-((dimethylamino)methyl)-3-methyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-2-(4-(2-fluoroethyl)piperazin-l-ylV4- methoxyphenvDacrylamide
Using Intermediate 67 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 538.3 [M+H]+.
Example 80
Compound 80: N-(5-(4-f4-((dimethylamino)methyl)-3-p-tolyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morphoIinophenyl)acrylamide
Using Intermediate 69 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 569.3 [M+H]+.
Example 81
Compound 81: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-(4-fluorophenyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide Using Intermediate 71 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 585.3 [M+H]+.
Example 82
Compound 82 : N-(5-(4-(4-(azetidin-l -ylmethyl)-3-p-to.yl-lH-pyrazol- 1 -vDpyrimidin- 2-ylamino)-4-methoxy-2-morpholinophenyDacrylamide
Using Intermediate 69 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 581.3 [M+H]+.
Ή NMR: δ (DMSO-d6), 1.08-1.23 ppm (4H, m), 1.96 ppm (2H, t), 2.37 ppm (4H, s), 2.85-2.86 ppm (5H, m), 3.18 ppm (4H, t), 3.57 ppm (3H, s), 3.81-3.83 ppm (5H, m), 3.91 ppm (3H, s), 5.86 ppm (IH, d), 6.45-6.50 ppm (IH, d), 6.72-6.81 ppm (IH, q), 6.96 (IH, s), 7.28-7.32 ppm (3H, m), 7.90 ppm (2H, d), 8.19 ppm (IH, s), 8.52 ppm (IH, d), 9.07 ppm (2H, d), 9.17 ppm ( 1 H, s)
Example 83
Compound 83: N-(2-(dimethylaminoV5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH- pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 73 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 513.3 [M+H]+.
Ή NMR: δ (DMSO-d6), 2.21 ppm (6H, s), 2.66 ppm (6H, s), 3.46 ppm (2H, s), 3.91 ppm (3H, s), 5.77-5.81 ppm (IH, dd), 6.37-6.43 ppm (IH, d), 6.75-6.84 ppm (IH, q), 6.91 (IH, s), 7.33 ppm (IH, d), 7.40-7.51 ppm (3H, m), 8.04 ppm (2H, d), 8.16 ppm (IH, s), 8.52 ppm (IH, d), 8.98 ppm (IH, br), 9.1 1 ppm (IH, s), 9.28 ppm (IH, s)
Example 84
Compound 84: N-(2-(azetidin-l-yl)-5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH- pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 74 and dimethylamine, the title compound was prepared as described in Example 1; MS (ESI) m/z 525.3 [M+H]+.
Example 85
Compound 85: N-(4-methoxy-2-(4-methylpiperazin-l-ylV5-(4-(3-phenyl-lH-pyrazol- l-yl)pyrimid -2^1amino phenyl)acrylamide Using Intermediate 77, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 51 1.3 [M+H]+.
Example 86
Compound 86: N-(5-(4-(3-tert-buryl-4-((dimethylamino)methyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 79 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 535.3 [M+H]+. Ή NMR: δ (DMSO-d6), 1.39 ppm (9H, s), 2.15 ppm (6H, s), 2.83-2.85 ppm (4H, t), 3.40 ppm (2H, s), 3.81 ppm (4H, t), 3.90 ppm (3H, s), 5.86 ppm (IH, d), 6.35-6.41 ppm (IH, d), 6.68-6.77 ppm (IH, q), 6.94 (IH, s), 7.18 ppm (IH, d), 8.09 ppm (IH, s), 8.46 ppm (IH, d), 8.88 ppm (IH, s), 9.01 ppm (IH, s), 9.12 ppm (IH, s) Example 87
Compound 87: N-r2-(azetidin-l-yl -5-(4-(4-(azetidin-l-ylmethylV3-phenyl-lH- pyrazol-l-vnpyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 74 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 537.3 [M+H]+.
1H NMR: δ (DMSO-d6), 1.05-1.30 ppm (4H, m), 1.97 ppm (2H, t), 2.20-2.27 ppm (3H, m), 3.15 ppm (4H, t), 3.57 ppm (2H, s), 3.83-3.86 ppm (10H, m), 5.77 ppm (IH, d), 6.24 ppm (IH, s), 6.33-6.38 (IH, d), 6.51-6.60 ppm (IH, q), 7.22 ppm (IH, d), 7.42-7.52 ppm (3H, m), 7.93-8.00 ppm (3H, m), 8.18 ppm (IH, s), 8.46 ppm (IH, d), 8.73 ppm (IH, s), 9.32 ppm (IH, s)
Example 88
Compound 88: N-(5-(4-(4-((dimethylamino)methyl)-3-(thiophen-2-vI)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl acrylamide Using Intermediate 80 and dimethylamine, the title compound was prepared as described in Example 1; MS (ESI) m/z 561.2 [M+H]+. Ή NMR: δ (DMSO-d6), 2.22 ppm (6H, s), 2.84 ppm (4H, t), 3.51 ppm (2H, s), 3.81 ppm (4H, t), 3.91 ppm (3H, s), 5.82-5.86 ppm (1H, dd), 6.39-6.45 ppm (1H, d), 6.70-6.79 ppm (1H, q), 6.96 (1H, s), 7.19 ppm (1H, t), 7.27 ppm (1H, d), 7.62 ppm (1H, d), 7.78 ppm (1H, d), 8.18 ppm (1H, s), 8.53 ppm (1H, d), 9.06 ppm (1H, s), 9.15 ppm (2H, s) Example 89
Compound 89: N-(5-(4-f4-(fdimethylamino)methyl)-3-(2,5-dimethylphenyl)-lH- PVrazol-l-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenvnacrylamide
Using Intermediate 82 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 583.3 [M+H]+.
Example 90
Compound 90: N-(4-methoxy-2-morpholino-5-(4-(3-phenyl-4-(pyrrolidin-l-ylmethyl)- lH-pyrazol-l-yl)pyrimidin-2-ylamino)phenyl)acrylamide
Using Intermediate 64 and pyrrolidine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 581.3 [M+H]+. i NMR: δ (DMSO-d6), 1.65-1.75 ppm (4H, m), 2.85 ppm (4H, s), 3.66 ppm (2H, s), 3.81 ppm (4H, t), 3.91 ppm (3H, s), 5.79-5.83 ppm (1H, d), 6.35-6.40 ppm (1H, d), 6.69-6.78 ppm (1H, q), 6.96 (1H, s), 7.34..ppm (1H, d), 7.42-7.52 ppm (3H, m), 8.04 ppm (2H, d), 8.19 ppm (1H, s), 8.53 ppm (1H, d), 9.04 ppm (1H, s), 9.12 ppm (2H, d)
Example 91
Compound 91 : N-(5-(4-(4-(hvdroxymethyl)-3-phenvI-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 83, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 528.2 [M+H]+.
Example 92
Compound 92: N-(5-(4-f4-((ethyl(methvI)amino)methyl)-3-phenyl-lH-pyrazol-l- vnpyrimidin-2-ylaminoV4-methoxy-2-morphoIinophenyl)acrylamide Using Intermediate 64 and N-ethylmethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 569.3 [M+H]+.
Ή NMR: δ (DMSO-de), 1.04 ppm (3H, t), 2.17 ppm (6H, s), 2.84-2.86 ppm (4H, t), 3.53 ppm (2H, s), 3.81-3.82 ppm (4H, t), 3.91 ppm (3H, s), 5.81 ppm (1H, d), 6.36-6.42 ppm (1H, d), 6.69-6.78 ppm (1H, q), 6.96 (1H, s), 7.34 ppm (1H, d), 7.36-7.51 ppm (3H, m), 8.07 ppm (2H, d), 8.19 ppm (1H, s), 8.54 ppm (1H, d), 9.06 ppm (1H, s), 9.14 ppm (2H, d)
Example 93
Compound 93: N-(5-(4-(4-((dimethylamino)methyl)-3-isopropyI-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 84 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 521.3 [M+H]+. Example 94
Compound 94: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l- vDpyrimidin-2-ylamino)-4-methoxy-2-((2- methoxyethyl)(methyI)amino)phenyI)acrylamide Using Intermediate 85 and dimethylamine, the title compound was prepared as described in Example 1; MS (ESI) m/z 557.3 [M+H]+.
Example 95
Compound 95: N-(5-(4-(4-(azetidin-l-ylmethyl -3-phenyl-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-4-methoxy-2-((2-methoxyethvn(methvnamino)phenyl)acrylamide
Using Intermediate 85 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 569.3 [M+H]+. Example 96
Compound 96: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide
Using Intermediate 86 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 555.3 [M+H]+.
1H NMR: δ (DMSO-d6), 2.22 ppm (6H, s), 3.47 ppm (2H, s), 3.87 ppm (3H, s), 4.42-4.49 ppm (3H, m), 4.61-4.65 ppm (2H, t), 5.83 ppm (1H, d), 6.40-6.46 ppm (1H, dd), 6.73 ppm (1H, s), 6.78-6.87 ppm (1H, q), 7.35 ppm (1H, d), 7.40-7.52 ppm (3H, m), 8.05 ppm (2H, d), 8.18 ppm (1H, s), 8.54 ppm (1H, d), 9.12 ppm (2H, d), 9.30 ppm (1H, s) Example 97
Compound 97: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-phenyl-lH-pyrazol-l-yl)pyrimidin- 2-vIamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenvnacrylamide
Using Intermediate 86 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 567.3 [M+H]+.
Example 98
Compound 98: N-(5-(4-(4-f(dimethylamino)methyl)-3-phenyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-(pyrrolidin-l-yl)phenyl)acrylamide
Using Intermediate 87 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 539.3 [M+H]+.
Example 99
Compound 99: N-(5-(4-(4-(azetidin-l-vImethyl)-3-phenvI-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-4-methoxy-2-(pyrrolidin-l-yl)phenyl)acrylamide
Using Intermediate 87 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 551.3 [M+H]+.
Example 100
Compound 100: N-(5-(4-(3-tert-buryl-4-((dimethylamino)methyQ-lH-pyrazol-l- yl)pyrimidin-2-vIamino)-4-methoxy-2-((2- methoxyethyl)(methyl)amino)phenyl)acrylamide
Using Intermediate 88 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 537.3 [M+H]+.
Example 101
Compound 101 : N-(5-(4-(4-(azetidin-l-ylmethylV3-tert-butyl-lH-pyrazoI-l- vI)pyrimidin-2-ylamino')-4-methoxy-2-(f2- methoxyethyl)(methyl)amino)phenyl)acrylamide
Using Intermediate 88 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 549.3 [M+H]+.
Example 102
Compound 102 : N-(5-( 4-(3-tert-butyl-4-( (dimethylamino)in ethyl)- 1 H-pyrazoI- 1 - vI)pyrimidin-2-ylamino 4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)aci lamide
Using Intermediate 89 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 535.3 [M+H]+.
Example 103
Compound 103: N-(5-(4-(4-(azetidin-l-ylmethylV3-tert-butyI-lH-pyrazoI-l- yl)pyrimidin-2-vIamino)-4-methoxy-2-(methyl(oxetan-3-yl¼mino)phenyl)acrylamide
Using Intermediate 89 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 547.3 [M+H]+.
Example 104
Compound 104: N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-fpyrrolidin-l-yl)phenyl)acrylamide
Using Intermediate 90 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 519.3 [M+H]+.
Example 105
Compound 105: N-(5-(4-(4-(azetidin-l-ylmethylV3-tert-butyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-(pyrrolidin-l-yl)phenyl)acrylamide
Using Intermediate 90 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 531.3 [M+H]+.
Example 106
Compound 106: N-(5-(4-(3-cvclopropyl-4-((dimethylamino)methylVlH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-((2- methoxyethyD(methyl¼mino)phenyl)acirlamide
Using Intermediate 91 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 521.3 [M+H]+.
Example 107
Compound 107: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-cyclopropyl-lH-pyrazol-l- vDpyrimidin-2-ylamino)-4-methoxy-2-((2- methoxyethyl)(methyI)amino)phenyl)acrylamide
Using Intermediate 91 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 533.3 [M+H]+.
Example 108
Compound 108; N-(5-(4-(3-cvclopropyl-4-f(dimethylamino)methyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-(methyl(oxetan-3-vnamino)phenyl)acrylamide
Using Intermediate 92 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 519.3 [M+H]+.
Example 109
Compound 109: N-(5-(4-(4-(azetidin-l-ylmethvn-3-cyclopropyl-lH-pyrazol-l- vnpyrimidin-2-ylaminoV4-methoxy-2-(methyl(oxetan-3-yl amino)phenyl)acrylamide
Using Intermediate 92 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 531.3 [M+H]+.
Example 110
Compound 110: N-(5-(4-(3-cvclopropyl-4-((dimethylamino')methyl')-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-(pyrrolidin-l-yl)phenyl)acrylamide
Using Intermediate 93 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 503.3 [M+H]+.
Example 111
Compound 111: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-cvclopropyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-(pyrrolidin-l-yl)phenyl)acryIamide
Using Intermediate 93 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 515.3 [M+H]+.
Example 112
Compound 112: N-(5-(4-(4-((dimethylamino)methyl)-3-isopropyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-((2- methoxyethylKmethvOamino)phenyl)acrylamide
Using Intermediate 94 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 523.3 [M+H]+.
Example 113
Compound 113: N-f5-(4-f4-(azetidin-l-ylmethyl)-3-isopropyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-((2- methoxyethylHmethvDamino phenvOacrylamide
Using Intermediate 94 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 535.3 [M+H]+.
Example 114
Compound 114: N-(5-(4-(4-((dimethylamino)methyl)-3-isopropyl-lH-pyrazol-l- vI)pyrimidin-2-vIamino)-4-methoxy-2-(methyl(oxetan-3-yOamino)phenyl)acrylamide
Using Intermediate 95 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 521.3 [M+H]+.
Example 115
Compound 115: N-(5-(4-(4-(azetidin-l -ylmethyl)-3-isoprop yl-1 H-pyrazol- 1- yl)pyrimidin-2-ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acryIamide
Using Intermediate 95 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 533.3 [M+H]+.
Example 116
Compound 116: N-(5-(4-(4-((dimethylamino)methyl)-3-isopropyI-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-(pyrrolidin-l-yl)phenyl acrylamide
Using Intermediate 96 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 505.3 [M+H]+.
Example 117
Compound 117: N-(5-(4-(4-(azetidin- 1 -ylmethvD-3-iso p r op yl- 1 H-p yrazol- 1 - vnpyrimidin-2-ylamino)-4-methoxy-2-(pyrrolidin-l-vnphenyl)acrylamide
Using Intermediate 96 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 517.3 [M+H]+.
Example 118
Compound 118: N-(5-(4-(4-(azetidin-l-ylmethylV3-(thiophen-2-yl -lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 80 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 573.2 [M+H]+. Example 119
Compound 119: N-(5-(4-f4-razetidin-l-ylmethylV3-isopropyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 84 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 533.3 [M+H]+.
Example 120
Compound 120: N-(5-(4-(4-(fdimethylamino)methyl)-3-phenyl-lH-pyrazol-l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 98 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 569.3 [M+H]+.
Example 121
Compound 121 : N-(5-(4-(4-(azetidin-l-ylmethyl)-3-phenyl-lH-pyrazoI-l-vI)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 98 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 581.3 [M+H]+.
Example 122
Compound 122: N-(5-(4-(3-cvclopropyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)- 5-methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 100 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 533.3 [M+H]+.
1H NMR (500MHz, DMSO-d6) δ ppm 0.89-0.96 (m, 4H), 2.05-2.09 (m, 1H), 2.30 (br s, 4H), 2.46 (s, 3H), 2.85-2.87 (m, 4H), 3.18 (br s, 4H), 3.82 (t, J = 4.5 Hz, 4H), 3.90 (s, 3H), 5.79 (dd, J = 1.5, 10.0 Hz, 1H), 6.33 (dd, J = 1.5, 17 Hz, 1H), 6.64-6.69 (m, 1H), 6.95 (s, 1H), 7.88 (s, 1H), 8.35 (s, 1H), 8.85 (s, 1H), 8.90 (s, 1H), 9.03 (s, 1H).
Example 123
Compound 123: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-cvclopropyl-lH-pyrazol-l-yl)-5- methylpyrimidin-2-vIamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 100 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 545.3 [M+H]+. Example 124
Compound 124: N-f5-(4-(4-((dimethylamino)methyl)-3-isopropyl-lH-pyrazol-l-yl)-5- methvIpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenvI)acrylamide
Using Intermediate 4 and dimethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 535.3 [M+H]+.
Example 125
Compound 125: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-isopropyI-lH-pyrazol-l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morphoIinophenvnacrylamide
Using Intermediate 4 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 547.3 [M+H]+.
Example 126
Compound 126: N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-2-('ethyl(2-methoxyethyl)amino)-4- methoxyphenvDacrylamide
Using Intermediate 101 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 551.3 [M+H]+.
Example 127
Compound 127: N-(5-(4-(4-((dimethylamino)methvn-3-(furan-3-yl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 102 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 545.3 [M+H]+.
Example 128
Compound 128: N-(5-(4-(4-((dimethylamino)methyl)-3-(pyridin-3-yl)-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 103 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 556.3 [M+H]+.
Example 129
Compound 129: N-(2-(4-acetylpiperazin-l-yl -5-(4-(3-cvclopropyl-4-
((dimethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4- methoxyphenvDacrylamide
Using Intermediate 104 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 560.3 [M+H]+.
Example 130
Compound 130: N-(5-(4-f3-(azetidin-l-ylmethvn-4-(furan-3-vn-lH-pyrrol-l-vn-5- fluoropyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 105 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 5 / '4.3 [M+H]+.
Example 131
Compound 131: N-(5-(4-(3-((dimethylamino)methyl)-4-(furan-3-vn-lH-pyrrol-l-ylV 5-fluoropyrimidin-2-ylamino')-4-methoxy-2-morpholinophenyl')acrylamide
Using Intermediate 105 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 562.3 [M+H]+.
Example 132
Compound 132: N-(5-(4-(3-cvclopropyl-4-((dimethylamino)methylVlH-pyrazol-l-ylV
5-methylpyrimidin-2-ylamino)-4-methoxy-2-(methyl(oxetan-3- yl)amino)phenyl)acrylamide
Using Intermediate 106 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 533.3 [M+H]+.
1H NMR: δ (DMSO-d6), 0.88-0.93 ppm (5H, m), 2.05-2.06 ppm (2H, m), 2.15 ppm (6H, s), 2.44 ppm (6H, s), 3.43 ppm (2H, s), 3.84 ppm (3H, t), 4.37~4.46(3H, m), 4.59~4.63(2H, m), 5.80 ppm (IH, d), 6.33-6.39 ppm (IH, dd), 6.68 ppm (IH, s), 6.69-6.83 ppm (IH, q), 7.94 ppm (IH, s), 8.34 ppm (IH, s), 8.79 ppm (IH, s), 8.94 ppm (IH, s), 9.25 ppm (IH, s)
Example 134
Compound 134: N-(2-(4-acetylpiperazin-l-yl)-5-(4-(4-(azetidin-l-ylmethyl)-3-phenyl- lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 107 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 608.3 [M+H]+.
Example 135 Compound 135: N-f2-f4-acetylpiperazin-l-yl)-5-(4-(4-((dimethylamino)methyl)-3- phenyl-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxyphenvnacrylamide
Using Intermediate 107 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 596.3 [M+H]+.
Ή NMR: δ (DMSO-d6), 2.06 ppm (3H, s), 2.22 ppm (6H, s), 2.81-2.85 ppm (5H, m), 3.47 ppm (2H, s), 3.67 ppm (4H, t), 3.90 ppm (3H, s), 5.82-5.85 ppm (1H, dd), 6.40-6.45 ppm (1H, d), 6.72-6.84 ppm (1H, q), 6.97 (1H, s), 7.35 ppm (1H, d), 7.42-7.52 ppm (4H, m), 8.05 ppm (1H, d), 8.18 ppm (1H, s), 8.54 ppm (1H, d), 9.13-9.18 ppm (3H, m)
Example 136
Compound 136: N-(5-(4-f4-((dimethylamino')methyl)-3-(pyridin-4-yl)-lH-pyrazol-l- vI)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 108 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 556.3 [M+H]+.
Example 137
Compound 137: N-(2-(4-acetylpiperazin-l-yl)-5-(4-(3-cvclopropyI-4-
((ethyl(methyl)amino)methyl -lH-pyrazol-l-vnpyrimidin-2-ylamino)-4- methoxyphenyl)acrylamide
Using Intermediate 104 and N-methylethanamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 574.3 [M+H]+.
1H NMR: δ (DMSO-d6), 0.91-0.95 ppm (5H, m), 1.04 ppm (3H, t), 2.05 ppm (6H, s), 2.17 ppm (3H, s), 2.80-2.84 ppm (5H, m), 3.55-3.57 ppm (2H, m), 3.66 ppm (4H, t), 3.88 ppm (3H, s), 5.80 ppm (1H, d), 6.33-6.39 ppm (1H, dd), 6.69-6.78 ppm (1H, q), 6.94 (1H, s), 7.11 ppm (1H, d), 8.09 ppm (1H, s), 8.44 ppm (1H, d), 8.91 ppm (1H, s), 9.05 ppm (1H, s), 9.14 ppm (1H, s)
Example 138
Compound 138: N-(2-(4-acetylpiperazin-l-yl)-5-(4-(4-(azetidin-l-ylmethyl)-3- cvclopropyl-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 106 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 572.3 [M+H]+. *H NMR: δ (DMSO-d6), 0.81-0.95 ppm (5H, m), 1.93 ppm (3H, t), 2.06 ppm (3H, s), 2.80-2.84 ppm (5H, m), 3.11 ppm (4H, t), 3.51 ppm (3H, s), 3.61-3.72 ppm (6H, m), 3.82-3.92 ppm (5H, m), 5.84 ppm (IH, d), 6.41-6.46 ppm (IH, d), 6.72-6.81 ppm (IH, q), 6.94 (IH, s), 7.10 ppm (IH, d), 8.09 ppm (IH, s), 8.43 ppm (IH, d), 8.86 ppm (IH, s), 9.05 ppm (IH, s), 9.16 ppm (IH, s)
Example 139
Compound 139: N-(2-(azetidin-l-yl)-5-(4-(4-(azetidin-l-ylmethyl -3-cvcIopropyl-lH- PyrazoI-l-yl)pyrimidin-2-ylamino)-4-methoxyphenyl acrylamide Using Intermediate 109 and azetidine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 501.3 [M+H]+.
Ή NMR: δ (DMSO-d6), 0.88-0.93 ppm (5H, m), 1.92-1.99 ppm (3H, m), 2.21 ppm (3H, t), 3.11 ppm (4H, t), 3.48 ppm (2H, s), 3.80-3.88 ppm (9H, m), 5.73 ppm (IH, d), 6.22 ppm (IH, s), 6.29-6.34 ppm (IH, d), 6.49-6.52 ppm (IH, q), 6.99 (IH, d), 7.90 ppm (IH, s), 8.06 ppm (IH, s), 8.36 ppm (IH, d), 8.48 ppm (IH, s), 9.29 ppm (IH, s)
Example 140
Compound 140: N-(5-(4-(3-cvclopropyl-4-f(ethyl(methyl)amino)methyl)-lH-pyrazol- l-vnpyrimidin-2-ylaminoV4-methoxy-2-morpholinophenvnacrylamide
Using Intermediate 39 and N-ethylmethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 533.3 [M+H]+. 1H NMR: 6 (DMSO-d6), 0.91-0.94 ppm (4H, m), 1.03 ppm (3H, t), 2.07-2.14 ppm (4H, m), 2.83-2.85 ppm (4H, t), 3.50 ppm (2H, s), 3.79-3.81 ppm (4H, t), 3.89 ppm (3H, s), 5.76-5.82 ppm (IH, dd), 6.32-6.38 ppm (IH, dd), 6.67-6.76 ppm (IH, q), 6.93 (IH, s),
7.11 ppm (IH, d), 8.08 ppm (IH, s), 8.43 ppm (IH, d), 8.88 ppm (IH, s), 8.99 ppm (IH, s),
9.12 ppm (IH, s)
Example 141
Compound 141: N-(2-(azetidin-l-ylV5-(4-(3-(azetidin-l-ylmethyl)-4-methyl-lH- Pyrrol-l-ylV5-fluoropyrimidin-2-ylaminoV4-methoxyphenyl acrylamide Using Intermediate 110 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 492.2 [M+H]+.
Example 142
Compound 142: N-(5-(4-(3-(azetidin-l-ylmethyl)-4-methyl-lH-pyrrol-l-yl)-5- fluoropyrimidin-2-ylaminoV2-(dimethylamino)-4-methoxyphenvnacrylamide Using Intermediate 111 and azetidine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 480.4 [M+H]+.
Example 143
Compound 143 ; N-(2-(dimethyIamino)-5-(4-(3-((dimethylamino)methyl)-4-methyl- lH-pyrroI-l-yl)-5-fluoropyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 111 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1; MS (ESI) m/z 468.2 [M+H]+.
Example 144
Compound 144: N-(2-((2-(dimethylamino)ethyl)(methvnamino)-5-f4-(3-
((dimethylamino)methyl)-4-(trifluoromethvn-lH-pyrrol-l-vI)-5-fluoropyrimidin-2- ylamino)-4-methoxyphenyl)acrylamide
Using Intermediate 113 and dimethylamine hydrochloride, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 578.3 [M+H]+.
Example 145
Compound 145: N-(5-(4-(4-((ethyl(methyl)amino)methyl)-3-methyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Using Intermediate 13 and N-ethylmethylamine, the title compound was prepared as described in Example 1 ; MS (ESI) m/z 507.4 [M+H]+.
Comparative Example 1
Compound 146: 4-(3-((dimethylamino)methyl)-4-methyl-lH-pyrrol-l-yl)-N-(3,5- dimethylphenyl)pyrimidin-2-amine
Compound 146 was prepared as described in US 8626132 B2; MS (ESI) m/z 356.4 [M+H]+.
Comparative Example 2
Compound 147: l-((l-(2-(3,5-dimethyIphenylamino)pyrimidin-4-yl)-3-methyl-lH- pyrazol-4-yl)methyl)azetidin-3-ol
Compound 147 was prepared as described in US 8626132 B2; MS (ESI) m/z 365.3 [M+H]+. Comparative Example 3
Compound 148: (R)-l-((l-(2-(3,5-dimethyl-4-(2-(pyrrolidin-l- yI)ethoxy)phenylamino)pyrimidin-4-yl)-3-methyl-lH-pyrazol-4-yl)methyl)pyrrolidin-
3- ol
Compound 148 was prepared as described in US 8626132 B2; MS (ESI) m/z 492.5 [M+H]+.
Comparative Example 4
Compound 149: l-((l-(2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyIamino)pyrimidin-
4- yl)-3-methyl-lH-pyrazol-4-yl)methyl)azetidin-3-oI
Compound 149 was prepared as described in US 8626132 B2; MS (ESI) m/z 425.4 [M+H]+.
Comparative Example 5
Compound 150: l-((4-methyl-l-(2-(2-methylbiphenyl-4-ylamino)pyrimidin-4-yl)-lH- pyrrol-3-yl)methyl)azetidin-3-ol
Compound 150 was prepared as described in US 8626132 B2; MS (ESI) m z 426.3 [M+H]+.
Comparative Example 6
Compound 151: l-((3-cyclopropyl-l-(2-(4-(2-hydroxyethoxy)-3,5- dimethylphenylamino)pyrimidin-4-yl)-lH-pyrazoI-4-yI)methyl)azetidin-3-ol
Compound 151 was prepared as described in US 8626132 B2; MS (ESI) m/z 451.5 [M+H]+.
Comparative Example 7
Compound 152: 4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l-yl)-N-(2- methoxy-4-morpholino-5-nitrophenyl)pyrimidin-2-amine
Using Intermediate 64, compound 152 was prepared as described in the preparation of example 1; MS (ESI) m/z 531.2 [M+H]+.
Comparative Example 8
Compound 153: Nl-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l- yl)pyrimidin-2-yl)-6-methoxy-4-morphoIinobenzene-l,3-diamine Using compound 152, compound 153 was prepared as described in the preparation of example 1; MS (ESI) m/z 501.4 [M+H]+.
Comparative Example 9
Compound 154: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyI-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)but-3-enamide
Using compound 153, compound 154 was prepared as described in the preparation of example 1; MS (ESI) m/z 569.3 [M+H]+.
Comparative Example 10
Compound 155: (E)-N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)pent-2-enamide
Using compound 153, compound 155 was prepared as described in the preparation of example 1; MS (ESI) m/z 583.3 [M+H]+.
Comparative Example 11
Compound 156: (Z)-N-(5-(4-(4-((dimethylamino)methyI)-3-phenyl-lH-pyrazol-l- yI)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)hex-3-enamide
Using compound 153, compound 157 was prepared as described in the preparation of example 1; MS (ESI) m/z 597.3 [M+H]+.
Comparative Example 12
Compound 157: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl- ΙΗ-py razol- 1 - yl)pyrimidin-2-yIamino)-4-methoxy-2-morpholinophenyl)propionamide
Using compound 153, compound 157 was prepared as described in the preparation of example 1; MS (ESI) m/z 557.7 [M+H]+.
Comparative Example 13
Compound 158: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-phenyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)propionamide
Using compound 153, compound 158 was prepared as described in the preparation of example 1; MS (ESI) m/z 569.7 [M+H]+. Comparative Example 14
Compound 159: N-(5-(4-(4-(azetidin-l-ylmethyl)-3-phenyl-lH-pyrazol-l- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)-2-fluoroacrylamide
Using compound 153, compound 159 was prepared as described in the preparation of example 1; MS (ESI) m/z 585.6 [M+H]+.
BIOLOGICAL ASSAYS
1. Kinase Inhibition Assay
Compounds of the present invention were assayed to measure their capacity to inhibit a kinase panel which includes SYK, KDR, JAK3, and EGFR mutants.
Method: Inhibition of enzymatic activity of SYK, KDR, JAK3, and EGFR mutant kinase
Compounds of the invention were initially diluted to lOmM in 100 % DMSO for storage and made into kinase buffer solution to create a compound concentration ranging from luM and lOuM. Serial dilutions of compounds of the invention were dispensed into the 96-well plate (Greiner Biosciences™) at 6 μΐ^ each. The first generation reversible inhibitor Erlotinb and the irreversible inhibitor Afatinib were used as reference compound. Purified human, full-length SYK, KDR, and truncated human JAK3, EGFR mutants such as del E746-A750, L858R, L858R/T790M and del E746-A750/T790M (Carna Biosciences™), were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes (EGFR mutants for 2 hours) at room temperature. Next, ATP (Teknova™) of approximate ATP concentration (ImM for EGFR mutants) and substrate solution (Ulight™-TK peptide for SYK, Ulight™-Jakl for KDR and JAK3, and Ulight™- PolyGT for EGFR mutants (PerkinElmer™)) was added (12 μΐ, each) to the wells containing the compound solution and enzyme and incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PerkinElmer™) was added (12 iL each) to the reaction mixture to stop the phosphorylation. Following the addition of the stop solution and 5 minutes of shaking, the detection solution containing the Europium-labeled antibody, water, and Lance detection buffer was added (12 iL each) to the reaction mixture and incubated again for 50 minutes. Substrate phosphorylation was a function of the 665 nm emission measured following the addition of the detection solution and 50 minutes of incubation.
The potency of compound was assigned as < 20 nM in IC50, 21 to 200 nM in IC50, 201 to ΙΟΟΟηΜ in IC50 and >1000nM in IC50. The IC50 value was determined by GraphPad Prism 5. Result
Compounds of Formula (I) exhibited useful pharmacological properties. As used herein, the half maximal inhibitory concentration (IC50) indicates 50% inhibition on the given kinase activity (e.g., 0 % inhibition in control treated with no inhibitor) by the compounds of Formula (I). Compounds of Formula (I) exhibited various levels of inhibition of the given protein kinase on the panel. Certain compounds exhibited a potent inhibition of all test EGFR mutants and good selectivity over other kinases, KDR and SYK as shown in Tables 1 to 5.
For example, Compound 73 of Formula (I), namely, N-(5-(4-(4-
((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxy-2- morpholinophenyl)acrylamide, was shown to potently inhibit the kinase activity of JAK3 and all four EGFR mutants at the ImM ATP concentration (< 20nM in ICso) but to poorly inhibit that of SYK and KDR at approximate ATP Km concentration (see Tables 1 to 5).
Reference compound Erlotinib shows moderate inhibition against EGFR Del E746-
A750 mutant and EGFR L858R mutant (20-200nM in IC50) but no or little inhibition against other EGFR mutants, SYK, KDR and JAK3(>1000nM in IC50). The irreversible inhibitors Afatinib displayed potent inhibition against all EGFR mutants and JAK3 (< 20nM in IC50) but no or little inhibition against SYK and KDR (>1000nM in IC50). Therefore, some compounds of Formula (I) displayed strong potency and kinase selectivity similar to the compound 73 and those are equally similar to the irreversible inhibitor Afatinib in terms of potency against all test EGFR mutants. However, unlike Afatinib inhibiting both EGFR mutants and wildtype, some of Formula (I) including compound 73 shows no or little inhibition against EGFR wildtype (see Table 1, Table 2 and Figure 1), suggesting that they are selective to EGFR wildtype. In addition, potent and selective inhibition (<20nM) of JAK3 by some of compounds of Formula (I) indicate that they could be therapeutically valuable to treat JAK3 mediated diseases such as rheumatoid arthritis, immune diseases, leukemia, lymphoma and metastatic cancer.
Table 1. The kinase potency EGFR mutant(T790M) by the representative compounds of Formula (I).
Biochemical potency: < 20 nM, 20-200 nM, 201-1000nM and >1000nM
Figure imgf000090_0001
<20 60 20-200 112 <20
20-200 61 <20 113 <20
<20 62 <20 114 <20
<20 63 20-200 115 <20
<20 64 <20 116 <20
20-200 65 201-1000 117 <20
<20 66 20-200 118 <20
<20 67 20-200 119 <20
<20 71 <20 120 <20
<20 72 20-200 121 <20
<20 73 <20 122 <20
<20 74 <20 123 <20
201-1000 75 <20 124 <20
<20 76 <20 125 <20
<20 77 <20 126 20-200
<20 78 <20 127 <20
<20 79 <20 128 <20
<20 80 <20 129 <20
<20 81 201-1000 130 <20
<20 83 <20 131 <20
<20 84 <20 132 <20
<20 85 <20 134 <20
<20 86 20-200 135 <20
<20 87 <20 136 <20
<20 88 <20 137 <20
<20 89 20-200 138 <20
<20 91 201-1000 139 <20
<20 92 <20 140 <20
<20 93 <20 141 <20
<20 94 <20 143 <20
<20 95 <20 144 <20
201-1000 96 20-200 145 20-200 45 20-200 97 20-200 146 >1000
46 <20 98 20-200 147 >1000
47 <20 99 20-200 148 >1000
48 <20 100 20-200 149 >1000
49 <20 101 <20 150 >1000
50 <20 102 <20 151 >1000
51 <20 103 <20 152 >1000
52 <20 104 <20 153 >1000
53 20-200 105 20-200 157 >1000
54 <20 106 <20 - 158 >1000
55 <20 107 <20 159 >1000
Table 2. The kinase potency EGFR mutants by the representative compounds of Formula (I).
Biochemical potency: < 20 nM, 20-200 nM, 201-lOOOnM and >1000nM
Figure imgf000092_0001
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
20-200 20-200 20-200 <20
<20 20-200 <20 <20
201-1000 201-1000 201-1000 20-200
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 20-200
201-1000 201-1000 201-1000 20-200
<20 20-200 <20 <20
<20 <20 <20 <20
<20 20-200 <20 <20
<20 <20 <20 <20
20-200 20-200 20-200 20-200
<20 20-200 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 20-200 <20 <20
<20 <20 <20 <20
<20 20-200 <20 <20
20-200 20-200 <20 <20
<20 <20 <20 <20
20-200 20-200
<20 20-200 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 20-200 <20 <20
20-200 20-200 20-200
<20 <20 <20 <20
20-200 201-1000 20-200 <20 20-200 <20 <20
<20 20-200 <20 <20
<20 20-200 <20
<20 <20 <20 <20
20-200 201-1000 20-200 20-200
<20 20-200 20-200 <20
20-200 20-200 20-200 20-200
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
20-200 20-200 20-200 20-200
<20 20-200 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 20-200 20-200 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
20-200 20-200 <20 <20
<20 20-200 <20 <20
<20 20-200 20-200 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20
<20 <20 <20 <20 97 20-200 <20 <20 <20
98 <20 20-200 20-200
99 <20 20-200 20-200
100 <20 <20 <20 <20
101 <20 <20 <20
102 <20 <20 <20
103 <20 <20 <20
106 <20 <20 <20 <20
107 <20 <20 <20 <20
108 <20 <20 <20 <20
109 <20 <20 <20 <20
112 <20 <20 <20 <20
113 <20 <20 <20 <20
114 <20 <20 <20 <20
115 <20 <20 <20 <20
118 <20 <20 <20 <20
119 <20 <20 <20 <20
120 <20 <20 <20 <20
121 <20 <20 <20 <20
122 <20 <20 <20 <20
123 <20 <20 <20 <20
124 <20 <20 <20 <20
125 <20 <20 <20 <20
126 <20 <20 <20 <20
127 <20 <20 <20 <20
128 <20 <20 <20 <20
129 <20 <20 <20 <20
130 <20 <20 <20 <20
131 <20 <20 <20 <20
132 <20 <20 <20 <20
134 <20 <20 <20 <20
135 <20 <20 <20 <20 136 <20 <20 <20 <20
137 <20 <20 <20 <20
138 <20 <20 <20 <20
139 <20 <20 <20 <20
140 <20 <20 <20 <20
141 <20 <20 <20 <20
142 <20 <20 <20 <20
145 <20 <20 <20 <20
146 >1000 >1000 201-1000 201-1000
147 >1000 >1000 201-1000 >1000
148 >1000 >1000 ■ 201-1000 201-1000
149 >1000 >1000 201-1000 >1000
150 >1000 >1000 201-1000 >1000
151 >1000 20-200 20-200 201-1000
152 >1000 >1000 >1000 >1000
153 >1000 >1000 >1000 >1000
156 >1000 >1000 201-1000 20-200
157 >1000 >1000 - >1000 >1000
158 >1000 > 1000 >1000 >1000
159 >1000 >1000 20-200 20-200
Table 3. The kinase potency of JAK3 by the representative compounds of Formula (I).
Biochemical potency: < 20 nM, 20-200 nM, 201-1000nM and >1000nM
Figure imgf000096_0001
29 <20 54 <20 122 <20
32 <20 55 <20 123 <20
34 20-200 62 <20 124 <20
36 <20 65 20-200
Table 4. The kinase potency of SYK by the representative compounds of Formula (I).
Biochemical potency: < 20 nM, 20-200 nM, 201-lOOOnM and >1000nM
Figure imgf000097_0001
31 20-200 77 201-1000 135 >1000
32 201-1000 78 >1000 138 >1000
33 >1000 79 201-1000 139 >1000
34 201-1000 80 >1000 140 >1000
35 >1000 81 >1000 141 201-1000
36 >1000 82 >1000 142 201-1000
37 201-1000 83 >1000 143 201-1000
38 >1000 84 >1000 146 20-200
39 >1000 86 >1000 147 20-200
40 >1000 87 >1000 148 201-1000
41 201-1000 88 201-1000 149 >1000
42 >1000 90 >1000 150 >1000
43 >1000 92 >1000 151 201-1000
44 >1000 93 >1000 152 >1000
45 >1000 94 >1000 153 >1000
46 201-1000 95 >1000 156 >1000
47 201-1000 96 >1000 157 >1000
48 201-1000 97 >1000 158 >1000
49 201-1000 100 >1000 159 >1000
50 >1000 101 >1000
Table 5. The kinase potency of KDR by the representative compounds of Formula (I).
Biochemical potency: < 20 nM, 20-200 nM, 201-lOOOnM and >1000nM
Figure imgf000098_0001
29 >1000 54 >1000 82 >1000
32 >1000 55 >1000 122 >1000
34 >1000 62 >1000 123 >1000
36 >1000 65 >1000 124 >1000
2. Cell viability assay Compounds of the invention are tested for their effects on NSCLC cell lines to illustrate efficacy of the invention at the cellular level. Mis-regulation and, in particular, over-activation of EGFR mutants have been implicated in increased proliferation of NSCLC lines. Among those cell lines, the cell viability of NSCLC PC9 depends on activation of EGFR del E746-A750 mutant as that of HI 975 cell does on activation of EGFR L858R/T790M mutant. And cell viability of H2073 depends on EGFR wildtype.
Therefore, the viability of PC9 by compound of Formula (I) represents cellular potency of test compound against EGFR del E746-A750 mutant and that of HI 975 does that against EGFR L858R/T790M mutant. And that of H2073 represents EGFR wildtype potency in NSCLC line.
Method
Compounds of the invention and references were tested against H2073, PC9 and HI 975 obtained from the American Type Culture Collection (ATCC, Manassas, VA). This cell line was maintained with an Roswell Park Memorial Institute (RPMI) medium (GIBCO™) containing 10 % fetal bovine serum (FBS; GIBCO™) and 0.05 mM 2- mercaptoethanol. The cells were seeded at 3x10 cells/100 μΕ/well into 96 well culture plate, and serially diluted compound was then added. The first generation reversible inhibitor Erlotinb and the irreversible inhibitor Afatinib were used for reference inhibitor. After 72-hour incubation period at 37 °C, the cells were subjected to an ATP Lite (Promega) assay to determine the cytotoxic effects of compound.
The potency of compound was assigned as < 20 nM in IC5o, 21 to 200 nM in IC50, 201 to ΙΟΟΟηΜ in IC50 and >1000nM in IC50. The IC50 value was determined by GraphPad Prism 5. Result
As used herein, the half maximal inhibitory concentration (ICso) indicates 50% inhibition on the given cell's viability by the compounds of Formula (I).
Table 6 shows cellular viability of mutant EGFR expressing cells as compared to wildtype EGFR expressing cell and provides the selectivity ratio of wildtype EGFR expressing cell to mutant expressing cell for each test compound. Compounds of Formula (I) exhibited an potent inhibition range (<20nM in IC50) in PC9 cell and furthermore in H1975 cell where Erlotinib did not show any potent inhibition. For example, Compound 73 of Formula (I), namely, N-(5-(4-(4-((dimethylamino)methyl)-3 -phenyl- lH-pyrazol-1- yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, showed potent inhibition in both PC9 and HI 975 cell but not in H2073, whereas Afatinib showed potent inhibition in H2073, PC9 and H1975. Unlike Afatinib, some of this invention showed great EGFR wildtype selectivity in cellular level (for example, compound 73 with > 200 fold selective in cellular potency shown in Table 6). Table 6. The anti-proliferation activity against H2073, PC9 and H1975 by the selected compounds of Formula (I).
Cellular potency: < 20 nM, 20-200 nM, 201-1000nM and >1000nM
Fold comparison (selectivity): < 20 fold, 20-100 fold, 101-200 fold and >200 fold
Figure imgf000100_0001
74 >1000 <20 <20 >200 >200
75 >1000 20-200 20-200 101-200 101-200
76 >1000 20-200 20-200 101-200 101-200
78 >1000 <20 <20 >200 >200
79 >1000 20-200 20-200 101-200 101-200
82 >1000 20-200 20-200 101-200 101-200
84 20-200 <20 <20 <20 <20
86 201-1000 <20 <20 20-200 20-200
92 >1000 <20 <20 >200 >200
93 201-1000 <20 <20 20-200 20-200
100 >1000 20-200 20-200 101-200 101-200
106 >1000 20-200 20-200 101-200 101-200
118 201-1000 <20 <20 20-200 20-200
122 >1000 <20 <20 >200 >200
123 >1000 <20 <20 >200 >200
124 >1000 <20 <20 >200 >200
146 >1000 >1000 >1000 <20 <20
147 >1000 >1000 >1000 <20 <20
148 >1000 >1000 >1000 <20 <20
149 >1000 >1000 >1000 <20 <20
151 >1000 >1000 >1000 <20 <20
154 >1000 20-200 201-1000 <20 <20
155 >1000 201-1000 201-1000 <20 <20
156 >1000 >1000 >1000 <20 <20
157 >1000 >1000 >1000 <20 <20
158 >1000 20-200 201-1000 <20 <20
159 >1000 >1000 >1000 <20 <20
3. Western Analysis Compounds of the invention and references are tested for their effects on NSCLC cell lines to measure molecular potency against phosphorylation level of wildtype and mutant EGFR and illustrate selectivity over p-wildtype EGFR. The inhibition level of phosphorylation of mutant EGFR in NSCLC lines PC9 and HI 975 should be illustrated to understand whether it is correlated with kinase enzyme potency and cellular potency of the compound. Based on these results, the selectivity of the compound against EGFR mutants over EGFR wildtype can be addressed in physiologically relevant molecular level.
Method
NSCLC lines H1299, PC9, and HI 975 were treated with the indicated concentration of compounds for 4 hours. The first generation reversible inhibitor Erlotinib and the irreversible inhibitor Afatinib were used for reference inhibitor. For wild EGFR activation experiment, HI 299 cell line was simultaneously treated with addition of 3 nM EGF ligand. Cells were lysed in RIPA buffer (25mM Tris'HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing protease and phosphatase inhibitor cocktail (Thermo scientific). Equivalent amounts of protein were separated by NuPAGE 4-12% Bis-Tris Gel system (Invitrogen™), and then transferred to polyvinylidene difluoride membranes. Membranes were probed with an anti-phospho- Y1067 EGFR antibody (Cell Signaling Technology™) and then stripped with Restore Western Blot Stripping Buffer (Thermo Scientific™). Membranes were probed again with an anti-EGFR or anti-actin antibody (Cell Signaling Technology™) for assessing loading control. The membranes were visualized by enhanced chemiluminescence.
To calculate inhibition of phosphorylation level of p-EGFR wildtype, p-EGFR del
E746-A750 and p-EGFR L858R/T790M, the intensity of each band treated by indicated concentration of inhibitor was measured by densitometer to translate to numeric value and numeric value of each intensity was compared over that of each actin control at indicated concentration. The IC5o value was determined by GraphPad Prism 5.
Result
As used herein, the half maximal inhibitory concentration (IC50) indicates 50% inhibition on the given phosphorylation level at Y1068 of each EGFR protein (e.g., p- EGFR wildtype, p-EGFR del E746-A750 and p-EGFR L858R/T790M) by the compounds of Formula (I).
Table 7 shows inhibition of phosphorylation level of mutant EGFR as compared to wildtype EGFR and provides the selectivity ratio of wildtype to mutant for each test compound. Selected compounds of Formula (I) such as compound 26 and 73 exhibited a potent inhibition against p-EGFR del E746-A750 and p-EGFR L858R/T790M but not p- EGFR wildtype (shown in Figure 1 and Table 7), while Afatinib showed potent inhibition against both p-EGFR wildtype, p-EGFR del E746-A750 and p-EGFR L858R/T790M. While Afatinib revealed 28.7 fold selectivity in p-EGFR dell9/p-EGFR wildtype and 9.6 fold selectivity in p-EGFR L858R, T790M/ p-EGFR wildtype, compound 26 displayed 572.4 fold and 1440.3 fold selectivity, respectively. Therefore, some of the compounds of the invention showed better EGFR wildtype selectivity in molecular potency level than Afatinib.
Table 7. The potency in phosphorylation level of EGFR wildtype and mutants by representative compounds of Formula (I)
Molecular potency: < 20 nM, 20-200 nM, 201 -1 OOOnM and > 1 OOOnM
Fold comparison (selectivity): < 20 fold, 20-100 fold, 101-200 fold and >200 fold
Figure imgf000103_0001

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula (I) :
Figure imgf000104_0001
I
wherein:
X is CH or N;
R1 is H, R8 or -OR8;
R is hydrogen, C1-6 alkyl, 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S, wherein the heteroaryl or aryl is optionally and independently substituted at one or more "carbon atoms
* 13
with R ; and wherein the heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
R is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR9R10, NRnR12, or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R13; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R ;
R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3> C1-6 alkyl, C3 -7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
R6 is hydrogen or C1-6 alkyl;
R7 is hydrogen, -CH2OH, -CH2OR8, Ci-3 alkyl, (CH2)nNR9R10, (CH2)nNRnR12, C(0)NR9R10, or C(0)NRnR12, wherein each n is independently 1 or 2;
R is selected from Ci-6 alkyl or C3-7 cycloalkyl;
R9 is selected from C1-6 alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the C1-6 alkyl or C3-7
o
cycloalkyl is optionally substituted with halogen or -OR , and wherein the 4-7 membered
Q
heterocyclyl having one nitrogen atom is optionally and independently substituted with -R , -C(0)RK, -C(0)ORs, or C(0)NHR8;
R10 is C1-6 alkyl, C3-7 cycloalkyl, or (CH2)nNR9R9, wherein each n is independently
1 or 2;
1 1 12
R and R , taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which R11 and R12 are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons with halogen, hydroxyl, -OR8, -NR9R10, or -NRnR12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms , in addition to the nitrogen atom to which R11 and R12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms with -R8, -C(0)R8, -C(0)OR8, -C(0)NHR8, -S02R8, -S02NH2, or -S02NR8 2; and
R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl,
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 or pharmaceutically acceptable salt thereof, wherein said compound is represented by Formula (II):
Figure imgf000105_0001
II
wherein:
R3 is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR9R10, NRnR12, or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R ; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R ;
R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3j C1-6 alkyl, C3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
R6 is hydrogen or C1-6 alkyl;
R7 is hydrogen, -CH2OH, -CH2OR8, C1-3 alkyl, (CH2)nNR9R10, (CH2)nNRnR12, C(0)NR9R10, or C(0)NRuR12, wherein each n is independently 1 or 2;
R8 is selected from Ci-6 alkyl or C3-7 cycloalkyl;
R9 is selected from Ci- alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein C1-6 alkyl or C3-7 cycloalkyl is optionally substituted with halogen or -OR , wherein the 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R8, -C(0)R8, -C(0)OR8, or C(0)NHR8;
R10 is C1-6 alkyl, C3- cycloalkyl, or (CH2)nNR9R9, wherein each n is independently
1 or 2;
Rn and R12, taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which R11 and R12 are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons with halogen, hydroxyl, -OR8, -NR9R10, or -NRuR12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms , in addition to the nitrogen atom to which R and R are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms with -R8, -C(0)R8, -C(0)OR8, -C(0)NHR8, -S02R8, -S02NH2, or -S02NR8 2; and R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl.
3. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein said compound is represented by Formula (III):
Figure imgf000106_0001
III
wherein: R is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR9R10, NRnR12, or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R13; and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3, Ci-6 alkyl, C3.7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
R6 is hydrogen or Ci-6 alkyl;
R7 is hydrogen, -CH2OH, -CH2OR8, C1-3 alkyl, (CH2)nNR9R10, (CH2)„NRnR12, C(0)NR9R10, or C(0)NR1 !R12, wherein each n is independently 1 or 2;
R is selected from C1-6 alkyl or C3- cycloalkyl;
R9 is selected from Ci-6 alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein C1-6 alkyl or C3 -7 cycloalkyl is optionally substituted with halogen or -OR8, wherein the 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R8, -C(0)R8, -C(0)OR8, or C(0)NHR8;
R10 is Ci.6 alkyl, C3-7 cycloalkyl, or (CH2)nNR9R9, wherein each n is independently
1 or 2;
11 12
R and R , taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which R11 and R12 are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons with halogen, hydroxyl, -OR8, -NR9R10, or -NRuR12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms , in addition to the nitrogen atom to which R and R are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms with -R8, -C(0)R8, -C(0)OR8, -C(0)NHR8, -S02R8, -S02NH2, or -S02NR8 2; and
R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said compound is represented by Formula (IV):
Figure imgf000108_0001
IV
wherein:
X is CH or N;
R1 is H, R8 or -OR8;
R is hydrogen, Ci-6 alkyl, 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R ; and wherein the heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, CI, Br, CN, or CF3;
R5 is hydrogen, CF3> C1-6 alkyl, C3- cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
R7 is hydrogen, -CH2OH, -CH2OR8, C1-3 alkyl, (CH2)nNR9R10, (CH2)nNRl lR12, C(0)NR9R10, or C(0)NR1 'R'2, wherein each n is independently 1 or 2;
R is selected from Ci-6 alkyl or C3-7 cycloalkyl;
R9 is selected from C1- alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein Ci-6 alkyl or C3-7 cycloalkyl is optionally substituted with halogen or -OR8, wherein the 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with -R8, -C(0)R8, -C(0)OR8, or C(0)NHR8;
R10 is C1-6 alkyl, C3-7 cycloalkyl, or (CH2)nNR9R9, wherein each n is independently
1 or 2;
R 11 and R 12 , taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which R11 and R12 are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons with halogen, hydroxyl, -OR8, -NR9R10, or -NRnR12; or
ii) a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms , in addition to the nitrogen atom to which R11 and R12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms with -R8, -C(0)R8, -C(0)OR8, -C(0)NHR8, -S02R8, -S02NH2, or -S02NR8 2; and R13 is selected from halogen, CN, CF3, R8, -OR8 or C2-4 alkenyl.
5. The compound of any one of claims 1-3, wherein R1 is -OCH3; R4 is H, -CH3, F, or CI; R5 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, pyridinyl, thiophenyl, furanyl, N-methyl pyrrolidinyl, N-methyl pyrazolyl, or phenyl; R is methyl; and n is 1.
6. The compound of claim 4, wherein R1 is H; R2 is furanyl, thiophenyl, N-methyl pyrazolyl, or phenyl; R4 is H, -CH3, F, or CI ; R5 is hydrogen, Cj-6 alkyl, C3-7 cycloalkyl, pyridinyl, thiophenyl, furanyl, N-methyl pyrrolyl, N-methyl pyrazolyl, or phenyl; and n is 1.
7. The compound of claim 5, wherein R2 is H; R6 is H; R3 is morpholino, N-methyl piperazinyl, piperidinyl, azetidinyl, pyrrodinyl, 4-acetylpiperidinyl, N,N-dimethylamino, l,4-oxazepan-4-yl, or 4-methyl-l,4,-diazepan-l-yl; and R7 is -(CH2)NR9R10 or - (CH2)NRnR12.
8. The compound of claim 6, wherein R7 is -(CH2)NR9R10 or -(CH2)NR' !R12.
9. The compound of claim 7, wherein R9 is methyl, ethyl, propyl, cyclopropylmethyl, or cyclobutylmethyl; and R10 is methyl, ethyl, propyl, cyclopropylmethyl, oxetanyl, oxethanemethyl, N-methyazetinyl, Ν,Ν-dimethylethyl, or methoxyethyl; and NRnR12 is azetidinyl, 3 -hydroxy azetidinyl, 3-methoxy azetidinyl, pyrrolidinyl, (S)-3 -hydroxy pyrrolidinyl, (R)-3-hydroxy pyrrolidinyl, (3R,4S)-3,4-dihydroxypyrrolidinyl, (3S,4R)-3- hydroxy-4-methoxypyrrolidinyl, piperidinyl, morpholinyl, N-methylpiperazinyl, azamorpholinyl, N-methylazapiperazinyl, N-acetyl piperazinyl, or thiomorpholinyl.
10. The compound of claim 8, wherein R9 is methyl, ethyl, propyl, cyclopropylmethyl, or cyclobutylmethyl; and R10 is methyl, ethyl, propyl, cyclopropylmethyl, oxetanyl, oxethanemethyl, N-methyazetinyl, Ν,Ν-dimethylethyl, or methoxyethyl; and NR R is azetidinyl, 3 -hydroxy azetidinyl, 3-methoxy azetidinyl, pyrrolidinyl, (S)-3 -hydroxy pyrrolidinyl, (R)-3-hydroxy pyrrolidinyl, (3R,4S)-3,4-dihydroxypyrrolidinyl, (3S,4R)-3- hydroxy-4-methoxypyrrolidinyl, piperidinyl, morpholinyl, N-methylpiperazinyl, azamorpholinyl, N-methylazapiperazinyl, N-acetyl piperazinyl, or thiomorpholinyl.
1 1. The compound of claim 5 or 6, wherein R is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl, 2-thiophenyl, 2-furanyl, 3-furanyl, 3-pyridyl, 4-pyridyl or phenyl.
12. The compound of claim 1, selected from:
N-(3 -(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxyphenyl)acrylamide,
N-(3-(4-(4-((3 -hydroxyazetidin- l-yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-4-methoxyphenyl)acrylamide,
N-(3-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)phenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)phenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-5-methylphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -(4-fluorophenyl)- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(3-(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(4-methoxy-3 -(4-(3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)phenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-5 -methylphenyl)acrylamide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin- 2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 2-morpholinophenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol-
1- yl)pyrimidin-2-ylamino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((3-hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-
2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-(4-methylpiperazin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-(piperidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin- 2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(((3R,4S)-3,4-dihydroxypyrrolidin-l-yl)methyl)-lH-pyrazol-l-yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-mo holino henyl)acrylamide,
N-(5-(4-(4-(((3 S,4R)-3 -hydroxy-4-methoxypyrrolidin- 1 -yl)methyl)- 1 H-pyrazol- 1 - yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-lH-pyrazol-l-yl)-5-methylpyrimidin-2- ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(4-methoxy-5-(5-methyl-4-(4-((methyl(l-methylazetidin-3-yl)amino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-2-moφholinophenyl)acrylamide,
N-(5-(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-rnethoxy-2-rnorpholinophenyl)acrylamide,
N-(5-(4-(4-(((3R,4S)-3,4-dihydroxypyrrolidin-l-yl)methyl)-3-methyl-lH-pyrazol- l-yl)-5-rnethylpyrimidin-2-ylamino)-4-rnethoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(((3S,4R)-3-hydroxy-4-methoxypyrrolidin-l-yl)methyl)-3-methyl-lH- pyrazol-l-yl)-5-methylpyrimidin-2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
(R)-N-(5-(4-(4-((3 -hydroxypyrrolidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-methoxy-2-moφholino henyl)acrylamide,
(S)-N-(5-(4-(4-((3 -hydroxypyrrolidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5- methyl yrimidin-2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(4-(4-((3-hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-l-yl)phenyl)acrylamide,
N-(5-(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-(piperidin-l-yl)phenyl)acrylamide,
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5 -(4-(4-((3 -hydroxyazetidin- 1 - yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)-4- methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)- 4-metho y-2-moφholinophenyl)acrylamide,
N-(4-methoxy-5-(5-methyl-4-(4-(mo holinomethyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-2-(4-methylpiperazin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4- methoxy-2-moφholinophenyl)acrylamide,
(S)-N-(5-(4-(4-((3 -(dimethylamino)pyrrolidin- 1 -yl)methyl)- 1 H-pyrazol- 1 - yl)pyrimidi -2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5 -methylpyrimidin-2-ylamino)- 4-methoxy-2-(4-methylpiperazin- 1 -yl)phenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide, N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-2- (dimethylamino)-4-methoxyphenyl)acrylamide,
(R)-N-(5-(4-(4-((3-(dimethylamino)pyrrolidin-l-yl)methyl)-l H-pyrazol- 1- yl)pyrimidin-2-ylamino)-4-methoxy-2-mo holinophenyl)acrylarrlide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5 -methylpyrimidin-2-ylamino)- 4-methoxy-2-( 1 ,4-oxazepan-4-yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)- 4-methoxy-2-(4-methyl- 1 ,4-diazepan- 1 -yl)phenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5 -methylpyrimidin-2-ylamino)- 2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(4-(((3S,4R)-3-hydroxy-4- methoxypyrrolidin- 1 -yl)methyl)- 1 H-pyrazol- 1 -yl)-5-memylpyrimidm-2-ylamino)-4- methoxyphenyl)acrylamide,
N-(4-methoxy-5 -(4-(4-((3 -methoxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(((3S,4R)-3-hydroxy-4-methoxypyrrolidin- 1 -yl)methyl)-3 -methyl- 1 H- pyrazol-l-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(4-methylpiperazin-l-yl)phenyl)acrylamide,
N-(5 -(4-(3 -((3 -hydroxyazetidin- 1 -yl)methyl)-4-methyl- 1 H-pyrrol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(5-chloro-4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)-5-chloropyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(5-chloro-4-(4-(((3 S,4R)-3-hydroxy-4-methoxypyrrolidin- 1 -yl)methyl)-3- methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxy-2- morpholinophenyl)acrylamide,
N-(5-(5-chloro-4-(4-((dimethylamino)methyl)-3 -methyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l -yl)pyrimidin-2-ylamino)- 4-methoxy-2-( 1 H-pyrazol- 1 -yl)phenyl)acrylamide,
N-(5-(5-chloro-4-(4-(((3R,4S)-3,4-dihydroxypyrrolidin-l-yl)methyl)-3-methyl-lH- pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin- 1 - yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -cyclopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-(((3S,4R)-3-hydroxy-4-methoxypyrrolidin-l-yl)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylarnide,
N-(3 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-5 -( 1 -methyl- 1 H-pyrazol-4-yl)phenyl)acrylamide,
N-(5 -(4-(4-((3 -hydroxyazetidin- 1 -yl)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-4-methoxy-2-( 1 -methyl- 1 H-pyrazol-4-yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-( 1 -methyl- 1,2,3 ,6-tetrahydropyridin-4-yl)phenyl)acrylamide,
N-(5-(4-(3-(azetidin- 1 -ylmethyl)-4-methyl- 1 H-pyrrol- 1 -yl)-5-fluoropyrimidin-2- ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(5-(5-fluoro-4-(4-(((3S,4R)-3-hydroxy-4-methoxypyrrolidin-l-yl)methyl)-3- methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxy-2- morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5 -fluoropyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5-methylpyrimidin-2-ylamino)- 4-isopropoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)- 1 H-pyrazol- 1 -yl)-5 -methylpyrimidin-2-ylamino)-
4- methoxy-2-( 1 -methyl- 1,2,3 ,6-tetrahydropyridin-4-yl)phenyl)acrylamide,
N-(4-(4-(4-(azetidin-l-ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-
5- methoxybiphenyl-2-yl)acrylamide,
N-(5-(4-(4-(hydroxymethyl)-3-methyl-lH-pyrazol-l-yl)pyrimidin-2-ylamino)-4- methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin-l-ylmethyl)-3-tert-butyl-lH-pyrazol-l-yl)-5-methylpyrimidin- 2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(4-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 2',5-dimethoxybiphenyl-2-yl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 2-(4,4-difluoropiperidin- 1 -yl)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3,5-dimethyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(2-(dimethylamino)-5-(4-(4-((dimethylamino)methyl)-3-methyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((3 -fluoroazetidin- 1 -yl)methyl)-3-methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, N-(5-(4-(4-(azetidin-l-ylmethyl)-3-methyl-lH-pyrazol-l-yl)-5-methylpyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(5-chloro-4-(4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-2-(4-(2-fluoroethyl)piperazin-l-yl)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -p-tolyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -(4-fluorophenyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3-p-tolyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-mo holinophenyl)acrylamide,
N-(2-(dimethylamino)-5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1- yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-(azetidin- 1 -yl)-5 -(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(4-methoxy-2-(4-methylpiperazin- 1 -yl)-5-(4-(3 -phenyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)phenyl)acrylamide,
N-(5 -(4-(3 -tert-butyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(2-(azetidin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-(thiophen-2-yl)-lH-pyrazol-l-yl)pyrimidin- 2-ylamino)-4-niethoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -(2,5-dimethylphenyl)- 1 H-pyrazol- 1 - yl) yrimidin-2-ylamino)-4-methoxy-2-mo holino henyl)acrylamide,
N-(4-methoxy-2-moipholino-5-(4-(3-phenyl-4-(pyrrolidin-l-ylmethyl)-lH-pyrazol- 1 -yl)pyrimidin-2-ylaniino)phenyl)acrylamide,
N-(5-(4-(4-(hydroxymethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4- methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((ethyl(methyl)amino)methyl)-3 -phenyl- 1 H-pyrazol- 1-y l)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide, N-(5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)- 4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -tert-butyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -tert-butyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -tert-butyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dirnethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)aniino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -cyelopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-rnethoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylarnino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -cyelopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -cyelopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5 -(4-(4-((dimethylamino)methyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-((2-methoxyethyl)(methyl)amino)phenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide, N-(5-(4-(4-((dimethylamino)methyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-(pyrrolidin- 1 -yl)phenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -(thiophen-2-yl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)-5- methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol- 1 -yl)-5 -methylpyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)-lH-pyrazol-l-yl)-5- methylpyrirnidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(4-(azetidin- 1 -ylmethyl)-3 -cyclopropyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-rnethoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-((dimethylamino)methyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -isopropyl- 1 H-pyrazol- 1 -yl)-5 -methylpyrimidin- 2-ylamino)-4-n ethoxy-2-mo holinophenyl)acrylamide,
N-(5-(4-(3-tert-butyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-2-(ethyl(2-methoxyethyl)amino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3 -(ruran-3 -yl)- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(4-((dimethylamino)methyl)-3 -(pyridin-3 -yl)- 1 H-pyrazol- 1 -yl)pyrimidin- 2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(3-cyclopropyl-4-((dimethylamino)methyl)- 1 H- pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(3 -(azetidin- 1 -ylmethyl)-4-(furan-3 -yl)- 1 H-pyrrol- 1 -yl)-5 -fluoropyrimidin- 2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5 -(4-(3 -((dimethylamino)methyl)-4-(ruran-3 -yl)- 1 H-pyrrol- 1 -yl)-5 - fluoropyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-(5-(4-(3 -cyclopropyl-4-((dimethylamino)methyl)- 1 H-pyrazol- 1 -yl)-5 - methylpyrimidin-2-ylamino)-4-rnethoxy-2-(methyl(oxetan-3-yl)amino)phenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)-3 -phenyl- 1 H-pyrazol-
1- yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-((dimethylamino)methyl)-3 -phenyl- 1 H- pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(4-((dimethylamino)methyl)-3-(pyridin-4-yl)- 1 H-pyrazol- 1 -yl)pyrimidin-
2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, N-(2-(4-acetylpiperazin-l-yl)-5-(4-(3-cyclopropyl-4-((ethyl(methyl)amino)methyl)- 1 H-pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-(4-(azetidin- 1 -ylmethyl)-3-cyclopropyl- 1 H- pyrazol- 1 -yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-(azetidin- 1 -yl)-5 -(4-(4-(azetidin- 1 -ylmethyl)-3 -cyclopropyl- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(3-cyclopropyl-4-((ethyl(methyl)amino)methyl)- 1 H-pyrazol- 1 - yl)pyrimidin-2-ylamino)-4-methoxy-2-mo holinophenyl)acrylamide,
N-(2-(azetidin- 1 -yl)-5-(4-(3-(azetidin- 1 -ylmethyl)-4-methyl- 1 H-pyrrol- 1 -yl)-5- fluoropyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(5-(4-(3-(azetidin-l-ylmemyl)-4-methyl-lH-pyn-ol-l-yl)-5-fluoropyrimidin-2- ylamino)-2-(dimethylamino)-4-methoxyphenyl)acrylamide,
N-(2-(dimethylamino)-5-(4-(3-((dimethylamino)methyl)-4-methyl-lH-pyiTol^ 5-fluoropyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,
N-(2-((2-(dimethylamino)ethyl)(memyl)amino)-5-(4-(3-((dimethylamino)methyl)- 4-(trifluoromethyl)- 1 H-pyrrol- 1 -yl)-5 -fluoropyrimidin-2-ylamino)-4- methoxyphenyl)acrylamide,
N-(5 -(4-(4-((ethyl(methyl)amino)methyl)-3 -methyl- 1 H-pyrazol- 1 -yl)pyrimidin-2- ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,
or a pharmaceutically acceptable salt thereof.
13. A method of treating protein kinase-mediated disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof, that is effective in treating abnormal cell growth and immune disease.
14. A method of inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR, in biological sample or in a patient, comprising contacting the biological sample with or administering to the patient a compound according to any one of claims 1 - 12, or a composition thereof.
15. The method according to claim 14, wherein the at least one mutant is Del E746- A750, L858R or T790M.
16. The method according to claim 14, wherein the at least one mutant is at least one double mutant selected from Del E746-A750/T790M or L858R/T790M.
17. A use of a compound of any one of claims 1-12 for the manufacture of a medicament for treating protein kinase-mediated disease.
18. A use of a compound of any one of claims 1-12 for the manufacture of a medicament for inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR.
19. A pharmaceutical composition for treating protein kinase-mediated disease, comprising a compound of any one of claims 1-12 as active ingredients.
20. A pharmaceutical composition for inhibiting at least one mutant of EGFR selectively as compared to wild type EGFR, comprising a compound of any one of claims 1-12 as active ingredients.
PCT/KR2015/010784 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities WO2016060443A2 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
LTEP15850314.4T LT3207035T (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
EP19196713.2A EP3604294B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
KR1020177012969A KR102073854B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
KR1020237000623A KR102662358B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
KR1020217002019A KR102487451B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
CA2962914A CA2962914C (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
EP15850314.4A EP3207035B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
BR112017007769-8A BR112017007769B1 (en) 2014-10-13 2015-10-13 COMPOUNDS DERIVED FROM AMINOPYRIMIDINE, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND THERAPEUTIC USE THEREOF
NZ730012A NZ730012A (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
SI201531055T SI3207035T1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
RS20200101A RS59900B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
MX2017003181A MX2017003181A (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities.
RU2017116598A RU2727700C2 (en) 2014-10-13 2015-10-13 Compounds and a composition for modulating the kinase activity of egfr mutants
PL15850314T PL3207035T3 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
AU2015331166A AU2015331166B2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating EGFR mutant kinase activities
MX2020002168A MX2020002168A (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities.
CN201580055717.9A CN106795144B (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating EGFR mutant kinase activity
ES15850314T ES2770058T3 (en) 2014-10-13 2015-10-13 Compounds and compositions intended to modulate the kinase activities of mutant EGFR
DK15850314.4T DK3207035T3 (en) 2014-10-13 2015-10-13 COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES
KR1020207002949A KR102208775B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
PL19196713T PL3604294T3 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
CN202010422259.0A CN111686110B (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating EGFR mutant kinase activity
SG11201701960XA SG11201701960XA (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
JP2017519685A JP6524221B2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating EGFR mutant kinase activity
EP21171619.6A EP3929190A1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
PH12017500488A PH12017500488A1 (en) 2014-10-13 2017-03-14 Compounds and compositions for modulating egfr mutant kinase activities
HRP20200201TT HRP20200201T1 (en) 2014-10-13 2020-02-07 Compounds and compositions for modulating egfr mutant kinase activities
CY20201100143T CY1122737T1 (en) 2014-10-13 2020-02-17 COMPOUNDS AND COMPOSITIONS FOR REGULATING EGFR MUTANT KINASE ACTIVITIES
CY20211100670T CY1124359T1 (en) 2014-10-13 2021-07-26 COMPOUNDS AND COMPOSITIONS FOR REGULATING EGFR MUTANT KINASE ACTIVITIES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
US62/063,394 2014-10-13

Publications (2)

Publication Number Publication Date
WO2016060443A2 true WO2016060443A2 (en) 2016-04-21
WO2016060443A3 WO2016060443A3 (en) 2016-06-23

Family

ID=55654993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/010784 WO2016060443A2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Country Status (25)

Country Link
US (1) US9593098B2 (en)
EP (3) EP3929190A1 (en)
JP (3) JP6524221B2 (en)
KR (4) KR102073854B1 (en)
CN (2) CN106795144B (en)
AU (1) AU2015331166B2 (en)
BR (1) BR112017007769B1 (en)
CA (1) CA2962914C (en)
CY (2) CY1122737T1 (en)
DK (2) DK3207035T3 (en)
ES (2) ES2770058T3 (en)
HR (2) HRP20200201T1 (en)
HU (2) HUE054848T2 (en)
LT (2) LT3207035T (en)
MX (3) MX2017003181A (en)
NZ (1) NZ730012A (en)
PH (1) PH12017500488A1 (en)
PL (2) PL3207035T3 (en)
PT (2) PT3604294T (en)
RS (2) RS59900B1 (en)
RU (2) RU2020123547A (en)
SG (1) SG11201701960XA (en)
SI (2) SI3604294T1 (en)
TW (2) TWI664173B (en)
WO (1) WO2016060443A2 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018194356A1 (en) 2017-04-21 2018-10-25 Yuhan Corporation Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
KR20190007434A (en) * 2016-05-26 2019-01-22 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 EGFR inhibitor compound
WO2019042187A1 (en) 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 Aminopyrimidine compound and composition comprising same and use thereof
US10435388B2 (en) 2016-01-07 2019-10-08 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
JP2020528916A (en) * 2017-07-28 2020-10-01 ユハン コーポレーションＹｕｈａｎ Ｃｏｒｐｏｒａｔｉｏｎ Intermediates useful for the synthesis of selective inhibitors of protein kinases and the process for preparing them
WO2020201097A1 (en) 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
US20200360394A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Therapies with 3rd generation egfr tyrosine kinase inhibitors
US10858353B2 (en) 2017-07-28 2020-12-08 Yuhan Corporation Intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021209893A1 (en) 2020-04-14 2021-10-21 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
WO2021239786A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab Egfr tkis for use in the treatment of non-small cell lung cancer
US11286253B2 (en) 2017-07-28 2022-03-29 Yuhan Corporation Process for preparing aminopyrimidine derivatives
US11466000B2 (en) 2019-03-19 2022-10-11 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
WO2022253261A1 (en) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
KR20230054567A (en) 2021-10-15 2023-04-25 제이투에이치바이오텍 (주) Compounds inhibiting ALK and/or EGFR mutation kinases and medical use thereof
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
EP4306113A2 (en) 2018-10-18 2024-01-17 Yuhan Corporation Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3929190A1 (en) * 2014-10-13 2021-12-29 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
KR102030886B1 (en) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 Novel imidazolyl pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
KR102388312B1 (en) * 2017-06-13 2022-04-19 베이징 아다메이들 바이오테크놀로지 리미티드 라이어빌리티 컴퍼니 Aminopyrimidine compound, preparation method and use thereof
CN108017633A (en) * 2018-01-30 2018-05-11 天津大学 N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls] -2- fluoropropenes amide derivatives and application
CN108047207A (en) * 2018-01-30 2018-05-18 天津大学 N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls] the deuterated objects of -2- fluoropropenes amides and application
EP3885346A4 (en) * 2018-12-21 2022-01-12 Shenzhen TargetRx, Inc. Aminopyrimidine compound used for inhibiting activity of protein kinase
MX2021010265A (en) 2019-02-26 2021-09-23 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies.
CN111747931A (en) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 Azaaromatic cyclic amide derivatives for the treatment of cancer
CN110128354A (en) * 2019-06-20 2019-08-16 大连大学 A kind of preparation method of the fluoro- 2- mesyl -4- aminopyrimidine of 5-
KR20210032093A (en) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Pyrimidine derivatives showing growth inhibition of EGFR mutation kinase and medical use thereof
KR20210152312A (en) * 2020-06-08 2021-12-15 주식회사 종근당 4-(4,5-dihydro-1h-pyrazol-1-yl)pyrimidine compound as cannabinoid receptor (cb1 receptor) antagonists and pharmaceutical composition including the same
WO2022053697A1 (en) 2020-09-14 2022-03-17 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
TW202227425A (en) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 Heteroaryl derivatives, preparation method for the same, and a pharmaceutical composition comprising the same as an active ingredient
KR20220085735A (en) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 Isoxazolidine derivative compounds, and uses thereof
JP2024516721A (en) * 2021-05-07 2024-04-16 ボロノイ インコーポレイテッド Heteroaryl derivatives, methods for producing same, and pharmaceutical compositions containing same as active ingredient
EP4342895A1 (en) * 2021-05-17 2024-03-27 Voronoi Inc. Heteroaryl derivative compound and use thereof
TW202342057A (en) 2022-02-07 2023-11-01 美商健生生物科技公司 Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2024096624A1 (en) * 2022-11-03 2024-05-10 Voronoi Inc. Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
JP2006508997A (en) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Chk-, Pdk- and Akt-inhibiting pyrimidines, their preparation and use as pharmaceuticals
JP4428565B2 (en) 2004-10-05 2010-03-10 東京エレクトロン株式会社 Treatment liquid application equipment
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (en) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 Grease composition and rolling bearing with grease
CN101242832B (en) 2005-08-25 2011-08-10 霍夫曼-拉罗奇有限公司 Fused pyrazole as p38 MAP kinase inhibitors
JP2007117465A (en) 2005-10-28 2007-05-17 Sharp Corp Dust collector and vacuum cleaner having the same
JP2009531943A (en) 2006-03-29 2009-09-03 ケーティーフリーテル・カンパニー・リミテッド Digital processing apparatus and additional service providing method using the same
CN101437519A (en) 2006-03-31 2009-05-20 艾博特公司 Indazole compounds
NZ589843A (en) * 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
KR101705158B1 (en) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr inhibitors and methods of treating diseases
JP5740409B2 (en) 2009-11-13 2015-06-24 ジェノスコ Kinase inhibitor
HUE029988T2 (en) 2011-02-25 2017-04-28 Yuhan Corp Diaminopyrimidine derivatives and processes for the preparation thereof
CN105348266B (en) * 2011-07-27 2018-04-10 阿斯利康(瑞典)有限公司 3 chlorine N [3 (the base amino of the pyrimidine 2) phenyl] propionamides or its salt of substitution
WO2013109882A1 (en) * 2012-01-20 2013-07-25 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
CN104583195B (en) * 2012-09-12 2018-08-17 山东亨利医药科技有限责任公司 Nitrogenous heteroaromatic ring derivative as tyrosine kinase inhibitor
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2015025197A1 (en) * 2013-08-22 2015-02-26 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
CN111875585B (en) * 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 Kinase inhibitors
EP3929190A1 (en) * 2014-10-13 2021-12-29 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (en) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3 (2 pyrimdinyl-amino) phenylacryloyl amine compounds and its application

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10435388B2 (en) 2016-01-07 2019-10-08 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
US11098030B2 (en) 2016-05-26 2021-08-24 Recurium Ip Holdings, Llc EGFR inhibitor compounds
KR102444835B1 (en) 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 EGFR inhibitor compounds
KR20190007434A (en) * 2016-05-26 2019-01-22 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 EGFR inhibitor compound
JP7030066B2 (en) 2016-05-26 2022-03-04 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー EGFR inhibitor compound
JP2019516766A (en) * 2016-05-26 2019-06-20 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー EGFR inhibitor compound
US11981659B2 (en) 2017-04-21 2024-05-14 Yuhan Corporation Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
KR20230175161A (en) 2017-04-21 2023-12-29 주식회사유한양행 A salt of aminopyridine derivative compound, its crystalline form and a manufacturing process thereof
US11453656B2 (en) 2017-04-21 2022-09-27 Yuhan Corporation Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
KR20180118535A (en) 2017-04-21 2018-10-31 주식회사유한양행 A salt of aminopyridine derivative compound, its crystalline form and a manufacturing process thereof
JP7126514B2 (en) 2017-04-21 2022-08-26 ユハン コーポレーション Salts of Aminopyridine Derivative Compounds, Their Crystalline Forms, and Processes for Their Preparation
WO2018194356A1 (en) 2017-04-21 2018-10-25 Yuhan Corporation Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
JP2020517611A (en) * 2017-04-21 2020-06-18 ユハン コーポレーションＹｕｈａｎ Ｃｏｒｐｏｒａｔｉｏｎ Salts of aminopyridine derivative compounds, their crystalline forms, and their preparation process
JP7390444B2 (en) 2017-04-21 2023-12-01 ユハン コーポレーション Salts of aminopyridine derivative compounds, their crystal forms, and their preparation processes
US10858353B2 (en) 2017-07-28 2020-12-08 Yuhan Corporation Intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same
US11286253B2 (en) 2017-07-28 2022-03-29 Yuhan Corporation Process for preparing aminopyrimidine derivatives
US11708362B2 (en) 2017-07-28 2023-07-25 Yuhan Corporation Process for preparing aminopyrimidine derivatives
JP7189932B2 (en) 2017-07-28 2022-12-14 ユハン コーポレーション Intermediates useful for the synthesis of selective inhibitors of protein kinases and processes for their preparation
EP3658553A4 (en) * 2017-07-28 2021-04-21 Yuhan Corporation Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same
US11198684B2 (en) 2017-07-28 2021-12-14 Yuhan Corporation Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
JP2020528916A (en) * 2017-07-28 2020-10-01 ユハン コーポレーションＹｕｈａｎ Ｃｏｒｐｏｒａｔｉｏｎ Intermediates useful for the synthesis of selective inhibitors of protein kinases and the process for preparing them
US11267810B2 (en) 2017-08-30 2022-03-08 Shenzhen Targetrx, Inc. Aminopyrimidine compound and composition comprising same and use thereof
JP2020531565A (en) * 2017-08-30 2020-11-05 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． Aminopyrimidine compounds, compositions containing this compound and their use
WO2019042187A1 (en) 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 Aminopyrimidine compound and composition comprising same and use thereof
EP3653622A4 (en) * 2017-08-30 2020-06-17 Shenzhen Targetrx, Inc. Aminopyrimidine compound and composition comprising same and use thereof
EP4306113A2 (en) 2018-10-18 2024-01-17 Yuhan Corporation Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
US11466000B2 (en) 2019-03-19 2022-10-11 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
WO2020201097A1 (en) 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
US20200360394A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Therapies with 3rd generation egfr tyrosine kinase inhibitors
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021209893A1 (en) 2020-04-14 2021-10-21 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
WO2021239786A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab Egfr tkis for use in the treatment of non-small cell lung cancer
WO2022253261A1 (en) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
KR20230054567A (en) 2021-10-15 2023-04-25 제이투에이치바이오텍 (주) Compounds inhibiting ALK and/or EGFR mutation kinases and medical use thereof
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
JP2020196740A (en) 2020-12-10
TW201619150A (en) 2016-06-01
JP6754864B2 (en) 2020-09-16
JP6524221B2 (en) 2019-06-05
RS61865B1 (en) 2021-06-30
SI3207035T1 (en) 2020-04-30
RU2020123547A (en) 2020-08-18
MX2017003181A (en) 2017-07-20
HRP20210949T1 (en) 2021-09-03
JP2019163277A (en) 2019-09-26
PT3207035T (en) 2020-02-19
JP2017530999A (en) 2017-10-19
BR112017007769B1 (en) 2023-10-10
EP3604294B1 (en) 2021-05-05
TW201938553A (en) 2019-10-01
EP3207035A4 (en) 2018-03-14
CN106795144A (en) 2017-05-31
WO2016060443A3 (en) 2016-06-23
US9593098B2 (en) 2017-03-14
RU2017116598A3 (en) 2018-11-21
EP3604294A1 (en) 2020-02-05
EP3207035B1 (en) 2019-11-20
HUE054848T2 (en) 2021-09-28
CY1122737T1 (en) 2021-03-12
CN111686110A (en) 2020-09-22
KR102487451B1 (en) 2023-01-11
NZ730012A (en) 2019-06-28
PL3207035T3 (en) 2020-06-01
KR102662358B1 (en) 2024-04-30
TWI664173B (en) 2019-07-01
KR20170066650A (en) 2017-06-14
PL3604294T3 (en) 2021-11-02
AU2015331166B2 (en) 2018-04-26
HRP20200201T1 (en) 2020-05-15
LT3207035T (en) 2020-02-25
KR20230010836A (en) 2023-01-19
KR102073854B1 (en) 2020-02-05
AU2015331166A1 (en) 2017-03-30
SG11201701960XA (en) 2017-04-27
US20160102076A1 (en) 2016-04-14
PT3604294T (en) 2021-07-29
KR102208775B1 (en) 2021-01-28
RU2017116598A (en) 2018-11-21
BR112017007769A2 (en) 2018-01-16
MX2021010761A (en) 2022-06-09
EP3207035A2 (en) 2017-08-23
EP3929190A1 (en) 2021-12-29
MX2020002168A (en) 2021-09-07
PH12017500488A1 (en) 2017-07-31
ES2879474T3 (en) 2021-11-22
SI3604294T1 (en) 2021-08-31
DK3207035T3 (en) 2020-01-27
DK3604294T3 (en) 2021-06-28
HUE048006T2 (en) 2020-05-28
CN111686110B (en) 2023-06-16
CN106795144B (en) 2020-06-16
TWI730331B (en) 2021-06-11
CY1124359T1 (en) 2022-07-22
RS59900B1 (en) 2020-03-31
KR20210011068A (en) 2021-01-29
LT3604294T (en) 2021-07-26
CA2962914C (en) 2018-10-23
ES2770058T3 (en) 2020-06-30
KR20200014944A (en) 2020-02-11
RU2727700C2 (en) 2020-07-23
CA2962914A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
AU2015331166B2 (en) Compounds and compositions for modulating EGFR mutant kinase activities
US10005761B2 (en) Compounds and compositions as protein kinase inhibitors
EP2498607B1 (en) Kinase inhibitors
US9890168B2 (en) 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
WO2014025128A1 (en) N2,n4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
KR20170031241A (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
JP7036939B2 (en) A novel pyrimidine derivative showing a growth inhibitory effect on cancer cells and a pharmaceutical composition containing the same.
KR20240074820A (en) Compounds and compositions for modulating egfr mutant kinase activities

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15850314

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/003181

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12017500488

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2962914

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015331166

Country of ref document: AU

Date of ref document: 20151013

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015850314

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015850314

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017519685

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017007769

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20177012969

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017116598

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017007769

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170413